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 Diffuse large B cell lymphoma (DLBCL) is the most common non-
Hodgkin lymphoma.  Currently, approximately 40% of DLBCL patients 
treated with standard of care therapies, which include a combination of 
immunotherapy (Rituximab; R) and chemotherapy (CHOP), will have disease 
that is refractory or will relapse. Tumour-associated macrophages can 
phagocytose opsonised DLBCL tumour cells and are therefore centrally 
important in determining therapeutic outcomes for patients treated with R-
CHOP. Recent data from our lab and from others suggests that the modulation 
of sphingosine-1-phosphate (S1P) signalling may therapeutically benefit some 
patients with this tumour.  
 In this study, the effects of S1P on macrophage functions relevant to 
DLBCL were investigated. Using in vitro phagocytosis assays, S1P signalling 
through the major receptor, S1PR1, suppressed the phagocytosis of rituximab-
opsonised DLBCL cells.  However, chemotherapy potently induced monocyte 
recruitment to DLBCL tumours in vivo and S1PR1 is a primary mediator of 
monocyte migration both in vitro and in vivo. This work suggests that S1PR1 
signalling inhibitors could improve the therapeutic efficacy of rituximab-based 
therapies for DLBCL patients. However, these drugs should be given only after 
chemotherapy and before rituximab administration so as to maximise the S1P-





 Achieving my PhD would not have been possible without the generosity of 
Professor Paul Murray.  I am so grateful to Paul for allowing me to do this project, 
for giving me the independence to pursue my ideas and assuaging my 
frustrations, and for making work full of fun and laughter.     
 I cannot begin to express my thanks to Professor Pam Kearns who has been 
my mentor, supervisor, and friend for ~15 years.  Pam has allowed me to grow 
into an independent researcher by giving me opportunities to achieve this 
milestone.  It has been life-changing.  Pam has been my biggest supporter and I 
am forever grateful.   
 I have had the privilege of working with amazing people at LCCTP, 
Avalon, POET, and at the University of Birmingham.  I thank them for sharing 
their knowledge and for the many wonderful memories.  Special thanks to Dr 
Navta Masand for helping me through long evenings in the lab; Dr Kate 
Vrzalikova and Dr Carmela De Santo for their guidance and advice; Dr Matt Pugh 
for his help with the pathology; Dr Robert Hollows for providing bioinformatics 
analysis; and special thanks to Professor Tanja Stankovic for her encouragement 
and support. 
Finally, I must acknowledge Dr Stuart Yuspa—my “science dad”.  I learned 
so much during my time at the National Cancer Institute which has made me the 
scientist I am today.  Stu lifted as he climbed teaching us perseverance, integrity, 
and to respect and value each other.  The environment of collaboration, 
community, and discovery at LCCTP forged friendships and strong bonds beyond 
the lab.  My heartfelt thanks to Stu and everyone from the Yuspa Lab. 
 
This work is dedicated to my mom, Brenda, my sisters, Mary and Nettie, 
my late grandparents, Dorothy and Johnnie Adams  
and to my beloved, Simon, Isak and Iris. 
 
Table of Contents 
 
 Chapter 1 Introduction ..................................................................................... 1 
  Non-Hodgkin lymphoma (NHL) .................................................................. 2 
1.1 Diffuse large B cell lymphoma (DLBCL) .................................................... 2 
1.1.1 Epidemiology of DLBCL .............................................................................. 2 
1.1.2 Classification of DLBCL .............................................................................. 5 
1.1.3 Normal B cell development ....................................................................... 16 
1.1.4 Molecular pathogenesis of DLBCL ........................................................... 19 
1.1.5 Standard and emerging treatments for DLBCL ...................................... 23 
1.1.6 Mechanisms of action of rituximab ........................................................... 27 
1.2 Tumour microenvironment (TME) ............................................................ 30 
1.2.1 Gene expression profiling of DLBCL microenvironment ........................ 31 
1.2.2 TME contributes to lymphomagenesis ..................................................... 34 
1.2.3 TME contributes to hallmarks of cancer .................................................. 35 
1.3 Monocytes and macrophages ..................................................................... 36 
1.3.1 M1 and M2 paradigm ................................................................................. 37 
1.3.2 Tissue resident macrophages .................................................................... 38 
1.3.3 Tumour associated macrophages (TAMs) ................................................ 40 
1.3.4 Macrophage chemotaxis ............................................................................. 43 
1.3.5 Macrophages are professional phagocytes ............................................... 44 
1.4 Sphingosine-1-phosphate (S1P) ................................................................ 46 
1.4.1 S1P formation ............................................................................................. 46 
1.4.2 Sphingolipid rheostat ................................................................................. 50 
1.4.3 S1P receptors .............................................................................................. 52 
1.4.4 S1P and macrophage recruitment and function ...................................... 56 
1.4.5 S1P in inflammation and cancer ............................................................... 57 
1.5 Hypothesis and aims .................................................................................. 60 
 
Chapter 2 Materials and methods ................................................................. 62 
2.1 Cell line cultivation and cryopreservation ............................................... 63 
2.2 Patient and healthy donor samples .......................................................... 64 
2.2.1 Ethical approval for research with human tissue ................................... 64 
2.2.2 Preparation of patient tissue for in vitro experiments ............................ 65 
2.3 In vitro monocytes/macrophage experiments........................................... 68 
2.3.1 Human monocyte isolation and macrophage polarisation ...................... 68 
2.3.2    Flow cytometry of human monocytes and macrophages ........................ 70 
2.3.3 ELISA for IL-10/IL-12 and human cytokine array .................................. 72 
2.4 Xenograft/syngeneic grafts of DLBCL ...................................................... 72 
2.4.1 Application of NC3Rs and experimental design ...................................... 72 
2.4.2 Tumour measurement and calculation of tumour volume ..................... 73 
2.4.3 Syngeneic A20 model of DLBCL ............................................................... 74 
2.4.4 Xenografts using DLBCL cell lines ........................................................... 74 
2.4.5 Preparation of stock compounds used for in vivo treatments................. 75 
2.4.6 In vivo efficacy experiments and statistical analysis .............................. 75 
2.5 IC50 determination .................................................................................... 79 
2.6 Sphingosine-1-phosphate for in vitro use ................................................. 79 
2.6.1 Preparation of sphingosine-1-phosphate stock solution ......................... 79 
2.6.2 Neutralising sphingosine-1-phosphate with Sphingomab ...................... 80 
2.7 Preparation of DLBCL cell line conditioned medium ............................. 81 
2.8 In vitro migration assay ............................................................................. 81 
2.9 Phagocytosis assay ..................................................................................... 82 
2.9.1 Phagocytosis assay with FITC+ latex beads ............................................ 82 
2.9.2 Phagocytosis assay with DLBCL cell lines .............................................. 82 
2.10 Annexin V/PI............................................................................................... 84 
2.11 Protein extraction and determination of concentration .......................... 84 
2.12 Western blot analysis ................................................................................. 85 
2.13 RNA extraction and cDNA synthesis ....................................................... 86 
2.14 Quantitative PCR (real-time PCR) ........................................................... 87 
2.15 RNAscope © fluorescent in situ hybridisation ......................................... 88 
2.16 Immunohistochemistry  ............................................................................. 89 
2.17 Cytospin of cell lines for immunohistochemistry..................................... 92 
2.18 Gene expression analysis ........................................................................... 92 
2.19 Measurement of S1P in DLBCL cell lines ................................................ 93 
2.20 Gene set enrichment analysis ................................................................... 93 
2.21 Statistical analysis ..................................................................................... 94 
Chapter 3 SPHK1 expression in DLBCL and its relationship to the 
expression    of macrophage genes.............................................. 95 
3.1 Introduction ................................................................................................ 96 
3.2 SPHK1 is overexpressed in DLBCL ......................................................... 97 
3.2.1 Evaluating SPHK1 in primary DLBCL .................................................... 97 
3.2.2 DLBCL cell lines overexpress SPHK1 .................................................... 100 
3.3 Evaluating genes correlated with SPHK1 in DLBCL ........................... 102 
3.3.1 SPHK1 and macrophage genes correlated in primary DLBCL ............ 102 
3.3.2 Macrophage signature genes positively correlated with SPHK1 are 
upregulated in primary DLBCL  ............................................................. 104 
3.3.3 Gene set enrichment analysis of SPHK1 correlated genes ................... 106 
3.3.4 Not all macrophages express SPHK1 in primary DLBCL .................... 112 
3.4 Discussion ................................................................................................. 115 
 
Chapter 4 Evaluating the S1P-mediated migration  monocytes and  
   macrophages .................................................................... 118 
4.1 Introduction .............................................................................................. 119 
4.2 In vitro polarisation of monocytes to M1 and M2 macrophages ........... 120 
4.2.1 Macrophage polarization with GM-CSF and M-CSF ............................ 120 
4.2.2 Monocytes/macrophages express S1PR1 and S1PR2  ........................... 123 
4.2.3 Monocytes/macrophages express low levels of S1PR3, S1PR4, and 
S1PR5 ........................................................................................................ 126 
4.2.4 Monocytes/macrophages express S1PR1 surface protein ..................... 130 
4.3 S1P mediated migration of monocytes, M1/M2 macrophages .............. 131 
4.3.1 CD14+ monocytes migrate to S1P........................................................... 131 
4.3.2 M1 and M2 macrophage migration is mediated by S1P ....................... 136 
4.4 Recruitment of mouse F4/80+CD121b+ cells to xenografts .................. 141 
4.4.1 Host macrophages are recruited to xenografts ...................................... 141 
4.4.2 BAF312 reduced infiltration of F4/80+CD11b+ cells in vivo ................ 147 
4.4.3 Optimising A20 engraftment, a syngeneic model of DLBCL................ 153 
4.4.4 BAF312 reduced infiltration of F4/80+CD11b+ cells in vivo ................ 156 
4.5 Discussion ................................................................................................. 158 
 
 
Chapter 5 Evaluating the effect of S1P on phagocytosis .......................... 161 
5.1 Introduction .............................................................................................. 162 
5.2 Phagocytosis of FITC+ latex beads ......................................................... 163 
5.2.1 Establishing the time point for phagocytosis assays............................. 163 
 5.2.2 S1P treated M1 had reduced phagocytosis of FITC+ beads ................. 166 
5.3 Phagocytosis of rituximab-opsonised DLBCL cell lines ........................ 169 
5.3.1 Evaluation of surface expression of CD20 on DLBCL cell lines ........... 169 
5.3.2 Reduced phagocytosis of rituximab treated DLBCL ............................. 170 
5.3.3 Treatment with BAF312 reversed the effect on phagocytosis .............. 178 
5.3.4 BAF312 and rituximab had no in vitro cytotoxicity of in SUDHL6 ..... 180 
5.4 Optimisation of rituximab-chemotherapy in vivo ................................. 183 
 5.4.1 Vincristine and doxorubicin are cytotoxic to DLBCL cell lines ............ 183 
 5.4.2 Complete response in vivo with vincristine 1mg/kg  ............................. 188 
 5.4.3 Complete response In vivo with vincristine (0.5mg/kg) and     
  rituximab (1mg/kg) combination ............................................................. 191 
 5.4.4 Treatment with BAF312 prior to rituximab reduces the efficacy of  
  rituximab and vincristine treatment in vivo  ........................................ 195 
5.5 Discussion ................................................................................................. 200 
 
Chapter 6 Conclusions and future perspectives ....................................... 203 
Appendices  ..................................................................................................... 210 
References  ..................................................................................................... 218 
  
  
List of Figures 
Chapter 1  
Figure 1.1 Frequency of non-Hodgkin lymphoma by types......................................... 3 
Figure 1.2 Cell of origin and oncogenic pathways in DLBCL subtypes ..................... 9 
Figure 1.3 Hans and Choi algorithm for IHC classification of DLBCL ................... 10 
Figure 1.4 Newly defined genetic subtypes of DLBCL Schmitz et al ....................... 14 
Figure 1.5 Stages of B cell development ..................................................................... 18 
Figure 1.6 Kaplan-Meier plots of patients treated with CHOP and R-CHOP ........ 25 
Figure 1.7 Mechanisms of action of rituximab ........................................................... 29 
Figure 1.8 Gene expression profiling of DLBCL reveals stromal gene signatures . 33 
Figure 1.9 Origin of macrophages in normal and neoplastic tissue ......................... 39 
Figure 1.10 Phagocytosis of apoptotic cells in homeostasis ........................................ 45 
Figure 1.11 Inside-out signaling of sphingosine-1-phosphate (S1P) .......................... 48 
Figure 1.12 Formation of S1P ........................................................................................ 49 
Figure 1.13 Sphingolipid rheostat ................................................................................. 51 
Figure 1.14 Compounds targeting S1P receptor signalling ........................................ 53 
 
Chapter 3 
Figure 3.1 SPHK1 is overexpressed in primary DLBCL ........................................... 99 
Figure 3.2 DLBCL cell lines express SPHK1 and secrete S1P ............................... 101 
Figure 3.3 Enrichment of macrophage genes positively correlated with SPHK1 . 103 
Figure 3.4 Macrophage signature genes upregulated in primary DLBCL ............ 105 
Figure 3.5 Gene enrichment analysis of genes +-correlated with SPHK1............. 107 
Figure 3.6 Enrichment of SPHK1 genes associated with migration ...................... 109 
Figure 3.7 Enrichment of SPHK1 genes associated with phagocytosis ................. 111 
Figure 3.8 CD68+ cells are abundant in primary DLBCL ...................................... 113 
Figure 3.9 Low frequency of SPHK1/CD68+ cells in primary DLBCL .................. 114 
Chapter 4 
Figure 4.1 Polarisation of CD14+ monocytes to M1 and M2 macrophages ........... 122 
Figure 4.2 Relative S1PR1 and S1PR2 expression in M1/M2 macrophages ......... 124 
Figure 4.3 Volcano plots of FDR vs mean CT for S1PR1 and S1PR2 .................. 125 
Figure 4.4 Relative expression of S1PR3, S1PR4 and S1PR5 in M1 and M2 ....... 127 
Figure 4.5 Volcano plots of FDR vs mean CT for S1PR3, S1PR4, and S1PR5 ... 128 
Figure 4.6 Summary of S1P receptor expression data for healthy donors ............ 129 
Figure 4.7 S1PR1 is detected in M1/M2 by flow cytometry .................................... 130 
Figure 4.8 Migration of CD14+ monocytes to MCP-1 and S1P ............................... 132 
Figure 4.9 Monocyte migration to DLBCL conditioned medium ............................ 135 
Figure 4.10 Migration of M1/M2 macrophages to MCP-1 and CXCL12 .................. 137 
Figure 4.11 Migration of M1/M2 macrophages to S1P is blocked by Sphingomab . 139 
Figure 4.12 Baseline migration of M1/M2 macrophages is S1P dependent ............ 140 
Figure 4.13 Engraftment kinetics of human DLBCL cell lines using NSG ............. 142 
Figure 4.14 F4/80+ cells found in DLBCL cell line xenografts ................................. 144 
Figure 4.15 Gating strategy for analysis F4/80+CD11b+ cells in xenografts .......... 145 
Figure 4.16 Percentage of host CD45+F4/80+CD11b+ cells in xenografts .............. 146 
Figure 4.17 Gating strategy for quantitating F4/80+CD11b+ cells in xenografts  . 148 
Figure 4.18 BAF312 reduced infiltration of F4/80+CD11b+ to OCI-Ly1 ex vivo .... 149 
Figure 4.19 BAF312 reduced infiltration of F4/80+CD11b+ to SUDHL6 ex vivo ... 150 
Figure 4.20 cPARP expression in SUDHL6 xenografts; vehicle vs BAF312 ........... 152 
Figure 4.21 Engraftment kinetics of A20 syngeneic lymphoma in BALB/c ............ 154 
Figure 4.22 F4/80+ cells infiltrated A20 tumours; ex vivo histological analysis ..... 155 
Figure 4.23 In vivo treatment with BAF312 reduced infiltration of F4/80+CD11b+  
cells to A20 syngeneic tumours ............................................................... 157 
 
Chapter 5 
Figure 5.1 Flow diagram of phagocytosis assay with FITC+ latex beads .............. 164 
Figure 5.2 Time course to determine optimal time point for phagocytosis............ 165 
Figure 5.3 S1P treated M1 macrophages had reduced phagocytosis of beads ...... 168 
Figure 5.4 DLBCL cell lines express CD20 .............................................................. 169 
Figure 5.5 Jurkat cells treated with rituximab in phagocytosis assay .................. 171 
Figure 5.6 Rituximab treated DLBCL; phagocytosis assay gating strategy ......... 173 
Figure 5.7 Reduced phagocytosis of rituximab treated SUDHL6 .......................... 174 
Figure 5.8 Reduced phagocytosis of ofatumumab treated SUDHL6 ...................... 175 
Figure 5.9 Reduced phagocytosis of rituximab treated OCI-Ly1 and OCI-Ly3 .... 177 
Figure 5.10 BAF312 blocks reduction of phagocytosis effect of S1P ........................ 179 
Figure 5.11 BAF312 does not induce apoptosis of SUDHL6  .................................... 181 
Figure 5.12 Rituximab does not induce apoptosis of SUDHL6 ................................. 182 
Figure 5.13 IC50 of vincristine in DLBCL cell lines .................................................. 185 
Figure 5.14 IC50 of doxorubicin in DLBCL cell lines ................................................ 186 
Figure 5.15 IC50 for rituximab could not be determined for DLBCL cell lines ...... 187 
Figure 5.16 Complete response of SUDHL6 in vivo with vincristine....................... 190 
Figure 5.17 Complete response of SUDHL6 in vivo with vincristine/rituximab ..... 193 
Figure 5.18 Absolute number of F4/80/CD11b cells in SUDHL6 ex vivo ................. 194 
Figure 5.19 BAF312 reduced effect of vincristine/rituximab in vivo ....................... 198 




List of Tables 
Chapter 1 
Table 1.1 DLBCL: Stages of disease  .............................................................. 4 
Table 1.2 2016 WHO classification for DLBCL ............................................ 12 
Table 1.3 Emerging treatments for DLBCL in clinical trials, Jan 2019 ..... 27 
 
Chapter 2 
Table 2.1 Summary of DLBCL cell lines  ..................................................... 67 
Table 2.2 Recipes for buffers and reagents  .................................................. 69 
Table 2.3 Antibodies used for flow cytometry  .............................................. 71 
Table 2.4 Drugs used for in vivo treatments  ............................................... 78 
Table 2.5 Probes used for qPCR  ................................................................... 88 
Table 2.6 Antibodies/probe used for IHC, western blot, RNAscope  ............ 91 
 
Chapter 3 
Table 3.1 Number of SPHK1 and migration genes in correlation  ............ 108 
Table 3.2 Number of SPHK1 and phagocytosis genes in correlation  ........ 110 
 
Chapter 5 
Table 5.1 Donor IDs of healthy donors used in phagocytosis assays ......... 176 
Table 5.2 Mean tumour volumes; vincristine vs vehicle  ........................... 189 
Table 5.3 Mean tumour volumes; vincristine and rituximab  .................... 192 
Table 5.4 Mean tumour volumes; vincristine, rituximab, BAF312 ........... 197 
Table 5.5 Treatment schedule: rituximab, vincristine, and BAF312......... 197 
 
  
List of Abbreviations 
ABC-type activated B cell type diffuse large B cell lymphoma  
ADCC antibody dependent cellular cytotoxicity  
ADCP antibody dependent cellular phagocytosis  
AID activation-induced cytidine deaminase  
AKT protein kinase B  
ANOVA analysis of variance  
ATP adenosine tri-phosphate  
BAF312 siponimod  
BALB/c inbred strain albino wild type mice  
BCR B cell receptor  
BSA bovine serum albumin  
CAR-T cells chimeric antigen receptor T cells  
CDC complement dependent cytotoxicity  
CFSE carboxyfluorescein succinimidyl ester  
CHOP cyclophosphamide, doxorubicin, oncovin (vincristine), prednisolone  
CM conditioned medium  
COO cell of origin  
CSR class switch recombination  
DLBCL diffuse large B cell lymphoma  
DLBCL, NOS diffuse large B cell lymphoma, not otherwise specified  
EBV Epstein-Barr virus  
EC50 effective concentration 50  
EC80 effective concentration 80  
ECL enhanced chemiluminescence  
EDA experimental design assistant  
ER endoplasmic reticulum  
ERK extracellular signal-regulated kinases  
ETOH ethanol  
FBS foetal bovine serum  
FDC follicular dendritic cells  
FDR false discovery rate = q < .01  
FFPE formalin fixed paraffin embedded  
GC  germinal centre    
GCB-type germinal centre B cell type diffuse large B cell lymphoma  
GEP gene expression profiling  
GM-CSF granulocyte-macrophage colony-stimulating factor  
GO gene ontology  
HDL high-density lipoprotein  
HPF high-power field  
HRP horse radish peroxidase  
HSC haematopoietic stem cell  
IC50 inhibitory concentration 50   
IgG immunoglobulin G  
IHC immunohistochemistry  
IMDM Isocove’s modified Dulbecco’s medium  
IMS industrial methylated spirits  
IP intraperitoneal  
ISH in situ hybridisation  
ITAM immunoreceptor tyrosine-based activation motif  
IV intravenous  
LPS lipopolysaccharide  
M1 GM-CSF polarised macrophages  
M2 M-CSF polarised macrophages   
MACS buffer magnetic activated cell sorting buffer  
MAPK mitogen-activated protein kinases  
MCP-1 monocyte chemoattractant protein 1  
M-CSF macrophage colony-stimulating factor  
MNC/MON monocytes (CD14+)  
MZ mantle and marginal zone  
NBF 10% neutral buffered formalin  
NC3Rs National Centre for the Replacement, Refinement, & Reduction of 
animals in research 
 
NFκB nuclear factor kappa-light-chain enhancer of activated B cells  
NHL non-Hodgkin lymphoma  
NSG NOD-scid IL2Rgammanull  
OS overall survival  
p p value < .05  
PBS phosphate buffered saline  
PBS-T phosphate buffered saline + tween 20  
PCR polymerase chain reaction  
PD-1/PDL-1 programmed cell death-1/ programmed cell death ligand-1  
PFS progression free survival  
P13K phosphatidylinositol 3-kinase  
PMSF phenylmethane sulfonyl fluoride  
PO oral gavage  
q-PCR quantitative or real-time PCR  
R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone  
RPMI 1640 Roswell Park Memorial Institute medium 1640  
S1P sphingosine-1-phosphate  
S1PR sphingosine-1-phosphate receptor  
SC subcutaneous  
SMH somatic hypermutation  
SOV sodium orthovanadate  
SPHK1 sphingosine kinase 1  
SPHK2 sphingosine kinase 2  
TAM tumour associated macrophages  
TBS tris buffered saline  
TBS-T tris buffered saline + tween 20  
TGFβ transforming growth factor beta  
TGI tumour growth inhibition  
TME tumour microenvironment  
WHO World Health Organisation  
ΔCT change in cycle threshold  










































 The majority (90%) of all lymphomas are classed as non-Hodgkin 
lymphoma (NHL) and are distinguished from Hodgkin lymphoma by the 
absence of large multi-nucleated tumour cells known as Hodgkin and 
Reed/Sternberg cells (HRS cells) (Kuppers, 2005).  NHL is the fifth most 
common cancer in the United Kingdom (UK) and is comprised of a broad range 
of malignancies that include both fast growing aggressive tumours such as 
diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma as well as more 
indolent neoplasms such as follicular lymphoma (Figure 1.1) (CRUK, 2015).  
Most NHL are B cell malignancies (85-90%) but a small portion are derived 
from T cells or natural killer (NK) cells (Shankland et al., 2012).   
1.1 Diffuse large B cell lymphoma 
1.1.1 Epidemiology of DLBCL 
 DLBCL is the most common NHL subtype making up 36% of NHL cases 
(Figure 1.1)  (Quintanilla-Martinez, 2015, Scott and Gascoyne, 2014).  In the 
UK, there are about 5000 new cases of DLBCL per year with a slight gender 
bias towards males and an overall median age of 65 years old (NICE, 2016, 
Ruhl JL, 2018).  DLBCL is a highly aggressive disease with a 5-year overall 
survival (OS) of 60% and those patients who are >65 years old have decreased 





(Gisselbrecht and Van Den Neste, 2018).  The frequency of relapse among 
DLBCL patients is approximately 30% with an additional 10% who are 








Figure 1.1 Frequency of various types of non-Hodgkin lymphoma (NHL).  Diffuse 
large B cell lymphoma (DLBCL) is the most common NHL making up 36% of all cases 
and is highly aggressive.  Follicular lymphoma, marginal zone lymphoma (MZL), and 
CLL/SLL (chronic lymphocytic leukaemia/small lymphocytic lymphoma) make up the 
next most common indolent lymphomas.  PTCL (peripheral T cell lymphoma) and 
MCL (mantle cell lymphoma) are less common but highly aggressive forms of NHL.  
Burkitt lymphoma is a high-grade highly proliferative and aggressive lymphoma 
which can be associated with Epstein-Barr virus.   





 DLBCL patients commonly present with enlarged lymph nodes in the 
neck, groin or abdomen but extra-nodal presentation of DLBCL is not 
uncommon, most often presenting in the stomach or gastrointestinal tract 
(Tilly et al., 2015).  More than half the patients are diagnosed with DLBCL are 
at later stages (Stage III and Stage IV) of disease (Table 1.1).  DLBCL patients 
at these advanced stages are treated with a combination of chemotherapy 
(CHOP; cyclophosphamide, doxorubicin, vincristine and prednisolone) and 
immunotherapy (R; rituximab).  Those with more localised disease at (Stage I 
and Stage II; Table 1.1) are also treated with R-CHOP but supplemented with 
radiation therapy. (Tilly et al., 2015)   
 
Table 1.1 Disease stages of DLBCL adapted from Tilly et al, 2015 
STAGE  
I Single lymph node or a group of adjacent nodes involved 
II Multiple lymph node regions on the same side of the diaphragm involved  
III 
Groups of lymph nodes found on both sides of the diaphragm involved 
(i.e. neck, chest or abdomen) 
IV 
Lymph nodes on both sides of the diaphragm with or without involvement 







 The addition of rituximab to CHOP therapy in 2000, resulted in 
increased survival from 40% to the current 5-year overall survival rate of 60% 
(Kunkel et al., 2000, Chapuy et al., 2018).  Nearly 20 years since the addition 
of rituximab, all DLBCL patients are still uniformly treated with R-CHOP or 
R-CHOP plus radiation regardless of clinical presentation, phenotype or 
genetic disparities. There has been no further improvement to overall survival 
since the introduction of rituximab to DLBCL treatment (Coiffier and Sarkozy, 
2016).  For those patients who relapse or are refractory, there are few 
alternative treatment options and are currently given salvage therapy which 
include rituximab plus combinations of other chemotherapeutic agents with 
little improvement in survival (Gisselbrecht and Van Den Neste, 2018).   
1.1.2 Classification of DLBCL  
 The complexity and heterogeneity of DLBCL has made stratification 
and classification challenging.  Alizadeh et al was the first to demonstrate and 
stratify DLBCL into disease subtypes (Alizadeh et al., 2000).   They 
hypothesised that DLBCL could be stratified by cell of origin (COO) at 
different stages of normal B cell differentiation (reviewed in section 1.1.4) 
which they demonstrated by gene expression profiling (GEP).  Using normal 
germinal centre B cells isolated from tonsil and a range of in vitro activated B 
cells isolated from peripheral blood, Alizadeh et al derived specific gene 
signatures for these B cells at the various stages of differentiation.  Then the 
gene expression profiles of untreated patient samples diagnosed with DLBCL 





lymphoma and leukaemia cell lines were compared with the gene signatures 
derived from the range of normal B cells (Alizadeh et al., 2000).   
 Alizadeh et al found that the DLBCL cases clustered into two distinct 
groups by gene expression: 1) germinal centre B cell type (GCB) DLBCL that 
clustered with normal germinal centre B cells and 2) the rest that clustered 
outside of this group they called the activated B cell type (ABC) (Alizadeh et 
al., 2000).  They also found some DLBCL cell lines that clustered with DLBCL 
patient samples by COO: SUDHL6 which clustered with patient GCB-DLBCL 
and OCI-Ly3 and OCI-Ly10 which clustered with patient ABC-DLBCL 
(Alizadeh et al., 2000).  Rosenwald et al took this work further and analysed a 
cohort of 240 DLBCL cases at presentation with clinical follow-up after 
treatment with CHOP (Rosenwald et al., 2002).   
 Using DNA microarray analysis, Rosenwald et al began by subtyping 
their cohort of DLBCL according to the GEP signatures derived by Alizadeh et 
al and found that their samples clustered into ABC, GCB, or into a third 
unclassifiable group, Type 3 (Rosenwald et al., 2002).  By histology, Rosenwald 
et al found that there were no histologic features specific to any of the three 
DLBCL subtypes.  Evaluating survival after CHOP between the GCB, ABC 
and Type 3 subtypes, they found that the GCB type had 60% OS survival while 
the ABC and Type 3 had 35% and 39% OS survival respectively in accordance 
with the survival results reported by Alizadeh et al (Rosenwald et al., 2002, 
Alizadeh et al., 2000).  But Rosenwald et al also recognised the diverse 





3-year survival while some ABC-type patients with complete response to 
CHOP (Rosenwald et al., 2002).  This observation suggested that DLBCL 
stratification required further exploration.   
 Oncogenic pathways that typified GCB-DLBCL and ABC-DLBCL 
subtypes were garnered from the gene expression profiling data from Alizadeh 
et al and Rosenwald et al.  Amongst the oncogenic pathways that are 
characteristic of GCB-DLBCL, are the deletion or loss of PTEN, and MYC 
and/or BCL2 translocations (Figure 1.2).  Oncogenic pathways considered 
hallmarks of ABC-DLBCL include mutations in NF-κB and BCR signalling as 
well as BCL6 translocations (Figure 1.2) (Sehn and Gascoyne, 2015).   
 Due to the high cost and low availability of GEP in the decade following 
COO classification of DLBCL, immunohistochemistry (IHC) algorithms were 
developed as an alternative.  IHC was rapid and more cost-effective compared 
to GEP therefore, several different IHC algorithms have been developed (Hans 
et al., 2004, Choi et al., 2009, Muris et al., 2006, Nyman et al., 2009, Meyer et 
al., 2011, Visco et al., 2012).  The Hans algorithm is the most commonly used; 
GCB-type DLBCL is positive for CD10 and BCL6 and negative for MUM1 
while ABC/non-GC-type DLBCL is characterised by CD10-negative BCL6- 
negative or CD10-negative BCL6-positive MUM1-positive (Figure 1.3).  
Another common algorithm used is the Choi algorithm which added GCET 
(germinal centre expressed transcript) and FOXP1 to the classification tree in 
order to further refine classification of DLBCL by IHC (Figure 1.3).  





with prognosis and lack reproducibility perhaps due to the differences in 
methodology and reagents (Swerdlow et al., 2016).  While GEP is considered 
the most accurate way of classifying DLBCL, it still leaves 10-15% of DLBCL 



























Figure 1.2 Oncogenic pathways in DLBCL subtypes.  ABC and GCB-types are 
characterised by specific molecular subtypes.  ABC-DLBCL is characterised by 
mutations in NF-κB/BCR signalling and BCL6 translocations.  GCB-DLBCL is 
characterised by the loss or deletion of PTEN.  High-grade lymphomas have 
been shown to be a subtype of GCB-DLBCL that have poor prognosis with R-
CHOP (Sha et al, 2019 and Ennishi et al, 2019). (Figure adapted from Sehn, L. 





















Figure 1.3 Hans and Choi algorithm for immunohistochemical 
classification of DLBCL.  (A) Hans (2004) and (B) Choi (2009) were two 
examples of IHC algorithms developed for DLBCL classification.  They differ 
in that Choi added GCET and FOXP1 to the original Hans algorithm.  There 
are other IHC algorithms available but Hans remains the most commonly 
used.  It is recognised that there are limitations to the IHC method of 
DLBCL classification and that gene expression profiling or RNA analysis for 
specific transcripts are more accurate though still not adequate in classifying 







 In 2016, the World Health Organisation (WHO) made changes to the 
2008 DLBCL classification which requires DLBCL, NOS to be designated as 
GCB-type or ABC/non-GC type by either IHC or GEP  (Swerdlow et al., 2016, 
Campo et al., 2011) (Table 1.2).  Other changes added to the 2016 classification 
of DLBCL include separate classifications for Epstein-Barr Virus (EBV) and 
Herpes Simplex Virus 8 (HHV8) associated DLBCL as well as the addition of a 
separate classification for high-grade lymphomas, NOS and high-grade 
lymphomas with BCL2 and/or BCL6 plus MYC rearrangements (“double-hit” 
and “triple-hit” lymphomas) (Swerdlow et al., 2016).   
 Barrans et al showed that DLBCL patients that harbour MYC plus 
BCL2 and/or BLC6 mutations and/or rearrangements were a separate 
subgroup of DLBCL that showed poor response to R-CHOP indicating that 
further stratification of GCB and ABC subtypes were needed (Barrans et al., 
2010).  Reported to occur in <10% of DLBCL cases, “double-hit” or “triple-hit” 
lymphomas are currently underdiagnosed as shown by the recent work from 
Sha et al and Ennishi et al published simultaneously in the Journal of Clinical 
Oncology  (Friedberg, 2017, Barrans et al., 2010, Sha et al., 2019, Ennishi et 
al., 2019).  They used gene expression profiling of DLBCL patients to reveal a 
molecularly distinct subgroup amongst the GCB types (Sha et al., 2019, 
Ennishi et al., 2019).  Sha et al defined a subgroup they call the molecular 
high-grade lymphoma (MHG) group which was more likely to be of GCB-type 
and found that the “double-hit” lymphomas actually only made up half of all 





Table 1.2    2016 WHO classification for DLBCL (Swerdlow, 2016) 
*Different from the 2008 classification.  DLBCL, NOS must be classified as GCB or 
ABC by immunohistochemistry or gene expression; addition of virus (EBV+ and 
HHV8+) associated DLBCL; recognition of high-grade lymphomas as separate 
disease types from GCB type DLBCL. 
 
o Diffuse large B-cell lymphoma (DLBCL), NOS 
o Germinal centre B-cell type* 
o Activated B-cell type* 
o T-cell/ histiocyte-rich large B-cell lymphoma 
o Primary DLBCL of the central nervous system (CNS) 
o Primary cutaneous DLBCL, leg type 
o EBV+ DLBCL, NOS* 
o DLBCL associated with chronic inflammation 
o Primary mediastinal (thymic) large B-cell lymphoma 
o Intravascular large B-cell lymphoma 
o ALK1 large B-cell lymphoma 
o Plasmablastic lymphoma 
o HHV8+ DLBCL, NOS* 
o High-grade B-cell lymphoma, with MYC and BCL2 and/or 
BCL6 rearrangements* 
o High-grade B-cell lymphoma, NOS* 
o B-cell lymphoma, unclassifiable, with features 




a “double-hit” gene signature in order to distinguish these tumours from the 
other GCB-types.  They found that within their cohort of GCB patients, 27% 
were positive for the “double-hit” gene signature (Ennishi et al., 2019).  These 





of a larger distinct subgroup of molecular high-grade lymphomas found within 
the GCB subtype that have poor response to R-CHOP further adding valuable 
nuances to the newly defined genetic subgroups of DLBCL published in 2018. 
  In 2018, Schmitz et al aimed to classify DLBCL by shared genomic 
abnormalities using a combination of exome and transcriptome sequencing and 
DNA copy number analysis (Schmitz et al., 2018). They obtained a cohort of 
fresh frozen DLBCL biopsies (N=574) mostly at presentation and enriched for 
ABC and unclassified DLBCL (Schmitz et al., 2018).  In order to do the DNA 
copy number analysis for samples where matched normal DNA was not 
available, they used the sequencing data from a cohort of 48 matched samples 
to developed multiple decision trees which allowed them to determine somatic 
mutations accurately (Schmitz et al., 2018).   
 Using these genetic algorithms for calling somatic mutations, Schmitz et 
al defined four types of genetic aberrations that stratified nearly half of the 
DLBCL samples in their cohort (Figure 1.4).  They called these four genetic 
groups 1) MCD (MYD88L265P and CD79B mutation), 2) BN2 (BCL6 fusion and 
NOTCH2 mutation), 3) N1 (NOTCH1 mutation), and 4) EZB (EZH2 mutation and 
BCL2 translocation) (Schmitz et al., 2018).  They found patients from the three 
COO of subtypes (ABC, GCB, and unclassified) were present in each of their 
genetic subgroups.  MCD and N1 groups were mainly comprised of ABC-
DLBCL while the EZB group was largely made up of GCB-DLBCL (Schmitz et 













Figure 1.4 Newly defined genetic subtypes of DLBCL Schmitz et al (2018).  
Four genetic subtypes were found using a combination of exome and 
transcriptome sequencing and DNA copy number analysis.  The groups were 
called: MCD (MYD88L265P and CD79B mutation), BN2 (BCL6 fusion and NOTCH2 
mutation), N1 (NOTCH1 mutation), and EZB (EZH2 mutation and BCL2 
translocation).  Each group contained tumours from the ABC, GCB or 
unclassified subtypes reflecting the heterogeneity within each COO subtype.  
Still more than half of the cohort evaluated by Schmitz et al could not be 
classified into one of the four new genetic subtypes they defined. (Image credit: 





More importantly, about half of the unclassified DLBCL in their cohort could 
be classified into the BN2 group.  ABC, GCB and unclassified DLBCL was 
spread across all of the newly identified genetic subtypes except for the N1 
group where GCB-DLBCL was notably absent (Schmitz et al., 2018).   
 Despite the identification of the new molecular groups, 53.5% of their 
DLBCL patients could not be classified into any of the four genetic subgroups 
highlighting the heterogenous genetic landscape of DLBCL (Schmitz et al., 
2018).  Schmitz et al also examined the survival data of the patients within the 
four genetic subtypes and found that N1 and MCD subtypes had a worse 
progression-free survival and overall survival than the EZB and BN2 subtypes 
regardless of COO.  For example, ABC-BN2 patients and the “other ABC” 
(56.5% of the ABC cohort that could not be classified into any genetic 
subgroup) had better OS than patients classified as ABC-MCD and ABC-N1 
patients.   The group they termed as “other GCB” (51.1% of GCB cohort that 
could not be classified into any genetic subgroups) had a better survival than 
the patients that were classified as GCB-EZB  (Schmitz et al., 2018).   
 In the same year, Chapuy et al published whole exome sequencing of 
304 DLBCL samples in which there were 135 matched normal samples.  While 
Schmitz et al used fresh frozen biopsies, 55% of the samples used by Chapuy et 
al were obtained from formalin-fixed paraffin embedded samples (FFPE).  
Chapuy et al found six clusters they designated as C0 – C5 which were similar 
to the genetic subgroups described by Schmitz et al.  Cluster 1 (C1) includes 





tumours which corresponds to the BN2 group from Schmitz; Cluster 2 (C2) had 
biallelic inactivation of TP53 which was found in both ABC and GCB subtypes; 
Cluster 3 (C3), mostly of the GCB subtype and could also be found in follicular 
lymphoma, had BCL2 mutations but also frequently had mutations in EZH2  
and PTEN which corresponds to the EZB group from Schmitz; Cluster 4 (C4) 
had mutations in the NF-κB and RAS/JAK/STAT1 pathways as well as in 
BCR/PI3K signalling and mutations in CD83, CD58, CD70 important in 
immune evasion; Cluster 5 (C5) was characterised by consistent gain in 18q 
and mutations in MYD88 and CD79B found mostly in ABC DLBCL 
corresponding to the MCD group described by Schmitz.  Finally, there was a 
small group termed by Chapuy et al as cluster 0 (C0), which had no defining 
genetic drivers.  (Chapuy et al., 2018)   
 Since Alizadeh’s seminal publication in 2000, COO has dominated the 
classification of DLBCL. Whether or not the concept of COO of DLBCL will 
continue to be relevant in light of the new genetic subtypes uncovered remains 
to be seen.  There are at least four newly defined genetic subgroups in DLBCL 
and along with COO could result in better treatment stratification for patients.  
To contextualise COO, B cell development is reviewed in the following section. 
1.1.3 Normal B cell development 
 Normal B cell development begins in the bone marrow (a primary 
lymphoid organ) with haematopoietic stem cells (HSCs) and proceeds to 





B cells emerge (Figure 1.4) (Seita and Weissman, 2010).  When cells acquire 
the pre-B cell receptor (pre-BCR), an important checkpoint in B cell 
development, rapid proliferation occurs (Martensson et al., 2010).   During this 
rapid proliferation, extensive rearrangements of the variable (V), joining (J) 
and diversity (D) gene segments occur on the heavy chain of the BCR and is 
initiated by RAG-1 and RAG-2 (recombinant activating genes 1 and 2) occurs 
(Bassing et al., 2002).   
 When immature B cells exit the bone marrow and encounter an antigen, 
they enter the dark zone of a germinal centre where B cells, now called 
centroblasts, undergo clonal expansion (LeBien and Tedder, 2008).  
Centroblasts then exit the dark zone and differentiate into centrocytes in the 
light zone where they undergo somatic hypermutation (SMH), point mutations 
of the V-regions in the heavy and light chains of the BCR, in order to produce 
B cells with high affinity for the specific antigen encountered (Figure 1.5) 
(Bassing et al., 2002).  Two types of selection then occurs when centrocytes 
bind antigen: negative selection, where B cells bind antigen and will undergo 
apoptosis; or positive selection, where centrocytes exit the germinal centre and 
undergo class switch recombination (CSR) on the heavy chain, switching µ 
(IgM) to γ, ε, or α (IgG, IgE, IgA) (Fast, 2013, Zhang et al., 2016b).  Activation-
induced cytidine deaminase (AID) mediates SMH and CSR (Fast, 2013).  As B 
cells exit the germinal centre, they can differentiate into memory B cells or 
plasma B cells which are long-lived and form the long-term humoral immunity 











Figure 1.5 Stages of B cell development.  Normal B cell development begins in the bone 
marrow with haematopoietic stem cells (HSC).  As B cells differentiate in the bone marrow, 
they lose CD34, a marker of stemness and gain CD19, a pan B cell marker.  Pre-B cell 
receptor (pre-BCR, green) is expressed leading to proliferation or differentiation into small 
pre-B cells.  Upon further rearrangements of the transiently expressed pre-BCR, naïve B cells 
with BCR (red) will enter the blood stream and circulate between the bone marrow and 
lymphoid organs.  When naïve B cells encounter antigen (blue triangle), they become 
activated resulting in clonal expansion in the dark zone of the germinal centre.  Germinal 
centre B cells or centroblasts, undergo somatic hypermutations (SHM) which increases 
affinity for the antigen.  B cells will then move through the light zone, where centroblasts 
differentiate into centrocytes.  Centrocytes are committed and along with the antigen 
presentation by follicular dendritic cells (FDC) and T helper cells, leads to further 
differentiation. Through negative selection, centrocytes may undergo apoptosis if the affinity 
for the antigen is low.  Those that do not apoptose, will undergo class switch recombination 
(CSR) which leads to activation of transcription factors.  Activation leads to migration out of 






1.1.4 Molecular pathogenesis of DLBCL  
 Our current understanding of the pathogenesis of B cell lymphomas 
has largely arisen from the study of normal B cell biology (Shaffer et al., 
2012). The theory of COO dictates that GCB-DLBCL and Burkitt lymphoma 
originate from germinal centre B cells while ABC-DLBCL originates from 
post-germinal centre plasmablasts (Shaffer et al., 2012, Alizadeh et al., 2000). 
Most malignant B cells hijack normal B cell signalling pathways either by 
mutation gain/loss of function or activation of autocrine receptors in order to 
grow and survive (Shaffer et al., 2012). Multiple signalling pathways are not 
only activated at the same time in lymphoma, but these pathways are 
interconnected creating a therapeutic challenge  (Shaffer et al., 2012).  
B Cell Receptor signalling  
 As already discussed, in normal cells, the B cell receptor (BCR) is used 
to bind antigen.  IgH and IgL chains are bound to CD79A and CD79B 
subunits that regulate BCR expression and internalisation. Unlike in normal 
cells, malignant B cells constitutively express BCR on the cell surface.  When 
the malignant B cell encounters antigen and is bound to BCR, CD79A and 
CD79B transmit downstream signals. Immune-receptor tyrosine-based 
activation motifs (ITAMs) on CD79A and CD79B recruit SYK, which in turn 
initiates a signalling cascade involving NF-κB, PI3K, and other signalling 
pathways to promote survival and proliferation. (Shaffer et al., 2012)  BCR 
signalling does not always require antigen.  This is known as tonic BCR 





revealed those genes that are vital for B cell maturation. For example, IgM or 
CD79B ablation in mice resulted in a lack of mature B cells in spleen or 
lymph nodes after 2 weeks. This phenotype was rescued in the case of IgM 
ablation where there was constitutively active p110α of PI3K.  But in mice 
with CD79A but without ITAM, their B cells were able to express BCR on 
their cell surface which resulted in no surviving mature B cells. Also, 
constitutive NF-κB signalling mediated by IKKβ did not result in B cells after 
BCR loss of function. (Shaffer et al., 2012, LeBien and Tedder, 2008).    
 BCR signalling in DLBCL involves somatic hypermutation of the IgV 
region.  In GCB-DLBCL, there is continuous mutation of the IgV regions.  
This results in GCB types to express IgG BCR eliciting ERK, MAPK and 
calcium responses known to promote B cell differentiation into marginal zone 
B cells and plasma cells (Shaffer et al., 2012).  While in ABC-DLBCL, there is 
a static set of IgV mutations resulting in ABC types to express IgM BCR.  
This is known to promote proliferation and suppress differentiation.  (Shaffer 
et al., 2012) 
NF-κB 
  The pathogenesis of lymphoma includes the NF- κB signalling pathway.  
The NF-κB family of proteins is made up of several subunits that form 
heterodimers mediating their entry or exit from the nucleus (Heckman et al., 
2002). NF-κB is used for survival by both normal and malignant B cells with 
activation occurring downstream of several receptors including B cell receptor 





 The classical NF-κB pathway in B cells is activated by cytokine 
stimulation such as IL-1, TNF-α, or pathogens that bind to BCR or CD40. This 
results in phosphorylation of IKKβ, which is part of the IKK complex (IkB 
kinase made up of α, β, ƴ (NEMO) subunits, and ubiquitination of IKKƴ which 
in turn allows for recognition of the proteasome leading to IKKβ degradation.  
Subunits of NF-κB in the cytoplasm can then translocate to the nucleus where 
gene transcription is activated (Shaffer et al., 2012, Jost and Ruland, 2007). 
Activation of the IKKβ requires the CBM (CARD11, BCL10, and MALT1) 
complex. CARD11 is in the cytosol until it is phosphorylated and able to 
translocate to the plasma membrane where it can bind BCL10 and MALT1 
(Shaffer et al., 2012). Constitutively activated NF-κB signalling by the 
classical pathway is a hallmark of ABC-DLBCL which promotes survival by 
acting as an antagonist to chemotherapy resulting in refractory disease 
(Shaffer et al., 2012).  
BCL-2 
 NF-κB can transcriptionally regulate another pro-survival gene, BCL-2, 
in lymphoma (Heckman et al., 2002).  BCL-2 was first described in Follicular 
lymphoma where the t(14;18) translocation is a hallmark of this disease but is 
also found in many DLBCL patients (Barrans et al., 2003).  In both normal 
and malignant cells, BCL-2 plays a role in the mitochondrial apoptotic 
pathway (Czabotar et al., 2014). In GCB subtype of DLBCL and Follicular 
lymphoma, the t(14;18) translocation is commonly active in pre-B cells rather 





have circulating B cells with this translocation residing in their memory B 
cells which indicates that BCL-2 expression is not sufficient to transform B 
cells nor does the presence of this translocation mean that BCL2 is expressed 
(Shaffer et al., 2012). But several groups have shown the presence of the 
t(14;18) translocation does not alter the expression of BCL-2 and that patients 
with both the translocation and BCL2 expression have the most adverse 
prognosis (Huang et al., 2002, Barrans et al., 2003).  
MYC 
 MYC expression in lymphoma confers poor prognosis and is expressed 
by a small subset of germinal centre B cells although contradictorily not in the 
highly proliferating B cells (Ott et al., 2010, Perry et al., 2014). During 
germinal centre formation, MYC is up regulated in these B cells just before 
BCL6 is activated which then represses MYC as they enter the dark zone (Ott 
et al., 2010). This BCL6-MYC switch is associated with the formation of the 
dark zone of germinal centres and expansion of the centroblasts. Then MYC is 
re-expressed in the light zone after NF-κB up-regulation which then re-enters 
the dark zone for more rounds of proliferation. MYC negative cells in the light 
zone exit as memory cells or early plasmablasts. BLIMP1 is then induced 
which promotes plasma cell differentiation and represses MYC. (Ott et al., 
2010)  
  In DLBCL, 10% of cases will have MYC translocations and only 2% will 
have amplification of MYC (Ott et al., 2010).  Most cases of MYC 





translocation/BCL2 rearrangement (Ott et al., 2010). MYC and BCL2 
expressing lymphomas or ‘double-hit’ lymphomas are particularly aggressive 
and difficult to treat. Barrans et al. evaluated a large cohort of DLBCL cases 
and found 12% of DLBCL cases were a double or triple hit MYC/BCL2/BCL6 
subtypes (Barrans et al., 2003). While Foot et al. looked at aggressive high-
grade B cell lymphomas regardless of histology/morphology and found an even 
larger proportion had MYC rearrangements as well as BLC2 and BCL6 
indicating that ‘double-hit’ lymphomas may be under diagnosed (Foot et al., 
2011). 
 Determining the biological and genetic differences in DLBCL can lead 
to more effective individualised therapy. Several genetic aberrations in 
DLBCL, including BCL2 and IRF4, are more easily exploited by targeted 
therapy while some such as MYC cannot (Ott et al., 2010). MYC is not 
considered a druggable target because of its encompassing role in gene 
activation so focus has been on downstream indirect effects on MYC.  
Inhibitors of BRD4 which regulates MYC transcription have shown 
therapeutic efficacy in mouse models as well as in clinical trials (Ott et al., 
2010). 
1.1.5 Standard and emerging treatments for DLBCL 
 Standard treatment for lymphoma prior to 1997 was a combination of 
chemotherapies known as CHOP (cyclophosphamide, doxorubicin, vincristine, 





the addition of rituximab, a monoclonal antibody to CD20, survival rates 
increased significantly to near 60% (Sehn, 2010).  The clinical trial as reported 
by Coiffier et al provided evidence of the increased survival in patients treated 
with R-CHOP compared to CHOP (Figure 1.6A) (Coiffier et al., 2002).  Yet the 
differences in overall survival of the ABC and GCB-type DLBCL have still not 
been resolved with ABC patients having a worse prognosis than GCB type.  
Lenz et al also did a prospective study of ABC and GCB patients treated with 
R-CHOP and found that GCB-type DLBCL had significantly higher overall 
survival than ABC-type DLBCL (Figure 1.6B) (Lenz et al., 2008).  In order to 
further improve survival for the 40% of DLBCL patients who do not have 
complete response, new therapeutic strategies are being explored. 
 There are a number of emerging treatments for DLBCL in clinical trials 
which are listed on www.clinicaltrials.gov accessed on January 2019 from the 
National Institutes of Health (NIH).  There were >200 clinical trials for 
DLBCL.  About 30% of the trials were for interventions using biologics, a class 
of drugs isolated from natural sources such as human, animal or 
microorganisms.  Biologics are more complex than conventional small molecule 
therapies where the structure is known, and may be effective for diseases that 
























Figure 1.6 DLBC patients treated with R-CHOP had increased survival.  (A) The 
addition of rituximab to standard of care in this study by Coiffier et al, resulted in 
an increased in OS to 70% in patients treated with R-CHOP compared to 63% in 
DLBCL patients treated with CHOP alone. (B) Lenz et al demonstrated that 
ABC-DLBCL had inferior survival compared to GCB-DLBCL after treatment 
with R-CHOP. 
 Reproduced with permission from (Coiffier B et al. N Engl J Med 2002;346:235-242.),Copyright Massachusetts Medical Society. 
Reproduced with permission from (Lenz G et al. N Engl J Med 2008;359:2313-2323.),Copyright Massachusetts Medical Society. 
A           OS of DLBCL treated CHOP vs R-CHOP 





 Highlighted in Table 1.3 are some of the clinical trials for DLBCL that 
are currently active (as of January 2019).  They include several rituximab-
similar monoclonal antibodies, anti-CD19 monoclonal antibodies (CD19 is a 
pan marker for B cells) as well as checkpoint inhibitors for PDL-1 and CTLA4, 
and recombinant IL-12. (Table 1.2) (Mueller et al., 2017).  Besides antibody 
therapy, CD19 can now also be targeted using CAR-T cells or chimeric antigen 
recombinant T cell therapy.  CAR-T cells involve engineering and clonal 
enhancement of autologous or allogeneic T cells to a specific target  (Mueller et 
al., 2017).  These CAR-T cells are injected into a patient and they work by 
binding to the target antigen on a cancer cell to induce apoptosis.  CAR-T cell 
therapy can have adverse effects such cytokine release syndrome (an increase 
of over 150 inflammatory cytokines in the body leading to organ damage and 
even death), or graft vs host reaction (GVH), or neurological events such as 
encephalopathy (Mueller et al., 2017).   
 CTL019 from Novartis, the first approved CAR-T cell therapy by the 
FDA (Federal Drug Administration), is engineered to recognise CD19 found on 
B cells for the treatment of acute lymphoblastic leukaemia but is also being 
trialled in DLBCL (Mueller et al., 2017).  They have found CTL019 beneficial 
in the majority of patients tested with many showing complete response/ 
remission (Schuster et al., 2017, Mueller et al., 2017).  While CTL019 has 
shown to be therapeutically effective as a single agent, Novartis is also 
currently trialling CTL019 in combination with pembrolizumab which blocks 





modulation of the tumour microenvironment could provide a more 
comprehensive treatment strategy.  As it stands, standard treatment for 











1.1.6  Mechanisms of action of rituximab 
 Rituximab, a monoclonal antibody targeting CD20 on B cells, was the 
first immunotherapy to be approved for cancer.  Several mechanisms of action 
(MOA) of rituximab have been reported (Figure 1.7) (Jaglowski et al., 2010, 
Herbrand, 2016).   
Table 1.3 Emerging treatments for DLBCL in clinical trials, January 2019 






 Rituximab can induce apoptosis in the absence of effector cells by 
causing the reorganisation of CD20 into lipid rafts as well as through the 
inhibition or downregulation of survival signals such as AKT, ERK1/2, or NF-
κB (Weiner, 2010).   In synergy with chemotherapy, apoptosis induced by 
rituximab can lead to chemosensitivity (Weiner, 2010).  Complement 
dependent cytotoxicity (CDC) is another mechanism of action for rituximab 
(Golay and Introna, 2012).  Complement protein, C1q binds to rituximab which 
initiates the complement cascade.  This results in the formation of a 
membrane attack complex (MAC) creating pores in the membrane leading to 
cell death (Jaglowski et al., 2010).  Complement can also result in phagocytosis 
if the complement receptor on macrophages bind to rituximab (Jaglowski et 
al., 2010). 
 Other mechanisms of action require interaction with effector cells either 
NK cells or macrophages.  ADCC (antibody dependent cellular cytotoxicity) can 
occur when NK cells bind to the Fc region on rituximab.  This induces NK cells 
to release perforin and granzymes which cause cell death (Gul and van 
Egmond, 2015).  Macrophages also can exert an antibody mediated response to 
rituximab-opsonised B cells.  Antibody dependent cellular phagocytosis 
(ADCP) is initiated when Fc receptors on macrophages bind to the Fc region on 











Figure 1.7 Mechanisms of action of rituximab.  Rituximab is a monoclonal antibody 
binding to CD20.  (1) Apoptosis can be induced through binding of rituximab to CD20 and the 
reorganization of CD20 into lipid rafts.  (2) Complement dependent cytotoxicity (CDC) can be 
induced by the binding of rituximab to FC receptors leading to the activation of complement 
through complement receptor and further binding to membrane attack complex (MAC).  (3) 
Antibody dependent cellular cytotoxicity (ADCC) can occur when NK cells bind to rituximab 
attached to CD20 on B cells.  This induces NK cells to lyse the antibody-bound cell.  (4) Antibody 
dependent cellular phagocytosis (ADCP) can be induced when macrophages bind to Fc region on 
rituximab bound to B cells which induces the macrophage to engulf the tumour cell.  
Complement may also induce phagocytosis by macrophages through activation of the 







It is not known which mechanism of action is predominant but increasing 
evidence in murine models show that ADCP may be the primary mechanism of 
action for rituximab in vivo (Golay and Introna, 2012, Gul and van Egmond, 
2015).   
 Murine studies pointed to ADCP as the main mechanism of action of 
rituximab through studies using the A20 murine lymphoma cell line in 
immune competent mice.  A20 was determined to be sensitive in vitro to 
rituximab but when engrafted in BALB/c mice, rituximab showed no efficacy 
in vivo (Minard-Colin et al., 2008). Therefore, they developed a cell line using 
primary lymphoma cells from B6 c-Myc TG mice with C57BL/6 background 
known as BL3750 showed in vivo sensitivity to rituximab (Minard-Colin et al., 
2008).  Moreover, monocyte depletion of C57BL/6 mice engrafted with BL3750 
reduced the therapeutic effect of rituximab in line with Riihijarvi’s 
observations in DLBCL patients that those with high CD68 had favourable 
prognosis with R-CHOP (Minard-Colin et al., 2008, Riihijarvi et al., 2015). 
This work highlighted the utility of modulating the microenvironment as part 
of the treatment strategy for DLBCL. 
1.2 Tumour microenvironment 
 The study of cancer had long been focussed on the study of malignant 
cells and how they differ from normal cells.  Currently, the contribution of non-
malignant components to tumourigenesis have recently become the focus of 





microenvironment (TME) is composed of residing lymphoid cells, inflammatory 
response cells, blood vessels, and collagen (Scott and Gascoyne, 2014). The 
expression of chemokines by different subtypes of lymphoma allows malignant 
cells to home to their preferential microenvironment where resident non-
malignant cells are induced to cultivate that microenvironment  (Scott and 
Gascoyne, 2014).  
 While biological and genetic abnormalities determine the phenotype of 
lymphoma cells, malignant cells themselves exert their influence on the 
location of lymphoma involvement and the make-up of the TME (Scott and 
Gascoyne, 2014). In short, malignant cells do not act in isolation but work in 
concert with their environment to enable progression, immune evasion and 
resistance to therapy (Scott and Gascoyne, 2014).  
1.2.1 Gene expression profiling of DLBCL tumour microenvironment 
 The tumour stroma of DLBCL is made up of the extracellular matrix 
(ECM), fibroblasts of diverse phenotypes, blood vessels, immune and 
inflammatory cells (Mbeunkui and Johann, 2009). Gene expression profiling 
confirmed that the non-malignant components of lymphomas play a vital role 
in disease progression and treatment response (Lenz et al., 2008). Several 
groups have profiled large cohorts of DLBCL confirming that GCB and ABC as 
distinct subtypes and also investigated the nature of the TME in DLBCL (Lenz 
et al., 2008, Alizadeh et al., 2000, Reddy et al., 2017).  Specifically, Lenz et al., 





stromal cells and defined distinct gene signatures based on the stromal 
component of DLBCL (Lenz et al., 2008).   They assumed all CD19-positive 
cells were malignant and all CD19-negative cells were not. This excluded the 
contribution of non-malignant B cell (i.e. regulatory B cells) and ignores CD19-
negative malignant B cells (Delage et al., 2019).   
 Lenz et al found that the gene signature from GEP of the non-malignant 
cells (CD19-negative) clustered into two clusters designated as stromal-1 and 
stromal-2 (Lenz et al., 2008). From multivariate analysis and combination of 
the expression of stromal-1 and stromal-2 gene signatures into a “stromal 
score” was predictive of survival: the higher the stromal score, the poorer the 
prognosis (Lenz et al., 2008).  The stromal score was variably distributed 
amongst ABC and GCB DLBCL samples (Figure 1.8) (Lenz et al., 2008).  
 The genes in the stromal-1 signature include genes of the extracellular 
matrix (ECM) and collagen synthesis, MMPs, TIMP2, and genes representing 
tumour associated macrophages (TAMs), myeloid derived suppressor cells and 
Tie2 expressing monocytes (Lenz et al., 2008). Stromal-2 signature genes 
include angiogenesis-promoting genes, vascular endothelial growth factor 
(VEGF) and endothelial markers such as PECAM1 and SPARCL1 (Lenz et 
al., 2008). Lenz et al assert that stromal-1 genes tend to be genes involved at 
initiation of the tumourigenesis (Lenz et al., 2008). When the tumour 
undergoes an angiogenic switch, the genes of stromal-2 are expressed and the 
tumour becomes more aggressive (Lenz et al., 2008). They found tumours 














Figure 1.8 Gene expression profiling of the DLBCL microenvironment reveals 
two stromal gene signatures.  Stromal-1 and Stromal-2 gene signatures were 
derived from the CD19-negative gene signatures of DLBCL.  Stromal-1 
includes genes of the extra cellular matrix and macrophages and stromal-2 is 
rich in vascular genes.  Lenz et al classified DLBCL by COO and then clustered 
them by stromal-1 and stromal-2.  ABC and GCB subtypes had genes from both 
stromal-1 and stromal-2 signatures and found that ABC had lower expression 
of stromal-1 genes.  Stromal-2 genes were variably distributed among ABC and 
GCB but Lenz et al found that those tumours with higher proportion of 
stromal-2 genes had a worse survival.   





1.2.2 Tumour microenvironment contributes to lymphomagenesis 
 The TME contributes to lymphomagenesis in several ways.  First, the 
TME contributes to drug resistance by protecting B cell malignancies from 
the initial effects of therapy and that cytokines, chemokines, growth factors, 
and the interaction of malignant B cells with components of the TME are 
essential for this to occur (Shain et al., 2015). Therapy may kill some tumour 
subpopulations but the TME can shield a few tumour cells allowing them to 
survive treatment resulting in minimal residual disease (MRD) (Shain et al., 
2015). These remaining tumour cells that survive through the stress of 
therapy along with its surrounding TME can begin a cascade of development 
and proliferation (Shain et al., 2015). The result is an even more complex, 
genetically altered, resistant phenotype that cause patients to relapse (Shain 
et al., 2015).  
 In early stages of tumour development, translocations in cell 
proliferation and survival genes together with epigenetic and genetic 
anomalies result in constitutive activation of oncogenes and inactivation of 
tumour suppressor genes that lead to malignant transformation (Shain et al., 
2015). Along with these, tumour cells can manipulate and usurp survival 
signals from the surrounding microenvironment for their own purpose (Shain 
et al., 2015).  As such, tumour cells do not act in isolation but are supported 
by the TME in cell homing and invasion, in resistance to cell death, 
proliferation, immunosuppression, self-renewal, and angiogenesis (Shain et 





the biological makeup of the stroma. The TME evolves with the malignancy 
and demonstrate sustained gene expression changes that support critical 
aspects of tumour growth (Shain et al., 2015). Little is known about the 
“normality” of the tumour-associated stromal cells such as immune cells, 
macrophages, fibroblasts and endothelial cells (Shain et al., 2015). In vitro 
experiments can only provide limited information as tumour associated cells 
in vitro do not accurately mimic all components of the in vivo TME such as 
hypoxia, inflammatory cells, chemokines and cytokines (Dvorak, 1986). 
Preclinical models are useful for studying the tumour and its associated 
stroma in situ from early through to late stages of development. 
1.2.3 Tumour microenvironment contributes to hallmarks of cancer 
 The experiments published by Lenz et al., draw attention to a field that 
began in 1889 when Stephen Paget published his hypothesis of “seed and soil” 
to explain the non-random pattern of metastasis (Witz, 2009, Paget, 1989).  
Paget’s work has since continued by others such as Isaiah Fidler who found 
that metastatic cells homed to different sites based not only on the 
characteristics of the tumour cells but also by the host microenvironment 
(Fidler, 2003). Fidler demonstrated that within 24hrs of intravenous injection 
of cells in mice, that less than 0.1% of tumour cells were still viable in 
circulation and that less than 0.01% of these surviving cells were capable of 
metastasis which demonstrates the aggressive selection occurring during 
engraftment (Fidler, 2003). When tumour cells are injected intravenously in 





they arrest (Fidler, 2003). Once the cells eventually pass through the lungs 
they migrate to specific organs such as the liver and spleen (Fidler, 2003). 
This suggests that subpopulations exist in the primary tumour which, when 
injected, home to a preferential microenvironment to propagate (Fidler, 2003). 
Extending from the work of scientists such as Paget and Fidler, the tumour 
microenvironment has been shown to be as important to cancer pathogenesis 
as the tumour cells themselves contributing to many of the hallmarks of 
cancer (Hanahan and Coussens, 2012).  
 For the initiation and maintenance of each hallmark of cancer, many 
genetic factors, for example MYC, are contributed by the tumour cell (Gabay et 
al., 2014).  But it is the host which provides the processes that impact MYC’s 
ability to initiate tumourigenesis (Gabay et al., 2014).  In vivo models have 
identified mechanisms of how host-dependent mechanisms influence MYC’s 
ability to initiate tumourigenesis (Pelengaris et al., 2004).  It has been shown 
that the suppression of MYC to endogenous levels in the mice could reverse 
tumourigenesis in a variety of cancers even in clonally and genetically 
heterogeneous tumours (Shroff et al., 2015, Lawlor et al., 2006). 
1.3 Monocytes and macrophages  
 The immune cells of the microenvironment are recruited to the tumour 
site using signals similar to an inflammatory response (Coutinho et al., 2015).  
As part of the innate immunity, monocytes will migrate to sites of 





cytokines present.  The current paradigm of macrophage polarisation and their 
role in inflammation and how they contribute to cancer progression is 
described in the following section. 
1.3.1 M1 and M2 paradigm 
 The first to label classically and alternatively activated macrophages as 
M1 and M2 was Mills et al (Mills et al., 2000).  Studying immune responses in 
mice, Mills discovered that C57BL6 and BALB/c mice had different T cell 
responses.  When C57BL6 mice were challenged with Leishmania major, he 
found their T cells produced INFγ, which activated their macrophages to 
produced nitric oxide (NO) and killed the parasite.  In contrast, T cells from 
BALB/c mice challenged with Leishmania major produced more IL-4 that 
suppressed macrophage activation and NO secretion leaving BALB/c mice 
were sensitive to parasitic infection.   
 These observations led Mills to consider that perhaps macrophages and 
not T cells were directing immune responses. He termed the macrophages that 
mediated these responses as M1 and M2 to reflect the Th1 and Th2 responses 
associated with their activation (Mills et al., 2000, Mills, 2015).  Mills found 
that macrophages do not merely respond to T cells but can control their own 
fate by secreting cytokines such as TGFβ1 to inhibit NO and increase IL-10 
and ornithine (Mills et al., 2000).  Metabolism of arginine by inducible nitrous 
oxide synthase (iNOS) is characteristic of M1-type macrophages where the 





kill indiscriminately (Mills, 2015). In contrast, M2-type macrophages will 
metabolise arginine using arginase resulting in urea and ornithine which 
promotes proliferation and wound-healing (Mills et al., 2000).  This concept 
has interesting applications in cancer and arginase inhibitors have been shown 
to inhibit proliferation of breast cancer and non-small lung cancer cells in vitro 
(Wang et al., 2018, Kotamraju et al., 2007).   
 These terms M1 and M2 have been taken further to include a multitude 
of macrophage phenotypes; M1, M2a, M2b, M2c, and M2d which are achieved 
through activation with different cytokines (Roszer, 2015, Mantovani et al., 
2002).  This goes beyond Mill’s intention who acknowledged that terms M1 and 
M2 were an oversimplification and that macrophages phenotypes are not 
clonal populations but a continuum of phenotypes (Mills et al., 2000).  It is 
likely that in any tissue either normal or neoplastic, there will be a range of 
macrophages in different phenotypic states co-existing (Figure 1.9).    
1.3.2 Tissue resident macrophages 
 There are macrophages that do not circulate but remain in tissues i.e. 
Kupffer cells in the liver and alveolar macrophages in the lung (Italiani and 
Boraschi, 2014).  Where the tissue resident macrophages come from is still 
unresolved (Hashimoto et al., 2013, Italiani and Boraschi, 2014).   Since the 
“mononuclear phagocyte system” proposed in 1969 by van Furth and Cohn, it 
is widely accepted that all macrophages in blood and tissue are derived from 





















Figure 1.9.   Origin of macrophages in homeostatic vs. neoplastic tissue.  
Tissue resident macrophages are said to be of yolk-sac embryonic origin and may 
also come from adult bone marrow.  These tissue resident macrophages are 
thought to be self-renewing.  Tumour associated macrophages (TAMs) found in 
neoplastic tissue are said to include not only the tissue resident macrophages but 
also from a pool of monocyte derived macrophages.  Differentiating between the 
tissue resident and monocyte derived macrophages is not clear but the recruited 
monocyte derived macrophages are the main pool of TAMs focussed on in this 





Hashimoto et al determined that tissue resident macrophages were able to 
divide and proliferate and that their depletion was not replenished by 
infiltrating macrophages (Hashimoto et al., 2013).   Tissue resident 
macrophages were instead replenished in situ which required GM-CSF and M-
CSF in order to repopulate (Hashimoto et al., 2013).  This is supported by 
reports that tissue resident macrophages (Kupffer, splenic, microglia) are 
formed at the embryonic stage and infiltrating macrophages which appear 
after infection are derived from classical monocytes (Murray and Wynn, 2011, 
Qian et al., 2011).   Contradictorily, it was also shown that tissue resident 
macrophages cleared by irradiation were repopulated by monocyte derived 
macrophages (Hashimoto et al., 2013).  It is likely that tissues will have 
various proportions of embryonically-derived tissue resident macrophages, 
bone marrow-derived macrophges and monocyte-derived macrophages (Figure 
1.9) (Italiani and Boraschi, 2014). 
1.3.3 Tumour associated macrophages  
 In the tumour, it is likely that tumour associated macrophages (TAMs) 
are made up both tissue resident and monocyte derived macrophages.  The 
work published by Lenz et al. highlighted the stromal component of the 
tumour as predictive of a patient’s response to therapy yet a 
microenvironment-derived biomarker remains elusive (Lenz et al., 2008, 
Kridel et al., 2015).  Within the tumour microenvironment, innate immune 





have been shown to play a role in tumour progression and may be potential 
targets for therapy (Qian and Pollard, 2010).  
 Macrophages are involved in promoting angiogenesis, invasion and 
migration of tumour cells, and immune suppression but also have roles in the 
early stages of tumour initiation  (Pham et al., 2018, Mantovani et al., 2017).   
It has been suggested that specific subpopulations of macrophages promote 
tumour growth and progression (Qian and Pollard, 2010) but it is difficult to 
definitively distinguish these subsets from each other.  Monocyte derived cells 
in vivo do not exist as distinct subpopulations but in stages along a continuum 
that change with environmental signals (Murray and Wynn, 2011, Mantovani 
and Locati, 2013).  
 Conditions that permit monocyte differentiation into macrophage 
subsets have been extensively studied in vitro (Mantovani et al., 2002, Lacey 
et al., 2012).  Two subsets have been identified: M1 are classically activated in 
the presence of GM-CSF, INFγ, or TNFα and M2 are alternatively activated by 
M-CSF, IL-4, and IL-10 (Lacey et al., 2012, Italiani and Boraschi, 2014).  M1 
has been shown to have pro-inflammatory and anti-tumour properties while 
M2 macrophages have anti-inflammatory and pro-angiogenic properties (Mills 
et al., 2000, Minutti et al., 2017, Van Overmeire et al., 2016).  Many groups 
report various cell markers to distinguish M1 from M2 as well as diverse in 
vitro conditions for differentiation into these subsets (Lacey et al., 2012, Van 
Overmeire et al., 2016, Italiani and Boraschi, 2014).  In cancer, TAMs have 





also seen TAMs with both M1 and M2 type markers in cancer xenografts and 
by immunohistochemistry of patient tumours  (Komohara et al., 2014, 
Mantovani et al., 2017, Shain et al., 2015). It is accepted that GM-CSF and M-
CSF are cytokines which can polarise monocytes to M1-like and M2-like 
phenotypes respectively that the resulting phenotypes have opposing 
inflammatory reactions (Lacey et al., 2012, Hashimoto et al., 2013).  For 
example, it has been shown that M1-GMCSF produced higher TNF and IL-12 
and lower levels of IL-10 than M2-MCSF (Lacey et al., 2012, Verreck et al., 
2004, Kamada et al., 2005).  While a variety of different cytokines will result in 
varying degrees of M1 and M2 polarisation in vitro, the work described in the 
following chapters in this thesis will use M1 to describe GM-CSF polarised 
monocytes and M2 as M-CSF polarised monocytes.   
 A study by Riihijarvi et al that the frequency of CD68 positive cells was 
associated with favourable prognosis in DLBCL patients treated with 
rituximab + CHOP and associated with poor outcome in patients given CHOP 
only (Kridel et al., 2015, Riihijarvi et al., 2015). While CD68 expression did not 
correlate with either GCB or ABC distinction by immunohistological method of 
diagnosis (Kridel et al., 2015, Riihijarvi et al., 2015), Riihijarvi et al did 
correlate mRNA and protein levels of CD68 with  CD163, a marker for M2 
alternatively activated macrophages and suggested that the effect of rituximab 
could be attributed to binding of Fc receptor of rituximab  (Riihijarvi et al., 





1.3.4 Macrophage chemotaxis 
 Chemotaxis of monocytes and macrophages to sites of infection is part of 
the innate immunity (Jones, 2000).  Macrophage migration is mediated by 
attractants that bind to serpentine receptors (i.e. S1P receptors) which then 
couple to G protein receptors that lead to activation of PI3K and other 
pathways (Jones, 2000). Surface receptor tyrosine kinases signalling through 
colony-stimulating factor-1 receptor (CSF-1R) which activate PI3K and 
JAK/STAT pathways will also mediate macrophage migration (Hamilton, 
1997).  Other chemokines that induce migration of classically activated (M1) 
and alternatively activated (M2) macrophages include: CXCL12 which 
mediates leukocyte trafficking during embryonic development and enhances 
the macrophage expression of CD14 and CD163; MCP-1 (CCL-2) which is 
highly expressed in rheumatoid arthritis and atherosclerosis; and CXCL10 (IP-
10) which is elevated in pancreatic cancers (Lunardi et al., 2014, Chen et al., 
2015, Durr et al., 2010, Deshmane et al., 2009, Xuan et al., 2015).  
The cytokines and chemoattractants that mobilise macrophages are well 
known, but the drivers for the physical changes that need to occur for the 
macrophages to move are only recently being published.  The actin skeleton of 
macrophages allow for migration towards a stimulus which can happen 
stochastically but can also occur in response to a chemoattractant (Mattila and 
Lappalainen, 2008).  Actin filaments support filopodia which protrude and 
extend outwards then the rest of the cell is propelled forward (Jones, 2000, 





FMNL2 and FMNL3, drive the protrusion of filopodia by interacting with 
Rac/Cdc42 which in turn activates the PI3K pathway (Kage et al., 2017). 
1.3.5 Macrophages are professional phagocytes 
 Named from the Greek for ‘big eaters’, macrophages have long been 
known as professional phagocytes.  In homeostasis, phagocytosis is required 
for the removal of dead cells which begins with the release of ‘find me’ signals 
such as S1P, CX3CL1, ATP, and UTP  from apoptotic cells to recruit remote 
phagocytes (Arandjelovic and Ravichandran, 2015).  In the case of S1P, it will 
bind to S1PR1 on macrophages and lead them towards the apoptotic cell where 
‘eat me’ signals present on dead cells to initiate the process of engulfment 
(Figure 1.10) (Arandjelovic and Ravichandran, 2015).   
 Receptors on macrophages that recognise apoptotic cell ligands (i.e. 
phosphatidylserine, MFGE8 (milk fat globule-EGF factor 8 protein), and TSP1 
(thrombospondin)) also have a role in inflammation and homeostasis 
(Arandjelovic and Ravichandran, 2015).  The reason for multiple “find me” 
signals is not yet known.  Despite the various receptors, it is known that the 
PI3K/AKT pathway is essential for actin filament reorganisation which allow 
macrophages to migrate and to phagocytose (Qian et al., 2004, Schlam et al., 






















Figure 1.10 Phagocytosis of apoptotic cells in homeostasis.  Apoptotic cells release 
‘find me’ signals such as S1P which bind to receptors on apoptotic cells i.e. S1PR1 
thereby recruiting phagocytes such as macrophages.  Macrophages express several 
phagocytic receptors which bind to apoptotic cells leading to engulfment.   






 Sphifngosine-1-phosphate (S1P) is a bioactive lipid vital for leukocyte 
trafficking, vascular formation, and regulation of apoptosis and exploring its 
role in cancer has led to the classification of S1P as an onco-lipid (Spiegel and 
Milstien, 2003, Pyne et al., 2018).  Sphingosine-1-phosphate (S1P) is a 
component of the tumour microenvironments upon which malignant cells may 
be dependent.  A potent regulator of a diverse repertoire of biological functions, 
S1P impacts homeostasis and disease (Tsai and Han, 2016).  Erythrocytes and 
high-density lipoproteins (HDL) are the major source of S1P in the body 
(Spiegel and Milstien, 2003).  The higher concentration of S1P in the blood 
creates a gradient to the lower concentration of S1P found in tissues which 
allows for leukocyte migration (Aoki et al., 2016).  
 S1P is formed within the cell and transported out where  extracellular 
S1P can then bind to G-coupled protein receptors S1PR1, S1PR2, S1PR3, 
S1PR4, and S1PR5 (Hait and Maiti, 2017, Spiegel and Milstien, 2003, Blaho 
and Hla, 2014).  Because of its varied effects on proliferation and migration, 
S1P signalling has been targeted therapeutically in autoimmune diseases and 
being explored in cancer such as breast, colon and lymphoma (Chimen et al., 
2015, Kunkel et al., 2013, Ogretmen, 2018).     
1.4.1 S1P formation  
 Sphingosine-1-phosphate (S1P) is formed by the ATP-dependent 





2003).  This is reversible with SGPP1/SGPP2 or S1P can be permanently 
degraded with sphingosine-1-phosphate lyase (SPL) (Spiegel and Milstien, 
2011).  S1P concentrations are tightly controlled by its constant formation and 
degradation.   
SPHK1 is located in the cytosol and is responsible for the formation of 
extracellular S1P (Spiegel and Milstien, 2003).  The translocation of SPHK1 to 
the plasma membrane occurs in response to growth factors and agonists, and 
SPHK1 can regulate itself by inducing its own intracellular translocation back 
to the cytosol (Nishino et al., 2019). Its translocation and  phosphorylation is 
fundamental to the activity of SPHK1 (Nishino et al., 2019).  SPHK1 
phosphorylates sphingosine to form S1P which is then transported out of the 
cell through ATP-binding cassette type transporters (ABCC1, ABCA1, and 
ABCG1) or SPNS2 (Takabe and Spiegel, 2014).  Transported extracellular S1P 
formed primarily by SPHK1 is induced by the growth factor, PDGF, and/or 
inflammatory cytokines such as TNF-α and interleukins (Spiegel and Milstien, 
2011).  Signalling through G-coupled protein receptors, S1PR1-5, S1P then 
activates cellular pathways such as JNK, ERK, AKT, and Rho in order to 
mediate migration, proliferation, and angiogenesis (Figure 1.11) (Takabe and 
Spiegel, 2014, Kwong et al., 2015). 
SPHK2 is located in the nuclear membrane, endoplasmic reticulum and 
mitochondria has a contrasting role to SPHK1 (Maceyka et al., 2005, 
Ogretmen, 2018).  Intracellular S1P produced by SPHK2 inhibits histone 





(Maceyka et al., 2005, Chen et al., 2016).   Though SPHK1 and SPHK2 are 
said to produce functionally distinct S1P, studies with knockout mice show 
that they can compensate for the loss of the other thereby maintaining 







Figure 1.11 Inside-out signalling of S1P.  S1P formed by SPHK1 is 
transported out of the cell where it can signal in either a paracrine or 
autocrine fashion.  Binding to S1P receptors can increase or inhibit activation 
of ERK, AKT, PLC, Rho, JNK pathways depending on the receptor and cell 












Figure 1.12 Formation of S1P.  S1P is formed by phosphorylation by SPHK1 or 
SPHK2.  SPHK2 is the main source of intracellular S1P where synthesis can 
occur in the nucleus and endoplasmic reticulum (ER).  S1P produced here can 
inhibit HDACs.  SPHK2 can also form S1P in the mitochondria where S1P can 
bind PHB2.  SPHK1 can translocate to the cell membrane and form S1P that 
will be transported out of the and is transported out of the cell by ABC or 





S1P transport out of the cell is said to occur through several transporters.  The 
ATP-binding cassette (ABC) type transporters (ABCC1, ABCA1, and ABCG1) 
were the first to be identified, followed by Spns2 and ApoM which showed to be 
highly specific transporters for S1P out of the cell (Takabe and Spiegel, 2014, 
Mitra et al., 2006, Aoki et al., 2016). 
1.4.2 Sphingolipid rheostat 
 The formation of sphingosine/ceramide or conversely of S1P is known as 
the sphingolipid rheostat which illustrates the controlled responses of the cell 
to stress (Figure 1.13) (Newton et al., 2015).  This model of S1P-ceramide 
signalling emphasises the contrasting biological functions mediated by S1P 
and ceramide (Hatoum et al., 2017, Newton et al., 2015).   S1P formation by 
SPHK1 is in response to TNF-α which leads to activation of PI3K/AKT, ERK, 
and NF-κB pathways to promote proliferation and inhibit apoptosis (Osawa et 
al., 2001, Rutherford et al., 2013).  Conversely, cytokines such as TNF-α and 
Fas ligand induces ceramide production which leads to apoptosis and 
senescence (Spiegel and Milstien, 2011).  When S1P is transported out of the 
cell, it can bind to S1PR1 resulting in transport back into the cell creating a 


















Figure 1.13 Sphingolipid rheostat.  The balance between ceramide/ 
sphingosine and S1P maintains homeostasis in vivo.  Increased ceramide 
leads to increased apoptosis and cell cycle arrest while increased S1P confers 
survival and proliferations.  This diagram also reflects the “inside-out” 
signalling of S1P is transported out of the cell and signals the same cell 





1.4.3 S1P receptors 
 S1P can bind to five receptors; S1PR1 (EDG1), S1PR2 (EDG5), S1PR3 
(EDG3), S1PR4 (EDG6), and S1PR5 (EDG8) which couple to G-proteins that 
activate transcriptional pathways that lead to many different cellular 
processes (Pyne and Pyne, 2000).  Originally named endothelial differentiation 
genes (EDG) due to the discovery of S1PR1 (EDG1) was Hla and Maciag set 
out to determine possible molecular mechanisms involved in angiogenesis (Hla 
and Maciag, 1990).  They used human umbilical vein endothelial cells 
(HUVECs) treated with a known tumour promoter phorbol 12-myristate 13-
acetate (PMA) and isolated a cDNA clone that was induced, edg-1.  They noted 
that edg-1 had similar structure to G-coupled protein receptor although at this 
time its ligand was yet unknown (Hla and Maciag, 1990).  Discovery of the 
other S1P receptors quickly followed It wasn’t until 1998, when the ligand for 
edg-1 was determined to be S1P (Lee et al., 1998).  
 Cells can have different patterns of expression of S1P receptors that 
may alter depending on maturation or activation state (Blaho and Hla, 2014).  
The functional roles of S1P receptor signalling can vary depending on cell type 
as well as on the cytokines in the environment and there is considerable 
interest in the targeting of these receptors therapeutically (Figure 1.14).   
 There have been antagonists and agonists have been developed to target 
S1P receptors.  Fingolimod was the first S1PR agonist targeting S1PR1, 
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Figure 1.14 Drugs that target S1P signalling. S1P signals through five G 
coupled protein receptors which activates transcription pathways to regulate 
immune cell trafficking and activation.  There are a number of drugs currently 
available that selectively target these receptors.  There is an antagonist for 
S1PR2, JTE013, and an agonist, CYM5220 which were not included in this 





(Blaho and Hla, 2014, Bolli et al., 2010).  Siponimod (BAF312) is currently 
approved by the FDA for the treatment of multiple sclerosis and is specific for 
S1PR1 and S1PR5 (Kappos et al., 2018).  A single S1PR2 antagonist  has been 
developed, JTE013, but was found to target S1PR1 in vitro while an agonist to 
S1PR2, CYM5220, has shown to have superior specificity (Pyne and Pyne, 
2011, Satsu et al., 2013).  Targeting these receptors in cancer will require an 
understanding of the effect of the particular receptor in tissue of interest. 
S1PR1    
 S1PR1 has the highest affinity for S1P compared to other receptors 
(O'Sullivan and Dev, 2013).  Immune cells including macrophages, B and T 
cells, dendritic cells, and NK cells express S1PR1 which can mediate 
migration, proliferation, anti-apoptosis, and cytoskeletal assembly (O'Sullivan 
and Dev, 2013).  Binding with S1P leads to coupling of S1PR1 to G1 which 
results in the activation of ERK and PLC (phospholipase C) (Spiegel and 
Milstien, 2011). 
 In homeostasis, S1PR1 mediates egress of patrolling immune cells from 
primary and secondary lymphoid organs and migration through the blood 
(Spiegel and Milstien, 2011, Wang et al., 1999).  S1PR1 is vital for the 
formation of vasculature as shown through S1PR1-/- mice which have impaired 
vasculature (O'Sullivan and Dev, 2013, Lee et al., 1999).  Disruption of S1PR1 
signalling using antagonists has been known to have therapeutic benefits for 
patients with multiple sclerosis (MS).  FTY720 or fingolimod was approved for 





developed.  Siponimod, a specific S1PR1/S1PR5 antagonist, has been recently 
approved by the FDA for the treatment of MS (Kappos et al., 2018).   
S1PR2 
 Unlike S1PR1, S1PR2 has been shown to reduce migration.  Cells that 
express high levels of S1PR2 will result in retention in the primary or 
secondary lymphoid organs.  Binding of S1PR2 to S1P which leads to coupling 
G1, Gq, and G12/13 resulting in upregulation of Rho and downregulation of Rac 
and AKT/PTEN (Sanchez and Hla, 2004).  It was also shown that binding of 
S1P to S1PR2 antagonises S1PR1-G1-PI3K.  S1PR2 has been shown to be 
critical in the formation of vasculature, where S1PR2 signalling results 
increased permeability which can be blocked by S1PR2 antagonist, JTE013.  
S1PR2 has been implicated in DLBCL, where S1PR2-/- mice were shown to 
develop DLBCL as they age (Aoki et al., 2016, Cattoretti et al., 2009).   
S1PR3 
 S1PR3 coupled with G1, Gq, and G12/13 activates ERK, and Rho/Rac 
inducing proliferation and migration (Sanchez and Hla, 2004).  Mediation of 
inflammatory responses and regulation of cardiac functions such as 
vasoconstriction and vasodilation are proposed roles for S1PR3 (Sanchez and 
Hla, 2004).  Intracellular signalling of S1PR3 is reported to have vital role in 
immune responses to bacteria mobilising monocytes to enhance bactericidal 






 Less is known about S1PR4 but some researchers report that dendritic 
cells and neutrophils are regulated by S1PR4 (Olesch et al., 2017, Sanchez and 
Hla, 2004).  It was also shown that S1PR4 may regulate development of 
peripheral immune blood cells(Sanchez and Hla, 2004).   S1PR4 couples with 
G1 and G12/13 leading to activation of ERK and PLC pathways as well as 
inducing MAPK and RhoA pathways which can affect actin filament assembly 
(Olesch et al., 2017, Xiong et al., 2019).     
S1PR5 
 S1PR5 couples with G1 and G12/13 and is important in the trafficking of 
NK cells from the bone marrow and shown to be highly expressed in patrolling 
monocytes and by cells of the central nervous system (Debien et al., 2013, Tsai 
and Han, 2016).  It was also shown that S1PR5 mediated cell survival in 
mature oligodendrocytes and to induce protective effect of autophagy in PC-3 
(prostate cancer) cell line (Chang et al., 2009). 
1.4.4 S1P and macrophage recruitment and function 
 Migration mediated by S1PR1, S1PR2 and S1PR3 were shown through 
experiments by Kon et al.  They stably transfected Chinese hamster ovary 
(CHO) cells with S1PR1, S1PR2 and S1PR3 then examined the migration of 
these cells along an S1P gradient (Kon et al., 1999).  They found that the 
S1PR1 and S1PR3 transfected cells migrated but S1PR2 transfected CHO 





phagocytosis.  It has been shown that alveolar macrophages from chronic 
obstructive pulmonary disease (COPD) patients were found to be less 
phagocytic compared to macrophages from healthy donors mediated by S1PR2 
expression (McQuiston et al., 2011).  Another study a similar result has shown 
that low expression of S1P2 led to better bacterial clearance and survival in 
patients with sepsis (Hou et al., 2015). These results point to a role of S1P in 
macrophage recruitment and function in inflammation. There are many 
studies which focus on the effects of S1P on migration and retention of 
macrophages in inflammation and in cancer (Yang et al., 2018, Weichand et 
al., 2017, Muller et al., 2017, Nagahashi et al., 2018a, Hait and Maiti, 2017). 
1.4.5 S1P in inflammation and cancer 
 Evidence of the oncogenic potential of SPHK1 and S1P came through 
experiments that demonstrated that the overexpression of SPHK1 
transformed NIH3T3 cells to fibrosarcoma (Pyne et al., 2018).  While non-
malignant cells contribute to S1P in the microenvironment, the neoplastic cells 
were the main source of SPHK1 expression and that S1P produced by SPHK1 
was responsible for the “inside-out” signalling (Nagahashi et al., 2018b, Pyne 
et al., 2018).  S1P is controlled by constant formation and degradation with 
lyases and phosphatases. The expression of these lyases and phosphatases 
(SGPP1 and SPL) were found to be under expressed in tumours compared to 
normal in gastric and breast cancers (Nakajima et al., 2017)  In addition, the 
malignant and non-malignant cells within the tumour have different patterns 





the TME to maintain proliferation, foster an anti-apoptotic environment, and 
induce alternatively activate macrophages to secrete anti-inflammatory 
cytokines (Nakajima et al., 2017).   
Tumours have been shown to rely on angiogenesis for trafficking, 
metastasis, and for their supply of essential nutrients  (Nucera et al., 2011, 
Shen et al., 2016).  S1P is shown to be involved in the recruitment of 
endothelial cells via S1PR1 to the tumour site and to enhance vascular 
formation (Zhang et al., 2013, Eklund et al., 2013).  S1P not only mobilises and 
recruits immune and endothelial cells to the microenvironment, but will also 
facilitate metastasis of tumour cells through the vasculature in tumours such 
as melanoma, breast, thyroid cancer cells  (Zhao et al., 2018, Nagahashi et al., 
2018b, Rodriguez et al., 2016, Wang et al., 2019).  S1P can foster an immune 
suppressive environment by alternatively activating macrophages and 
mediating the release of cytokines such as IL-10 and inhibition of IL-12 
(Weigert et al., 2007, Guillermet-Guibert et al., 2009, Maiti et al., 2017).  
 In homeostasis, S1P released from apoptotic cells protects macrophages 
from apoptosis and tumour cells have co-opted this in order to protect itself 
from chemotherapy-induced apoptosis (Guillermet-Guibert et al., 2009).  
Apoptosis is important for the resolution of inflammation as neutrophils are 
induced to apoptosis by the inhibition of S1P signalling (Perez et al., 2019).  
S1P can also have contradictory effects by inducing apoptotic effects as well as 
proliferative anti-apoptotic effects on the same cell depending on certain in 





(Gennero et al., 2002); ovarian cells in culture, if they are in suspension S1P 
induces apoptosis but induces survival if they are attached (Hong et al., 1999); 
and in hepatic myofibroblasts, which are important in the development of liver 
fibrosis, the balance of apoptosis and survival in hepatic myofibroblasts is 
mediated by S1PR1, S1PR2 and S1PR3 (Davaille et al., 2002).   
The effect of S1P on DLBCL pathogenesis has largely come from the 
observation that S1PR2 KO mice developed DLBCL as they aged (Cattoretti et 
al., 2009).  This observation has been further cemented by work of Stelling et 
al and Vockerodt et al which demonstrated that S1PR2 is a tumour suppressor 
in DLBCL absent mainly in the ABC subtypes.  Stelling et al found that 
S1PR2 expression in ABC-DLBCL was linked to a decrease in SMAD1/TGFβ1 
and an increase in FOXP1 expression (Stelling et al., 2018).  Interestingly, 
SMAD1 embryonic knockout mice do not form mature macrophages suggesting 
a link between S1PR2 and mature macrophages (McReynolds et al., 2007).  
Vockerodt et al further showed that in EBV+ DBCL, an increase in LMP1/AKT 
expression led to low expression of S1PR2 and that S1PR2 expression 
inhibited phospho-AKT (Vockerodt et al., 2019).   
There was one study which indicated that increased S1PR1 expression 
was associated with poor survival in DLBCL (Paik et al., 2014).  Paik et al 
found that S1PR1 as an independent prognostic indicator of OS in both GCB 
and non-GCB patients treated with R-CHOP.  S1PR1 and STAT3 expression 
was linked to poorer OS mainly in ABC-DLBCL (Paik et al., 2014). Our group 





(Lupino et al., 2019).   Further exploration of S1PR1 signalling in the 
pathogenesis of DLBCL has yet to be done but these findings suggest that 
therapeutically targeting S1PR1 in DLBCL may be beneficial.   
1.5 Hypothesis and aims 
 The combination of rituximab and chemotherapy make up the standard 
of care for all patients with DLBCL regardless of subtype.  Currently about 
40% of these patients do not respond or will relapse leaving them with few 
treatment options.  Because of the role S1P in macrophage recruitment and 
evidence of its involvement in the pathogenesis of DLBCL, studying the effects 
of S1P in the context of macrophage recruitment in DLBCL is worthwhile.  
Especially as ADCP is the primary cytotoxic mechanism of rituximab (part of 
the standard of care of DLBCL) which is exerted by macrophages 
(VanDerMeid et al., 2018).   It has been shown that S1P can exert 
contradictory functions on the same cell depending on certain conditions which 
may include macrophages.  Therefore, it is important to evaluate the 
conditions in which S1P effects recruitment and function of macrophages in 
the context of DLBCL.   
 Therapeutic modulation of S1PRs on macrophages could be an 
alternative treatment strategy for DLBCL.   But our current knowledge of the 
pattern of expression of the five S1P receptors on macrophages is limited to 
mouse macrophages (Muller et al., 2017).  It would be advantageous to study 





The expression of S1PR1 on primary human macrophages has been reported 
but the expression of the other S1P receptors has not been fully explored 
(Weichand et al., 2013a).  The effect of S1P on macrophages has focussed 
mainly on its role in recruitment and retention.  S1PR1 has also been 
implicated in the formation and recruitment of endothelial cells, and but up to 
now, its effect on macrophage function in DLBCL has not been fully explored.   
 This project will determine if S1P contributes to the recruitment of 
macrophages in DLBCL and the increased S1P concentration in the 
microenvironment could affect macrophage function.  The specific aims of this 
study are: 
1. Confirm the overexpression of SPHK1 in DLBCL and survey genes 
associated with macrophage recruitment and function for their 
differential expression in primary DLBCL datasets and correlation with 
SPHK1 expression;   
2. Evaluate the expression of S1P receptors in polarised macrophages from 
healthy donors;  
3. Determine if macrophages migrate to DLBCL in an S1P-dependent 
manner in vitro and in mouse models of DLBCL; 
4. Examine the effect of S1P on the phagocytosis of rituximab-treated 
DLBCL cell lines and determine which S1P receptor(s) are involved; 
5. Test the effect an S1P receptor antagonist on tumours from DLBCL 












CHAPTER 2  








Materials and Methods 
2.1 Cell line cultivation and cryopreservation 
 Human DLBCL cell lines were obtained from ATCC (American Type 
Culture Collection).  The FBS used in all experiments was heat inactivated.  
All cell lines were maintained in RPMI-1640 (GIBCO, Life Technologies) 
supplemented with 10% FBS (heat-inactivated foetal bovine serum, 
Invitrogen) except for OCI-LY1 which was maintained in IMDM (GIBCO, Life 
Technologies) + 20% FBS.  A20 mouse lymphoma cell line was a gift from M. 
Hoogenkamp and THP-1 (ATCC) were maintained in RPMI-1640 + 10% FBS + 
Glutamax + 10mM HEPES + 1mM Na Pyruvate + 0.05mM 2-mercaptoethanol 
(all from GIBCO, Life Technologies) See Table 2.1 for summary of cell lines.  
Cells were incubated in a humidified incubator (RS, Biotech) set at 37°C 5% 
CO2 and cultured according to ATCC guidelines.   
 Cells were counted first by doing a 1:10 or 1:100 dilution in trypan blue 
(Sigma Aldrich) then 10 l was added to a Neubauer haemocytometer 
(BLAUBRAND, Sigma Aldrich).  Cells were observed through an inverted 
microscope (Olympus CK30) and live cells were counted (those that did not 
take up trypan blue dye) within the four large corners.  The number of cells 
were divided by 4 and then multiplied by the dilution factor of 10 or 100 and 





 To cryopreserve cell lines, they were washed in PBS and resuspended in 
10% Dimethyl sulfoxide Hybri-max (DMSO, Sigma-Aldrich) + 90% FBS 
(GIBCO, Life Technologies) at approximately 1x107 /ml per cryovial (NUNC).  
They were stored in a Mr Frosty (Nalgene) cryogenic container at -80°C for up 
to one week then stored in liquid nitrogen long term.  To thaw, cells were 
briefly warmed in a 37°C water bath until just melting and immediately 
transferred to 9mls of cold RPMI-1640 (GIBCO, Life Technologies).  They were 
then centrifuged at 1000 RPM for 10 minutes in an Eppendorf 5810R 
centrifuge.  Supernatant was aspirated and cells were resuspended in 10 ml of 
complete growth medium (Table 2.1). 
2.2 Patient and donor samples  
2.2.1 Ethical approval for research with human tissue 
 Patient DLBCL sections were obtained with ethical approval from the 
Human Biomaterials Resource Centre (HBRC, Birmingham) and Birmingham 
Women’s and Children’s Hospital (BWCH) (HBRC_10_022).  Frozen DLBCL 
single cell suspensions were obtained with ethical approval from NHS GG&C 
Biorepository (NHS Glasgow Application/approval number 234).  Tonsils were 
obtained with consent from adult patients from Queen Elizabeth Hospital (QE, 
Birmingham) and fixed in 10% neutral buffered saline and embedded in 
paraffin or made into single cell suspensions (HBRC_12_071).  Leukocyte 
cones were obtained with consent through the National Blood Service and used 





blood and reactive lymph nodes were obtained with consent through HBRC 
from BWCH and QE (HBRC_15_217).   
2.2.2 Preparation of patient tissue for in vitro experiments 
 Patient lymphoma, reactive lymph nodes and tonsils were divided for 
(A) single cell suspensions and (B) for paraffin embedding.    
 (A) To prepare single cell suspensions, a portion of the tissue was briefly 
immersed in 70% ethanol and then in sterile PBS.  Tissue was then placed in 
70µM cell strainer which was placed over 60mm tissue culture dish with 3 ml 
sterile serum free RPMI (SF-RPMI).  The tissue was chopped to a mush with 
sterile scissors then mashed through the strainer with the rubber end of a 
syringe plunger.  The cells in single cell suspension were transferred to a 50 ml 
conical tube and brought up to 20 ml with SF-RPMI. Then 10ml of lymphoprep 
(Axis Shield) was placed into a fresh 50 ml conical tube and the cell suspension 
was carefully layered over the top.  The tubes were centrifuged at 1400 RPM 
for 30 minutes without brake at room temperature in an Eppendorf bench top 
centrifuge.  The buffy coat layer was removed into a fresh tube and topped up 
to 20 ml with SF-RPMI and counted as described in the previous section.  Cells 
were then spun and resuspended to no more than 1x108 cells/ml with 10% 
DMSO + 90% FBS.  One ml of cells was added to each cryovial (Nunc) and then 
placed in a Mr Frosty filled with 2-propanol (Fisher).  The Mr Frosty was kept 
in -80°C overnight to 1 week and then transferred to liquid nitrogen for long 





 (B) For paraffin embedding, tissue was fixed in 10% neutral buffered 
saline (Surgipath, Leica) for at least 48hrs.  Tissue was embedded in paraffin 







Table 2.1 Summary of DLBCL cell lines used  
* Mouse lymphoma cell line  
Abbreviations: RPMI1640 – Roswell Park Memorial Institute 1640 medium; FBS – foetal bovine 
serum (heat inactivated); IMDM – Isocove’s modified Dulbecco’s medium; GCB-DLBCL – 
germinal centre B cell like diffuse large B cell lymphoma; ABC-DLBCL – activated B cell like 
diffuse large B cell lymphoma; EBV – Epstein Barr Virus; HL – Hodgkin lymphoma.  
 









tumour from aging 
BALB/c mouse 
RPM1 1640 + 10%FBS + 2mM 
L-glutamine+ 1mM HEPES, 
1mM Na Pyruvate + hi L-





From inguinal tumour 
from 5yr female.  
Reclassified from 
Burkitt lymphoma 




From lymph node 
EBV+ 70yr female 




From ascites of 70yr 
male 




From a pleural effusion 
from 73yr female 




From bone marrow of 
44yr male 




From bone marrow of 
52yr male 




From peripheral blood 
of 48yr male 





effusion of 38yr male 





effusion of 17yr female 





effusion of 43yr  male 




From ascites of 29yr 
female previously with 
HL 






2.3 In vitro monocyte/macrophage experiments 
2.3.1 Human monocyte isolation and macrophage polarisation 
 Peripheral blood monocytes were isolated from leukocyte cones.  Blood 
was diluted with RPMI 1640 to 20 ml and layered over 10ml of lymphoprep 
(Axis Shield) then centrifuged at 1400rpm for 30 minutes without brake.  
Buffy coat layer was removed and washed in RPMI1640.  Cells were counted 
by trypan exclusion and resuspended in 800l of mini macs buffer (Table 2.2 
for recipe).  Then CD14-positive cells were isolated using Miltenyi human 
CD14+ magnetic beads according to manufacturer’s protocol.   
 CD14+ cells were resuspended to 2x107 cells/ml in macrophage medium 
(RPMI1640 + GLUTAMAX + 10% FBS all from GIBCO, Life Technologies).  
0.5-1 ml of cell suspension was added to 9 cm petri dishes (uncoated) and 9 ml 
of macrophage medium (mac medium, see Table 2.2) supplemented with 
5ng/ml human GMCSF (Peprotech) to polarise to M1 and 25 ng/ml human 
MCSF (Peprotech) to polarise to M2.  Cells were incubated for 7-10 days with a 





















50ml 10x d-PBS (GIBCO, Life Technologies) 
2ml   0.5mM EDTA pH 8.0 (Fisher) 
2.5g BSA (Sigma) 
38ml distilled water 
 
Heat to dissolve BSA then bring up to 500ml with distilled water 
and filter sterilise.  
 
Mac Medium 
500ml RPMI-1640 (GIBCO, Life Technologies) 
50ml    heat inactivated FBS (GIBCO, Life Technologies) 




0.25g citric acid (Fisher) 
1.26g sodium citrate (Fisher) 
800ml distilled water 
pH to 6  
Bring to 1L with distilled water 
 
TBS-T 
1.21g TRIS (Sigma Aldrich) 
8.77g NaCl (Sigma Aldrich) 
0.5ml Tween-20 (Thermo Scientific) 
1L distilled water 
PBS-T 








2.3.2 Flow cytometry of human monocytes and macrophages  
 CD14 monocytes from day of isolation and M1 and M2 polarised 
macrophages were analysed by flow cytometry using a panel of antibodies 
(Table 2.3).  Cell surface staining was done with CD14 and CD206 by adding 
antibodies at 1:100 dilution and incubating 20 min in the dark at 4°C.  The 
cells were then permeabilised using BD Cytofix/ Cytoperm according to 
manufacturer’s instructions prior to adding CD163 and CD68 at 1:100 dilution 
for 30 min and washing and resuspending in 1% FBS/PBS. Samples were 
analysed on a BD LSRII flow cytometer and data analysed using BD FACS 
DIVA v8.  BD CompBead anti-mouse (BD Biosciences) was used for single 








Table 2.3 List of antibodies for flow cytometry 
Antibody Clone Isotype Fluorophore Company 




































Efluor-450 Thermo Fisher 48-9459-42 
CD68* Y1/ 82A 
IgG2b 
kappa 
PE-Texas red Thermo Fisher 61-0689-42 
CD163 GH/ 61 
IgG1 
kappa 








APC R & D Systems FAB2016A 








FITC Thermo Fisher 11-0032-82 
CD11b M1/ 70 
IgG2b 
kappa 












Alexa Fluor 700 Thermo Fisher 56-0451-82 
F4/ 80 BM8 
IgG2a 
kappa 
PE Thermo Fisher 12-4801-82 
LY6 G RB6-8C5 
IgG2b 
kappa 
PerCP/Cy5.5 Biolegend 108428 






2.3.3 ELISA for IL-10/IL-12 and Human Cytokine Array 
 M1 and M2 macrophages were plated at 1x105 cells/well in 24-well low-
attachment plates (Corning).  50ng/ml of LPS, vehicle (4% fatty-acid free BSA 
in PBS), 1M S1P or 50ng/ml LPS+1M S1P was added to appropriate wells 
(all from Sigma Aldrich Aldrich). The cells were incubated 18-24hrs, and then 
cell culture supernatant was harvested and stored in -20°C.  Human IL-10 and 
IL-12 ELISAs (Biolegend) were performed as set out in the manufacturer’s 
protocol with the exception that assays were plated in 96-well plates with ¼ 
well volumes (Corning).  ELISAs were analysed on a Bio-Rad microplate 
reader spectrophotometer at wavelength 495nm and analysed using GraphPad 
Prism v8 software.   
 Thirty-five cytokines were also examined in the M1 and M2 macrophage 
conditioned medium from day 7 cultures.  Proteome Profiler Human Cytokine 
array kit (ARY005B) from R&D Systems was used according to manufacturer’s 
instructions.  ChemiDoc MP imaging system (BioRad) was used to acquire 
images until saturation of the positive controls were reached.  The images 
were analysed using ImageLab software v4.1.   
2.4 Xenograft/syngeneic grafts of DLBCL 
2.4.1 Application of NC3Rs and experimental design  
 All experiments involving animals for this thesis were done according to 





published by the National Centre for the Replacement Refinement & 
Reduction of Animals in Research (NC3Rs) (Kilkenny et al., 2010).  The 
Experimental Design Assistant (EDA) was available on-line at 
https://www.nc3rs.org.uk/experimental-design-assistant-eda which was used to 
design and determine sample sizes for each experiment.  A power calculation 
at 80% power with 95% confidence was used to determine sample sizes.     
2.4.2 Measuring tumours and calculating tumour volume 
 Once tumours were palpable, measurements were recorded at least 
2x/week.  Tumours were measured in two-dimensions (width and length) using 
calipers in millimetres (mm).  Tumour volumes were calculated using the 
formula (Blumenthal, 2005): 
tumour volume mm3 = ((width)2 x (length)) / 2 
where width was considered the smaller of the two measurements.   
 For treatment experiments, tumour volumes at initiation of treatment 
was considered initial tumour volume.  Tumour volumes at experimental 
endpoint was considered final tumour volume.  The change in tumour volume 
for each mouse was calculated using the formula: 
Δ tumour volume (mm3) = tumour volume final – tumour volume initial 






% Δ in tumour volume = (Δ tumour volume/ tumour volume initial)/ x 100 
As described in Chemosensitivity edited by Blumenthal and in accordance 
with the guidance written by Jackson Laboratory  (Blumenthal, 2005, 
Measuring treatment response in Patient Derived Xenograft (PDX) models at 
The Jackson Laboratory, 2017). 
2.4.3 Syngeneic A20 model 
 A20 cells were injected at 3x106 cells/mouse in the tail vein or 
subcutaneously in the flank of BALB/c mice (female 6-9 weeks old, Charles 
River).  A20 injected mice were monitored for engraftment using calipers to 
measure tumours.  Intravenously injected mice are monitored by palpation of 
the abdomen to assess for enlarged spleen or liver.  Mice were culled by 
Schedule 1 at experimental endpoint or at humane endpoints i.e. maximum 
tumour size 1.1cm or >18% weight loss. 
2.4.4 Xenografts using DLBCL cell lines 
 OCI-Ly1, OCI-Ly3, and SUDHL6 were used for in vivo experiments. A 
total of 3x106 cells/mouse was injected subcutaneously in the flank of NSG 
(female 6-8weeks, Charles River) mice.  Mice were monitored for engraftment 
by palpation of flank and when tumours were palpable, calipers were used to 
measure tumours.  Mice were culled by Schedule 1 at the experimental 
endpoint or at humane endpoints i.e. maximum tumour size 1.1cm or >18% 





2.4.5 Preparation of stock compounds used in vivo for treatments 
 Compounds and vehicles used for in vivo experiments are summarised 
in Table 2.4.  The stock concentration of vincristine (Sigma) was 10mg/ml in 
water for injection and stored in aliquots in -20°C. Stock doxorubicin (Sigma) 
was diluted to 5mg/ml in water for injection and stored in aliquots in -20°C. 
BAF312 (siponimod, SelleckChem) was diluted to 100mg/ml in DMSO-
Hybrimax (Sigma-Aldrich) to a milky white consistency and stored in aliquots 
at -20°C.  BAF312 was further diluted for oral administration in vehicle; 10% 
2-Hydroxypropyl-β-cyclodextrin (Cayman Chemicals) in sterile distilled water. 
2.4.6 In vivo efficacy experiments and statistical analysis 
 For the A20 model injected SC in the flank, solid tumours appeared 
around day 7-10.  IV injected mice were randomised and treated on day 4 and 
culled on day 30 as previously determined by an engraftment pilot study.  For 
the DLBCL cell line model, solid tumours appeared on day 14-21 post injection 
then randomised.  For all experiments, mice were randomised into treatment 
groups using a random number generator from GraphPad QuickCalcs free 
website (https://www.graphpad.com/quickcalcs/).  Mice with subcutaneous 
tumours were randomised when 75% of experimental mice had measurable 
tumours.  After randomisation, the average initial tumour volumes for each 
group was calculated.  Then using a method of stratified randomisation, each 
group was allocated an even distribution of the large, medium, and small 





average tumour volumes for each group on the initial day of treatment was as 
close to 1 as possible and therefore, as equal as possible.   
Treatments used in vivo are as follows:  
 The maximum tolerated dose of vincristine in mice is 1mg/kg IV once a 
week and for doxorubicin 5mg/kg IP twice a week (both Sigma-Aldrich) in 
vehicle, water for injection, confirmed in previous pilot experiments and in 
accordance with published work (Thompson et al., 1999, Mayer et al., 1990).  
Combination treatments in vivo were given by the following schedule and dose: 
single dose of vincristine at 0.5 mg/kg IV and 24hrs later rituximab 1mg/kg 
(MabThera, Roche) was given IV twice a week.  These doses were confirmed in 
previous pilot experiments.  BAF312 (siponimod, Selleck Chem) at 3mg/kg oral 
gavage was given three times a week as a single agent in accordance with 
published work (Gergely et al., 2012). See table 2.4 for treatment dosing and 
schedule. Blinding was employed at analysis stage where samples are coded 
during processing for flow cytometry, IHC, and further ex vivo analyses.   
 From previous work, I have found the in vitro IC50 does not correlate 
with in vivo efficacy.  This may be due to the complex mechanisms of action of 
some drugs in vivo as well as the ability of the mouse to clear and metabolise 
the drug.  For in vivo efficacy experiments, I would begin with 5 to 10 times 
the in vitro IC50 using the appropriate route of administration and scaling up 
dose as required.  All doses are first tested by performing a dose escalation 





in order to monitor any adverse effects or safety issues.  Initial dosing schedule 
is based on pharmacokinetic data obtained from collaborator or drug 
manufacturer.  Pilot studies were then performed to determine efficacy of 
tolerated/safe doses from the dose escalation studies. 
 Pilot studies to evaluate in vivo growth kinetics were completed in order 
to determine the appropriate window for treatment.  These pilot studies also 
allowed us to estimate the standard deviation of tumour engraftment of future 
experiments. Using this estimated standard deviation, I then used the UCSF 
Sample Size calculator (http://www.sample-size.net/) or EDA from the NC3Rs 
to calculate the appropriate sample size at 80% power to detect a difference of 














Table 2.4 Drugs used for in vitro and in vivo experiments 
 
Abbreviations: PBS – phosphate buffered saline; DMSO – dimethyl sulfoxide; PO – oral 

















water for injection 
Sigma-Aldrich 
D1515 
5mg/kg IP 2x/week 
human IgG  
isotype 
water for injection Invitrogen 02-7102 1mg/kg IV 3x/week 
rituximab 
(MabThera) 
ready to use ROCHE IV infusion 1mg/kg IV 3x/week 
vincristine 
(oncovin) 
water for injection 
Sigma-Aldrich 
V8879 












 water for injection 












2.5 IC50 determination 
 Appropriate seeding density for each cell line was calculated by using 
doubling time information from ATCC and DSMZ websites such that the 
maximum density would be reached in 96hrs: A20 (1x105 cells/ml); OCI-Ly1 
(1x106 cells/ml); OCI-Ly3 and SUDHL6 (2.5x105 cells/ml).  Cells were then 
plated at this seeding density into 96-well white bottom plates (Corning) in 
80l per well with complete medium.  Then compounds were serially diluted 
into 8 concentrations including a vehicle treatment and no cell controls at 5x 
the final concentration.  Appropriate vehicle or drug concentrations were 
added in 1:5 dilution (20l per well) in sextuplicate treatments to the 80l of 
cells for a total volume of 100µl. The perimeter wells of the 96-well plate were 
filled with PBS to prevent evaporation and edge effects from incubation.  
Plates were incubated at 37°C for 96hrs and then Cell Titre Glo solution from 
Promega was prepared and added to wells according to manufacturer’s 
instructions.  Plates were analysed on a VICTOR plate reader to measure 
luminosity.  Percent death of treated samples compared to control was 
calculated and the IC50 determined using GraphPad Prism v8 software. 
2.6 Sphingosine-1-phosphate for in vitro use 
2.6.1 Preparation of sphingosine-1-phosphate stock solution 
 A 95:5 ratio of methanol (Sigma Aldrich 676780) to diH2O solution was 
prepared.  The methanol: water solution was filtered through a 0.22µM syringe 





Sigma Aldrich) for a final concentration of 0.5mg/ml.  To dissolve S1P, the vial 
was gently vortexed and then heated to approximately 65°C in a water bath for 
10 minutes.  After incubation, the glass vial was placed in an ultrasonic water 
bath briefly until fully dissolved.  Low retention pipette tips (Corning) were 
used when pipetting S1P for all experiments.  The stock of dissolved S1P was 
stored in -20°C for up to 1 year.   
 To prepare S1P for experimental use, 50l of stock S1P was aliquoted 
into glass vials and allowed to evaporate in a biosafety cabinet for 3hrs or until 
a dried film was observed.  Dried aliquots of S1P were stored in -20°C for up to 
1 year.  To prepare working concentration of 125 M S1P, 520l of sterile 
4mg/ml fatty-acid free BSA (Sigma Aldrich) was added to the vial and 
incubated for 20 minutes at room temperature on a rolling platform.  The S1P: 
BSA solution was never vortexed as this caused bubbles resulting in lost 
volume.  Diluted S1P: BSA was stored in -20°C for up to 3 months. 
2.6.2 Neutralising sphingosine-1-phosphate with Sphingomab 
 Sphingomab LT002 (12.1 mg/ml) and isotype control LT0015 
(12.7mg/ml) (gift from Roger Sabaddini) were stored at -20°C.  1μM S1P was 
neutralised with 1μg/ml of Sphingomab or incubated with isotype control for 1 





2.7 Preparation of DLBCL cell line conditioned medium  
 To prepare conditioned medium from DLBCL cell lines, cells were 
diluted to 1x106 cells/ml in fresh complete medium.  Cells were incubated 
24hrs in a humidified incubator set to 37°C and 5% CO2.  After 24hrs, the 
conditioned medium was collected, centrifuged at 1500 RPM for 5 minutes, 
filtered through a 0.22μM syringe filter and used immediately or stored at        
-20°C.   
2.8 In vitro migration assay 
 Migration assays were performed in 24-well plates low-attachment 
plates (Corning) with 3 µM pore size cell culture inserts with high density PET 
membrane (Corning 353492). M1 and M2 macrophages were harvested and 
suspended to 1x106 cells/ml in complete mac medium.  To the bottom of the 24-
well plate, 600 l of conditioned medium was added then the cell culture insert 
was placed into the well. Into the cell culture insert, 100 l of M1 and M2 cell 
suspension was added then incubated for 4 hrs at 37°C.  Migrated cells were 
harvested into 5 ml Falcon polystyrene round-bottom tubes (Corning 352052) 
and washed with 1 ml PBS.  After centrifugation at 1500 RPM for 3 minutes, 
the supernatant was aspirated and the cells were resuspended in 300 l of 
PBS then counted using BD LSRII flow cytometer.  Acquisition was set to 40 
seconds per sample.   The volume of sample taken up by the flow cytometer 
within 40 seconds was calculated by measuring the remaining volume.  This 





2.9 Phagocytosis assay 
2.9.1 Phagocytosis assay with FITC + latex beads 
 M1 and M2 macrophages were stained with eFluor450 dye 
(Thermofisher) according to manufacturer’s instructions. Then macrophages 
were washed and then pre-treated with 1M S1P or vehicle for 1 hr at 37°C in 
1% FBS-mac medium.  After pre-treatment, M1 and M2 macrophages were 
divided into the appropriate number of tubes at 1x105 cells/100 l per tube.  
FITC positive rabbit IgG coated latex beads (Cayman Chemical) were spiked 
into each tube in a 1:100 dilution of and incubated for a further 1.5hrs at 37°C.  
The protocol was followed according to the manufacturer’s instructions. 
Diluted trypan blue included with the kit was added to quench signal from un-
engulfed FITC+ beads.  Then samples were kept cold during washes with 
assay buffer until analysis with the BD LSRII flow cytometer.  BD FACs DIVA 
v8, EXCEL v10, and Graph Pad Prism v8 were used for analysis of 
phagocytosis. Student’s t-test was used to calculate p-values. 
2.9.2 Phagocytosis assay with DLBCL cell lines 
 Dead cells from DLBCL cell line cultures were removed by lymphoprep 
(Axis Shield) the day before phagocytosis assay.  On the day of the assay, 
DLBCL cell lines and macrophages were harvested and counted.  M1 and M2 
macrophages were stained with CFSE cell tracking dye (Becton Dickinson) and 
DLBCL cell lines were stained with eFluor-450 cell tracking dye (eBioscience, 





macrophages were resuspended to 1x106 cells/ml in 1% FBS-mac medium and 
pre-treated with vehicle or 1M S1P for 1 hr at 37°C.  EFluor-450 positive 
DLBCL cell lines were resuspended to 1x106 cells/ml in 1% FBS-RPMI1640 
and pre-treated with isotype control (human IgG, Thermo Fisher), rituximab 
10 g/ml or ofatumumab 10 µg/ml, an alternative anti-CD20 monoclonal 
antibody (gift from Professor Stankovic) for 2-4hr at 37°C.   
 Pre-treated DLBCL and M1 or M2 macrophages were then co-cultured 
by adding 100 l of each into polystyrene round bottom FACs tubes or 8-well 
chamber slides at 37°C for 1.5hrs in the following combinations: single, vehicle 
+ isotype, vehicle + rituximab, S1P + isotype (IgG, Invitrogen), and S1P + 
rituximab or ofatumumab (both at 10µg/ml).  Each sample was then washed in 
cold 0.9% NaCl + 0.1% EDTA and then resuspended in cold PBS.  Samples 
were then analysed on BD LSRII for CFSE positive / eFluor 450 positive cells.  
At least 10,000 events were acquired and the total number of cells 
phagocytosed was calculated by total FITC+ macs/all macs counted. Analysis 
was done using BD FACS DIVA v8, EXCEL v10, and Graph Pad v8 and 
student’s t-test was used to calculate p-values.  Stained CFSE macrophages +/-
S1P with stained eFluor45 DLBCL cell lines were plated in triplicate on 8-well 
chamber slides.  After 1.5hr incubation, slides were fixed in formal saline for 







2.10 Annexin V/PI assay  
 DLBCL cell lines were plated at 1x106 / ml and treated with vehicle or 
drug at various concentrations for 24 hrs.  Samples were harvested and 
stained using BD Annexin V FITC kit I (Becton Dickinson) according to 
manufacturer’s instructions.  Samples were analysed on BD LSRII flow 
cytometer and BD FACS Diva 8 software within 1hr of addition of Annexin 
V/PI.    
2.11 Protein extraction and determination of 
concentration 
 Cell pellets were lysed using 1x RIPA buffer (Cell Signaling) + 1μM 
PMSF (Sigma Aldrich) and passed through 19G syringe (Terumo).  For lysates 
to be used to examine phosphorylated proteins, 1mM sodium orthovanadate 
(SOV) in PBS was added to cell pellets before lysing in RIPA buffer.  Lysates 
were centrifuged at 4°C max speed for 10 min and placed into fresh protease 
free microfuge tubes.  Lysates were stored long term at -80°C.   
 Concentration of protein was determined using protein assay reagent 
(BioRad) according to manufacturer’s instructions.  Stock 1mg/ml of bovine 
serum albumin (BSA, Sigma Aldrich) was used to prepare serial dilutions at 0, 
0.1, 0.2, 0.3, 0.4, 0.5 mg/ml for standard curve.   BSA standards and proteins of 
unknown concentration (neat or diluted 1:10) was loaded in triplicate in 96 
well flat bottom plate.  A 1:5 dilution of BioRad protein assay reagent in water 





microplate reader was used to measure absorbance at 595nm. Plotting of 
standard curve and interpolation of unknowns were done using GraphPad 
Prism v8 software.   
2.12 Western blot analysis 
 Protein previously isolated was diluted with 2x Laemmli Sample Buffer 
(BioRad) to the same concentration in all samples (usually 50 µg).  Samples 
were boiled at 95°C for 10 minutes and then immediately loaded into pre-cast 
10% SDS-page gel (BioRad).  Gels were run in 1x tris-glycine running buffer 
(Geneflow, Ltd.) at 120v for 1.5-2hr. 
 Proteins were transferred from gel onto nitrocellulose membrane (Bio 
Rad) using ready to use Trans-Blot Turbo Mini transfer packs along with the 
Trans-Blot Turbo Transfer System from Bio Rad at 25V for 7 min.   
 After transfer, membranes were incubated in blocking solution:  5% BSA 
in TBST-T or in 5% non-fat dried milk powder in TBST-T for 1hr to overnight.  
Primary antibody diluted to appropriate concentration in blocking solution was 
added to membranes and incubated on rocking platform overnight at 4°C.  The 
next day, the membranes were washed with TBS-T on rocking platform.  The 
TBS-T was changed every 10 minutes 3x.  Secondary antibody in appropriate 
species conjugated to horse radish peroxidase (HRP, DAKO) was diluted in 
blocking solution.  Membranes were incubated in diluted secondary antibody 
for 1hr at room temperature.  Membranes were then washed 3x in TBS-T for 





 Membranes were then incubated with enhanced chemiluminescence 
(ECL) reagent mixture (Amersham) for 1 minute and then immediately 
imaged using ChemiDoc MP imaging system (BioRad).  The images were 
analysed using the ImageLab software v4.1.   
 Membranes were then stripped with 1x mild stripping solution 
(Millipore) according to manufacturer’s instructions then blocked and probed 
with appropriate house-keeping antibody conjugated to HRP (Cell Signaling) 
for 30 minutes at room temperature.  No secondary was required.  After 3x 
washing with TBS-T at 10 minutes each, the membrane was then incubated 
with ECL and analysed as described above.  
2.13 RNA extraction and cDNA synthesis 
 At least 5x105 cells was pelleted and RNA was isolated using Qiagen 
Micro/Mini RNEASY kit according to manufacturer’s protocol.  RNA 
concentration was determined using nanodrop (Thermo Fisher) and then 
stored at -80°C prior to cDNA synthesis.  To prepare cDNA, 400ng or 200ng of 
RNA was added to rnase/dnase free PCR tubes along with 4μL Quanta 
Supermix and nuclease-free water to a total volume of 20μL.  Tubes were 
placed in PCR machine with following program; 25°C, 5 min; 42°C, 30min; 





2.14 Quantitative PCR (Real-Time PCR) 
 Quantitative PCR analysis for S1PR1, S1PR2, S1PR3, S1PR4, S1PR5, 
SPHK1, and SGPP1 (Thermo Fisher) was performed with cDNA diluted 1:10 
or 1:20 in water (Table 2.5)(Vockerodt et al., 2019).  GAPDH from Cell 
Signaling was used as housekeeping gene and diluted as for all probes.  Fast 
Start qPCR mix from R&D Systems was used according to manufacturer’s 
protocol and added to master mix.  Probes were used in 1:20 dilution for a total 
volume of 20 µl.  The samples, probes, and qPCR mix are added into 96 well 
PCR plate including a water control and centrifuged briefly.  Plate was placed 
in ABI 7500 qPCR machine using standard protocol.  Data was analysed using 
the 2 -ΔΔCT method (Guide to Performing Relative Quantitation of Gene 
Expression Using Real-Time Quantitative PCR, 2004) and compared with 
controls (i.e. normal B cells, unpolarised monocytes, or untreated cells) for 


























5’ primer: GTGCTAGGCGTCTTTATCGTC 



































Table 2.5 List of qPCR probes 
 
2.15 RNAscope© fluorescent- in situ hybridisation 
 FFPE (formalin fixed paraffin embedded) samples were incubated in a 
60°C oven for 1hr to overnight.  Slides were then processed according to 
RNAscope© Multiplex Fluorescent Assay kit version 2 protocol with the 
following changes: slides were incubated in boiling antigen retrieval buffer for 
20 minutes and incubated with protease plus at 40°C in hybridisation oven for 
15 minutes.  SPHK1 and IL-10 probes from ACD Bio were used along with 
Perkin Elmer TSA dye cy3.  For multiplex staining by fluorescent-IHC, prior to 





and then blocked for 30 minutes with Tris-NaCl blocking buffer (TNB buffer, 
Perkin Elmer).  Primary antibodies were used at the concentrations as shown 
in Table 2.6.  Then stained as for fluorescent-IHC in section 2.17. 
2.16 Immunohistochemistry (IHC) and fluorescent-IHC 
 FFPE sections were mounted on frost free slides by The Royal 
Orthopaedic Hospital Histology Department.  Slides deparaffinised in 
Histoclear II and IMS (industrial methylated spirits, Fisher) for 10 minutes 
each.    
 Following rinse with tap water, exogenous peroxidases were blocked in 
0.3% H2O2 (Sigma) followed by another rinse in tap water.  Citrate buffer was 
prepared to pH6 and boiled for 10 minutes in microwave.  For antigen 
retrieval, slides were slowly submerged and further heated for 10 minutes on 
medium power and then 10 minutes on low power.  Slides were cooled and a 
hydrophobic pen used to draw around tissue and then washed in with tris 
buffered saline with 0.1% tween-20 (TBS-T).  Tris-NaCl blocking buffer (TNB) 
from Perkin Elmer was prepared according to manufacturer’s instructions.  
Slides were blocked in TNB buffer for 30 minutes and then primary antibody 
diluted in TNB was added for 1hr room temperature or overnight at 4°C (Table 
2.6).  Primary antibody was then removed and slides washed TBS-T before 
addition of appropriate secondary antibody either biotinylated or with HRP for 
30 minutes (Table 2.6).  If biotinylated secondary used, then AVIDIN-D HRP 





diaminobenzidine peroxidase substrate kit) was added to each slide for 3-5 
minutes and then washed with TBS-T and counter-stained in Mayer’s 
haematoxylin for 5 minutes.   Slides were then rinsed in water before 
mounting with Omnimount (Sigma Aldrich).   
 For fluorescent IHC, the protocol remained the same as above with the 
following exceptions: xylene and ethanol were used in place of Histoclear II 
and IMS for de-paraffinization; after secondary antibody- HRP or biotinylated 
secondary plus AVIDIN-D HRP, the sections were then incubated with 
fluorescent dye diluted with assay diluent from Perkin Elmer for 10 minutes; 
slides were then heated in boiling citrate buffer pH6 for 15 minutes on low; 






Table 2.6 List of antibodies/probes for western, IHC and RNAscope 
RTU –  ready to use. 
Antibody Clone 












CD79a JCB117 mouse anti-human Leica PA0599 RTU 
CD163 10D6 mouse anti-human Leica CD163-L-CE 1:200 
























Hs-SPHK1 n/ a Human probe (C1) ACD Bio 416041 RTU 
pSPHK1 
(Ser225) 





















2.17 Cytospin of cell lines for immunohistochemistry 
 Cells were washed in PBS and re-suspended to 2x106 cells/ml.  Adhesive 
frost-free slides (Leica) was placed into Cytospin centrifuge (Thermo Fisher) 
according to manufacturer’s instructions and 100-200 µl of cell suspension was 
added to Shandon funnel.  Slides were centrifuged at 1000 RPM for 5 minutes 
and then fixed in 10% Neutral Buffered Formalin (10% NBF, Sigma Aldrich) 
for 5 minutes before storing in -20°C.   For IHC of cytospins, de-paraffinisation 
with Histoclear II was not required.  Instead, cytospins were immediately 
placed in 100% IMS and stained as described for normal IHC.   
2.18 Gene expression analysis 
 Reanalysis of published datasets were performed by Dr Robert Hollows 
(University of Birmingham).  RNAseq data for N=32 ABC-DLBCL and N=54 
GCB-DLBCL was downloaded with permission from NCBI dbGaP (Data Base 
of Genotypes and Phenotypes )at http://www.ncbi.nlm.nih.gov/gap with accession 
code phs000532.v5p2 (Morin et al., 2013).  The dataset for the normal GC-
DLBCL (GSE45982) was downloaded from the NCBI Gene Expression 
Omnibus data repository (http://www.ncbi.nlm.nih.gov/geo) (Beguelin et al., 
2013) .   
 Using Rsubread aligner, Dr Hollows, aligned sequence reads to hg19 
reference sequence in order to map the sequencing reads to individual genes 
with the featureCounts function (Robinson et al., 2010). In order to express 





using the trimmed mean of M values or TMM method then using edgeR 
package found in Bioconductor was converted to CPM  (Anders et al., 2013).  
Genes were considered to be differentially expressed between normal vs 
DLBCL if the p<0.05 adjusted for multiple comparisons and there was a fold 
change of <1.5 (Vockerodt et al., 2019). 
2.19 Measurement of S1P in DLBCL cell lines 
 DLBCL cell lines were prepared by Dr Kate Vrzalikova and S1P was 
quantified by Professor Sarah Spiegel (University of Virginia, USA) using 
liquid chromatography-electrospray ionisation-tandem mass spectrometry as 
previously described (Hait et al., 2009).  For measurement of S1P in cell 
lysates, DLBCL cell lines were counted, washed and snap frozen in liquid 
nitrogen.  For measurement of S1P in conditioned medium, 1x106 SUDHL4 
cells/ml were plated in fresh serum free and phenol red free RPMI 1640 
(Invitrogen).  Conditioned medium was collected at 2 minutes, 5 minutes, 10 
minutes and 15 minutes.  Cells were centrifuged at 4°C for 10 minutes at 
1000RPM and conditioned medium was collected and kept on ice.  Samples 
were then sent to Professor Spiegel for analysis. 
2.20 Gene Set enrichment analysis 
 Gene set enrichment analysis of genes positively correlated with SPHK1 
using Gene Ontology (GO) Enrichment Analysis Tool / PANTHER 
classification system from the Gene Ontology Consortium 





Ashburner et al., 2000, Mi et al., 2019a, Mi et al., 2019b)  All gene names were 
converted to standard nomenclature using HGNC (HUGO Genome 
Nomenclature Committee at https://www.genenames.org/cgi-
bin/symbol_checker.  Genes were loaded on to GO enrichment analysis tool and 
resulting biological processes were evaluated.  I then calculated p value and 
odds ratio using chi square method of observed vs expected.  Comparisons of 
gene lists (i.e. genes positively correlated with SPHK1 vs macrophage gene 
signature) were performed using Venny 2.1 (Oliveros, 2007-2015).  Genes 
associated with GO terms were obtained from the Gene Ontology tool. 
2.21 Statistical analysis 
 GraphPad Prism v8 was used for statistical analysis for all experiments.  
The Experimental Design Assistant developed by the NC3Rs and available at 
https://www.nc3rs.org.uk/experimental-design-assistant-eda was used to 
design in vivo experiments.  Power calculations and estimation of sample size 
was determined using the UCSF Sample Size calculator (http://www.sample-
size.net/).   
 P values were calculated using student’s t-test when comparing two 
variables (i.e. treated vs vehicle) and 2-way ANOVA was used when comparing 
>2 parameters (i.e. vehicle vs treatment A vs treatment B).  P values were 
adjusted for multiple comparisons.  The cut off for p value was < .05 and for 
















SPHK1 expression in DLBCL and its relationship to the 










Chapter 3     
SPHK1 expression in DLBCL and its relationship to 
the expression of macrophage genes 
3.1 Introduction 
  Our lab has previously investigated SPHK1 expression in DLBCL in 
the context of angiogenesis (Lupino et al., 2019).  Using RNAseq, an S1P-
response signature in HUVECs (human umbilical vein endothelial cells) was 
derived.  In addition, Lupino et al reported genes correlated with SPHK1 
expression in publicly available datasets of DLBCL overlapped significantly 
with a macrophage gene signature derived from five tumour types including 
DLBCL (Lupino, 2017).   
 In this chapter, the relationship between the expression of SPHK1 and 
macrophage genes is explored.  Specifically to 1) confirm the overexpression of 
SPHK1 in primary DLBCL and DLBCL cell lines, 2) survey the biological 
processes enriched in the genes positively correlated with SPHK1 using gene 
set enrichment analysis, and 3) use GO terms to obtain a list of genes 
associated with macrophage functions to compare with a set of genes 





3.2  SPHK1 is overexpressed in DLBCL 
3.2.1 Evaluating SPHK1 in primary DLBCL 
 The expression of SPHK1 was first examined in primary DLBCL.  To do 
this, published gene expression (RNAseq) datasets were re-analysed by Dr 
Robert Hollows, these included RNAseq data from four normal germinal centre 
(GC) B cells, 54 GCB-DLBCL and 32 ABC-DLBCL (Beguelin et al., 2013, 
Morin et al., 2013, Lupino, 2017).  This re-analysis identified a set of genes 
that were differentially expressed in DLBCL compared to normal GC B cells.  
Genes with a p value of < .05 and a fold difference of greater than +1.5 or -1.5 
were used for analysis and will be referred to as the “Morin” dataset.  In the 
Morin dataset, SPHK1 was found to be significantly overexpressed in both 
ABC and GCB type DLBCL compared to normal GC B cells with the 
expression SPHK1 in GCB-type tumours appeared to be higher than in ABC-
type (Figure 3.1A).   
 RNAscope© based fluorescent in situ hybridisation for SPHK1 combined 
with fluorescent IHC for CD79a was performed on 20 cases of primary DLBCL 
(9 non-GCB type and 11 GCB type) that had confirmed lesions present and 
three reactive tonsils as controls (Figure 3.1C-D).  SPHK1 expression was 
independently scored by a pathologist, Dr Matthew Pugh.  Three randomly 
chosen high power fields (HPF; 60x) were examined for each case and a score 
was given across each field of view. Scoring was as follows: <1 dot per cell=0; 1-





three HPF was used to calculate an SPHK1 score (Figure 3.1B and Appendix 
A1).  In 17/20 cases, there was a higher expression of SPHK1 compared to 
tonsils.  There was no significant difference between non-GCB and GCB types 





























































DLBCL SPHK1-cy3   CD79a-FITC 
Tonsil SPHK1-cy3   CD79a-FITC 
Figure 3.1 SPHK1 is overexpressed in primary DLBCL. (A) Re-analysis of a primary dataset 
DLBCL (32 ABC type and 54 GCB type) shows that SPHK1 mRNA levels were significantly 
higher in primary DLBCL compared to normal GC B cells (N=4). Student’s t-test was performed 
to test for statistical significance. (B) RNAscope© fluorescent in situ hybridisation for SPHK1 
was performed on N=3 tonsils and N=20 primary DLBCL (9 non-GCB and 11 GCB). 17/20 
DLBCL cells had higher SPHK1 score compared to tonsils. There was no significant difference in 
SPHK1 expression between non-GCB and GCB.  Student’s t-test was used to test for statistical 
significance.  Scoring for SPHK1 expression was independently performed by pathologist, Dr 
Matthew Pugh.  Three high power fields (60x) were assessed for each case. Each total field of 
view was scored per cell as: no dots =0; 1-5 dots =1; and >5 dots =2 and the average SPHK1 score 
of three fields was plotted for each case. (C) Representative images from tonsil and DLBCL 
fluorescent in situ hybridisation for SPHK1-cy3 (pink) and fluorescent IHC for CD79a-FITC 
(green). White arrows show SPHK1 expressing CD79a+ cells in both tonsil and DLBCL cases. 
White arrows indicate CD79a+ cells with SPHK1 expression.  Student’s t-test was used to 
calculate p values. 
 N= 9               N=11 





3.2.2 DLBCL cell lines overexpress SPHK1 
 Cell preps/lysates from a subset of the DLBCL cell lines and conditioned 
medium from SUDHL4 were sent to Professor Sarah Spiegel, at the University 
of Virginia, to measure the concentration of S1P.  These assays revealed a 
higher concentration of S1P in DLBCL cell lines compared with normal B cells 
(Figure 3.2A).  Secreted S1P by SUDHL4 was measured by Professor Spiegel 
appearing within 2 minutes in fresh medium (Figure 3.2B).   
 Western blotting analysis performed by Dr Kate Vrzalikova verified the 
protein expression of phospho-SPHK1 and total-SPHK1 in DLBCL cell lines 
(Figure 3.2C).  This includes ABC cell lines: OCI-Ly3 and U2932 and GCB cell 
lines: HT, Karpas 422, SUDHL4, SUDHL5, OCI-Ly1, OCI-Ly7, BJAB, and the 
EBV+ Farage cell line.  In addition, western blot analysis was used to confirm 
the SPHK1 expression in the A20 mouse lymphoma cell line using OCI-Ly3 as 
a positive control (Figure 3.2D).  Densitometry analysis using ImageJ software 
of the western blot was used to calculate the ratio of pSPHK1/tSPHK1 which 
shows that DLBCL cell lines express varying levels of pSPHK1 with OCI-Ly1 
with the lowest relative expression (Figure 3.2E). 
 Next, the expression of SPHK1 was examined in DLBCL cell lines by 
qPCR.  These included the ABC DLBCL cell lines: OCI-Ly3 and U2932; and 
the GCB DLBCL cell lines: HT, SUDHL4, SUDHL5, Farage, OCI-Ly1, OCI-
Ly7, and BJAB (Figure 3.2F).  All cell lines except for SUDHL4 and OCI-Ly7 


















Figure 3.2 DLBCL cell lines express SPHK1 and have higher S1P concentration than B 
cells.        (A) Lysates of DLBCL cell lines have higher levels of S1P than lysates of normal B 
cell.           (B) The concentration of S1P secreted by SUDHL4 over time was measured at 0, 
2, 5, 10, 15 min (analysis by Professor Sarah Spiegel at the University of Virginia using mass 
spectrometry). (C) Western blot analysis performed by Dr Kate Vrzalikova show that DLBCL 
cell lines express total-SPHK1 and phospho-SPHK1 proteins (D) Western blot analysis of 
mouse lymphoma cell line, A20, was performed and also showed expression of total and 
phospho-SPHK1.  (E) Densitometry of western blot of the ratio of pSPHK1/tSPHK1 as 
determined using ImageJ.  (F) DLBCL cell lines express SPHK1 as shown by qPCR.  SPHK1 
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3.3 Evaluating genes correlated with SPHK1 in DLBCL 
3.3.1 SPHK1 and macrophage genes are positively correlated in 
primary DLBCL 
 To confirm the link between SPHK1 expression and macrophage gene 
expression in primary DLBCL, two gene expression datasets originally used by 
a previous post-doctoral researcher was reanalysed (Lupino, 2017). The first 
was a macrophage gene signature described by Doig et al who used a 3-D 
network analysis to derive a macrophage gene signature from primary 
tumours including DLBCL, breast, colorectal, glioma, ovarian and testicular 
tumours (Doig et al., 2013). The second gene set was provided by Professor 
Rueben Tooze (University of Leeds).  Professor Tooze performed a gene 
expression meta-analysis of publicly available DLBCL datasets (Care et al., 
2015), and provided a list of genes that correlated with SPHK1.  Only genes 
that correlated with SPHK1 in at least 6 of the 10 DLBCL datasets with p 
value < .05 by the Spearman correlation test were used.   
 Of the 158 genes analysed, there were 90 genes identified that were 
positively correlated with SPHK1 and were also present in the macrophage 
gene signature (Lupino, 2017).  This represented a significant enrichment of 
macrophage genes in the set of genes positively correlated with SPHK1 (odds 
ratio (OR) = 30.29; p< .0001) (Figure 3.3A).  No macrophage signature genes 
were negatively correlated with SPHK1 expression (OR = 0.0; p< .0001) which 





















Figure 3.3 Enrichment of genes positively correlated with SPHK1 in 
DLBCL among macrophage signature genes.  Genes correlated with 
SPHK1 expression across >5 out of 10 publicly available datasets from 
DLBCL patients were compared with a macrophage gene signature derived 
from DLBCL, breast, colorectal, glioma, ovarian and testicular tumours.  
The results show (A) an enrichment of macrophage genes in the gene set 
positively correlated with SPHK1 and (B) a depletion in the gene set that 




Genes negatively correlated 
with SPHK1 
p <0.0001, OR= 0.0 
CI = 0.0000 to 0.0001 
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p <0.0001, OR= 30.29 



































































































3.3.2 Macrophage signature genes that are also positively correlated 
with SPHK1 are upregulated in DLBCL  
 Taking these 90 macrophage genes that were positively correlated with 
SPHK1, I next explored their differential expression using the Morin dataset 
of differentially expressed genes in ABC-type and GCB-type DLBCL.  In the 
macrophage signature, there were 72/90 genes positively correlated with 
SPHK1 that were also significantly upregulated in ABC-DLBCL. Only 3/90 of 
these genes were downregulated significantly in ABC-DLBCL.  Similarly, in 
the Morin dataset of differentially expressed genes in GCB-DLBCL, there were 
77/90 of the macrophage signature genes positively correlated with SPHK1 
that were upregulated.  Only 2/90 macrophage genes were downregulated in 






























Figure 3.4 Macrophage signature genes positively correlated with SPHK1 
are enriched in genes up-regulated in primary ABC and GCB DLBCL 
subtypes.   (A) Macrophage signature genes positively correlated with 
SPHK1 were significantly enriched (72/90) among genes upregulated in 
primary ABC-DLBCL, but depleted (3/90) among genes downregulated in 
ABC-DLBCL.   (B) Macrophage signature genes positively correlated with 
SPHK1 were significantly enriched (77/90) among genes upregulated in 
GCB-DLBCL and depleted (2/90) among genes downregulated in GCB-
DLBCL.   
A  
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p< .0001, OR= 21.27 
CI= 12.08 to 37.5 
87 
Genes downregulated in ABC-DLBCL 
p< .0001, OR= 0.03 







Genes upregulated in GCB-DLBCL 
p< .0001, OR= 13.35 






Genes downregulated in GCB-DLBCL 
P= .0001, OR= 0.02 













3.3.3 Gene set enrichment analysis of SPHK1 correlated genes 
highlights biological processes associated with 
monocytes/macrophages 
 So far, I have shown that genes positively correlated with SPHK1 
expression in DLBCL were enriched for macrophage signature genes, and that 
the majority of genes in the overlap were also upregulated in both subtypes of 
primary DLBCL.  Next, gene set enrichment analysis of genes positively 
correlated with SPHK1 was performed using the GO Enrichment Analysis 
Tool from the Gene Ontology Consortium at http://geneontology.org (Mi et al., 
2017, The Gene Ontology, 2017, Ashburner et al., 2000). This analysis revealed 
the expected enrichment of genes with biological activities including anti-
apoptosis, vascular and endothelial cell development, and cytokine regulation, 
which are functions associated with S1P (Figure 3.5).  
 However, in keeping with the enrichment of macrophage signature 
genes described above, there was also an enrichment of genes with functions in 
the chemotaxis and migration of monocytes/ macrophages, the development 
and activation of macrophages as well as the regulation of endocytosis and 
phagocytosis (Figure 3.5).  Taken together these data suggest that SPHK1 


























Figure 3.5 Gene set enrichment analysis of genes positively correlated with 
SPHK1 in DLBCL.  GO Enrichment Analysis Tool from the Gene Ontology 
Consortium at http://geneontology.org was used to explore the biological 
processes represented in the SPHK1 correlated gene set. The gene set 
enrichment analysis showed an expected enrichment of genes involved in 
cytokine regulation, endothelial cell proliferation, blood vessel formation and 
anti-apoptosis genes. Gene set enrichment analysis also showed an enrichment 
of genes involved in macrophage activation/migration, chemotaxis and 
phagocytosis, providing justification for the exploration of the role S1P in 





 The recruitment of monocytes/macrophages and their function as 
phagocytes are relevant in DLBCL given the mechanism of action of rituximab 
previously described.  Next, enrichment of the genes involved in the leukocyte 
/monocyte/ macrophage migration and phagocytosis were determined for genes 
positively or negatively correlated with SPHK1 
 To do this, a list of genes (N=351) classified under the GO terms 
leukocyte chemotaxis (GO:0030595); monocyte chemotaxis (GO:0090025); and 
macrophage migration (GO:0010759) was obtained.  Of these genes, 93 were 
positively correlated with SPHK1 which represented a significant enrichment 
(Table 3.1 and Figure 3.6A) and 8/351 were negatively correlated with SPHK1 
(Figure 3.6B) which represented a significant depletion. Using the Morin 
dataset of differentially expressed genes in ABC and GCB DLBCL, there were 
86/93 of the SPHK1 correlated migration genes were also upregulated in GCB-






Number of genes overlapping 
with Migration genes 
Genes positively correlated with 
SPHK1 in primary DLBCL 
2141 93 
Genes negatively correlated with 
SPHK1 in primary DLBCL 
1529 8 
Migration genes 351  
 
Table 3.1 Number of genes used for the comparison of SPHK1 correlated 



























p<0.0001, OR=7.9,  
CI=0.0119 to 0.0224 
A 
Genes negatively correlated 
with SPHK1 
p<0.0001, OR=0.0001,  
CI=0.0000 to 0.0003 
B 
258 





Figure 3.6 Overlap between genes positively correlated with SPHK1 and 
genes with a function in migration of leukocytes/ monocytes/ macrophages.  
(A) Amongst genes positively correlated with SPHK1, there was a significant 
enrichment of leukocyte migration genes including genes involved in monocyte 
and macrophage migration (93/351).  (B) These migration genes were 
significantly depleted (8/351) among those genes negatively correlated with 
SPHK1. Chi-square test was used to determine p value, odds ratio and 





Next, genes classified under the GO term phagocytosis (GO:0006909) was 
obtained.  A total of 344 phagocytosis genes were compared with the set of 
genes positively and negatively correlated with SPHK1.  66/344 phagocytosis 
genes positively correlated with SPHK1 (Table 3.2 and Figure 3.7A).   There 
were 8/344 phagocytosis genes negatively correlated with SPHK1 (Table 3.2 
Figure 3.7B).  Using the Morin dataset of differentially expressed genes in 
ABC and GCB DLBCL, there were 56/66 genes in the overlap were 
upregulated in ABC-type DLBCL 48/66 genes were upregulated in GCB-













Genes positively correlated with 
SPHK1 in primary DLBCL 
2141 66 
Genes negatively correlated with 
SPHK1 in primary DLBCL 
1529 8 
Phagocytosis genes 344  
Table 3.2 Number of genes used for comparison of SPHK1 correlated 




















Figure 3.7 Phagocytosis genes were enriched among genes positively 
correlated with SPHK1 in DLBCL.  (A) Amongst genes positively correlated 
with SPHK1, there was a significant enrichment of phagocytosis genes 
(66/344). (B) Phagocytosis genes were significantly depleted (8/344) among 
genes negatively correlated with SPHK1. Chi-square test was used to 
determine p value, odds ratio and confidence intervals.   
 




p<0.0001, OR= 0.0076  
CI= 0.0053 to 0.0109 
A 
Genes negatively correlated 
with SPHK1 
GO term  
Phagocytosis genes 
p<0.0001, OR=0.0001,  
CI= 0.0000 to 0.0003 
B 
278 






3.3.4 Macrophages do not regularly express SPHK1 in DLBCL  
 The overlap between SPHK1 and macrophage gene expression may be 
due to DLBCL-associated macrophages themselves expressing SPHK1. To 
explore this possibility, the same DLBCL cases as examined in section 3.2.1 
were stained for CD68 (Figure 3.8 and Appendix A1).  CD68 is a pan marker 
for macrophages (Pham et al., 2018).  Five HPFs were counted for CD68+ cells. 
The frequency of CD68 in the 20 DLBCL cases was an average of 198.6/HPF 
(Table 3.4).   
 A subset of these DLBCL cases (N=10) was stained using multiplex 
fluorescent RNAscope© for SPHK1 and fluorescent IHC for CD68. Only 12% of 
the CD68-positive macrophages also expressed SPHK1 per HPF (Figure 3.9 






























Figure 3.8 CD68+ cells were abundant in primary DLBCL.  DLBCL 
cases (N=20) were stained for CD68 by IHC. The average number of 
CD68+ cells per five high power fields (HPF) at 40x were counted. 

























































Figure 3.9 Frequency of SPHK1 expressing macrophages were low in 
primary DLBCL. SPHK1 expressing CD68+ cells were found at a frequency of 
3/25 CD68+ cells counted per HPF (60x) in N=10 DLBCL cases. This was 
confirmed by a pathologist, Dr Matthew Pugh.  White arrows indicate CD68+ 
cells that also expresses SPHK1.  
DLBCL 100x 
DLBCL 100X 








 SPHK1 plays a central role in modulating the proliferation and pro-
survival effects of S1P by counter-acting the pro-apoptotic and growth arrest 
effects of sphingosine and ceramide (Hatoum et al., 2017).  This has led to the 
recognition of S1P as an onco-lipid contributing to the pathogenesis of cancers 
such as breast and NHL and has sparked the therapeutic targeting of SPHK1, 
S1P and its receptors (Bayerl et al., 2008, Nagahashi et al., 2012).  The role of 
S1P in the pathogenesis of DLBCL, in particular is strengthened by the 
observation that disrupting S1PR2 in mice led to the development of DLBCL 
and the finding that S1PR2 is a tumour suppressor in DLBCL (Cattoretti et 
al., 2009, Stelling et al., 2018).   
 From re-analysed published datasets comparing DLBCL and germinal 
centre B cells, it was determined that SPHK1 is significantly over-expressed in 
ABC and GCB subtypes of DLBCL in line with published observations in NHL 
(Bayerl et al., 2008).  The limitation here is that the comparison was made 
using expression data from whole DLBCL tumours with GC B cells where it 
would have been more appropriate to have compared gene expression of whole 
tonsils or isolated various B cells subsets to isolated tumour cells.  To address 
this, RNAscope© was used to probe for SPHK1 mRNA in primary DLBCL and 
tonsil co-staining for the B cell marker, CD79A.  There were significantly 
higher levels of SPHK1 mRNA in B cells of DLBCL also by this appraisal thus 
supporting the observation that SPHK1 overexpression was primarily 





  DLBCL cell lines express SPHK1 in keeping with previous work 
(Lupino, 2017, Lupino et al., 2019) . Using qPCR, a panel of DLBCL cell lines 
was shown to have an overexpression of SPHK1 compared to normal B cells.   
Measurements of S1P from DLBCL cells also revealed a significantly higher 
S1P concentration than in normal B cells.  Densitometry analysis of SPHK1 
protein expression in DLBCL cell lines compared to the gene expression shows 
that though  
 Gene set enrichment analysis of the subset of genes that positively 
correlate with SPHK1 expression in DLBCL, highlighted processes involved 
with the promotion of monocyte/ macrophage migration in agreement with 
publications that describe the recruitment of monocytes/macrophages in 
inflammatory responses by S1P and its role in the clearance of apoptotic cells 
(Rodriguez et al., 2016, Weigert et al., 2009, Aoki et al., 2016).  SPHK1 
correlated genes associated with macrophage migration was also upregulated 
in ABC and GCB-DLBCL supporting the hypothesis that recruitment of 
monocytes/macrophages to DLBCL may be S1P-mediated.  This was 
investigated further in Chapter 4 of this thesis. 
 Gene set enrichment analysis of genes positively correlated with SPHK1 
also highlighted enrichment of genes with functions in endocytosis and 
phagocytosis.  This is of particular interest due to the proposed mechanisms of 
action of rituximab.  S1P may recruit phagocytes and influence their function.  
S1P mobilises monocytes/macrophages and the degradation of S1P may also be 





migration and phagocytosis genes correlated with SPHK1 were upregulated in 
DLBCL.  
 The correlation of SPHK1 and macrophage gene expression may be 
because macrophages also express SPHK1.  Macrophages are the dominant 
non-malignant immune cell type found in DLBCL and in the Morin dataset 
they analysed samples from whole tumour suspensions of DLBCL cases 
(Kridel et al., 2015, Gascoyne and Steidl, 2011, Scott and Gascoyne, 2014, 
Morin et al., 2013).  In the RNAscope© analysis for SPHK1 and CD68 showed 
that only a small fraction of macrophage in DLBCL express SPHK1 and none 
showed the high expression as seen in SPHK1/CD79A stained DLBCL 
samples.    
 Taken together, these results show that SPHK1 could be important in 
the formation of the tumour microenvironment of DLBCL, specifically, in the 
recruitment and retention of monocytes and macrophages.  This could be 
significant due to the current treatment for DLBCL that includes rituximab 
which works in part to enhance the phagocytosis of B cells by macrophages. 
While S1P may support the recruitment of macrophages to the tumour site, 
the aberrant expression of SPHK1 may also affect the phagocytic function of 
recruited monocytes and macrophages.  This possibility was explored further 



























Evaluating the S1P-mediated migration of 
monocytes and macrophages 
4.1 Introduction  
 It has been shown that increased macrophage infiltration to the 
microenvironment of DLBCL had lower progression-free survival (PFS 40%) 
and lower overall survival (OS 39%) in patients treated with CHOP, however 
this effect on prognosis reversed in (PFS 74% and OS 90%) patients given R-
CHOP (Riihijarvi et al., 2015, Pham et al., 2018).  In the previous chapter, 
SPHK1 was shown to be over-expressed in DLBCL. Gene set enrichment 
analysis of genes positively correlated with SPHK1 revealed an enrichment of 
genes with functions in monocyte/macrophage migration and phagocytosis. 
Importantly, the majority of these genes were also upregulated in primary 
DLBCL. 
 The specific aims of this chapter are to; 1) confirm the expression of S1P 
receptors in in vitro polarised macrophages; 2) confirm that monocytes and 
macrophages migrate to S1P; 3) determine if monocyte/macrophage migration 
to DLBCL conditioned medium (CM) in vitro is S1P-mediated; 3) identify 
which S1P receptor is responsible for migration of monocytes/macrophages to 





DLBCL recruit host macrophages and if so, are they reduced with S1P 
receptor antagonists.  
4.2 In vitro polarisation of monocytes to M1 and M2 
macrophages  
4.2.1 Macrophage polarisation with GM-CSF and M-CSF 
 Having shown that over-expression of SPHK1 in primary DLBCL is 
associated with macrophage gene signature, I next studied the effect of S1P on 
monocyte and macrophage functions.  CD14+ monocytes isolated from 
leukocyte cones from healthy donors were cultured with either GM-CSF or M-
CSF for 7 days (Leidi et al., 2009, Lacey et al., 2012).  Purity of the CD14 
isolation was confirmed and the phenotype of the cells determined by staining 
for CD14, CD68, CD163, and CD206 (Figure 4.1 A and B).   
 As mentioned in Chapter 1, there are no definitive markers for M1 and 
M2 given the spectrum of phenotypic states possible, therefore for this thesis, 
GM-CSF polarised M1-like macrophages was defined as CD68+CD206+/- and 
CD163- while M-CSF polarised M2-like macrophages was defined as 
CD68+CD206+ and CD163+ (Marchesi et al., 2015, Mantovani et al., 2002). 
The phenotype observed for GM-CSF-M1 was CD68positive CD14positive 
CD163negative and moderately CD206positive (Figure 4.1C).  M-CSF M2-like 
macrophages were CD68positive CD14positive and largely CD163positive CD206positive.  
There was also a population of cells that were CD68positive CD14positive but 





 M1 is said to secrete IL-12 and M2 is said to secrete IL-10, therefore, 
GM-CSF M1 and M-CSF M2 polarised macrophages were treated with LPS for 
24hrs  in order to induce cytokine secretion (Mantovani et al., 2002).  ELISA 
analysis of resulting conditioned media after LPS stimulation indicated that 
GM-CSF polarised macrophages had characteristic M1 cytokine expression; 
low IL-10 and high IL-12(p70) secretion.  M-CSF polarised macrophages 
exhibited characteristic M2 macrophage cytokine expression: high IL-10 and 
low IL-12(p70) secretion (Figure 4.1D).  An additional 35 cytokines were tested 
from a single donor using a cytokine array (Appendix A6).  Also, the SPHK1 
expression was evaluated by qPCR in the macrophages from 3 healthy donors 











































































































































































- LPS - LPS+ LPS + LPS
M1 M2
p=0.0156
Figure 4.1 Polarisation of CD14+ monocytes to M1 and M2 macrophages. (A) GM-CSF and 
M-CSF was used to polarise monocytes to M1 and M2 macrophages. (B) Representative dot 
plots of CD14+ isolated cells on day 0 show 100% purity with CD68 expression and low CD163 
and CD206 expression.  (C) Representative dot plots of M1 and M2 polarised macrophages for 
CD163 and CD206. (D) ELISA results from four independent donors for IL-10 and IL-12p70 
secretion show that M2 had higher secretion of IL-10 and M1 higher secretion of IL-12p70. 
The cytokines were measured from the culture medium of M1 and M2 polarised macrophages 
treated for 24 hr +/- LPS.  Student’s t-test to calculate p values. 






4.2.2 M1 and M2 macrophages express low levels of S1PR1 and high 
levels of S1PR2 
 S1P receptor expression in these cells was next measured by qPCR.  A 
total of 34/40 normal CD14+ donors samples showed robust polarisation of M1 
and M2 phenotypes and were analysed for S1P receptor expression.  There are 
five S1P receptors (S1PR1-5) and initially the focus of this study was on 
S1PR1 and S1PR2 as these are the most likely to be associated with functional 
differences in macrophages.  Relative expression of these receptors in M1 and 
M2 macrophages was compared to the donor’s own unpolarised monocytes in 
order to account for differences in base line expression between donors.   
 The relative expression of S1PR1 in M1 macrophages was generally 
lower than in monocytes (Figure 4.2A).  In contrast, the relative expression of 
S1PR2 was significantly higher in both M1 and M2 macrophages compared to 
monocytes (Figure 4.2B).  Volcano plots were plotted using FDR (false discover 
rate) < .01 versus the mean difference of the ΔCT for S1PR1 and S1PR2 
expression between monocytes and M1 and M2 macrophages (Figure 4.3A and 
B). The green dots signify low expression of S1P receptors and red dots signify 
high expression.  27/34 donors tested had a significantly negative mean 
difference in ΔCT for S1PR1 expression in M1 macrophages compared to 
monocytes (Figure 4.3A).  Three donors showed a significantly higher 
expression of S1PR1 in M1 macrophages compared to monocytes.  In the M2 
macrophages of these donors, 20/34 donors had a significant negative mean 





showed a significantly higher expression of S1PR1 in M2 macrophages 
compared to monocytes.  None of the samples had a high expression of S1PR1 
in both M1 and M2.  The 3/34 M1 samples and 2/34 M2 samples had a 

















Figure 4.2 Relative S1PR1 expression was generally lower and 
relative expression of S1PR2 was generally higher in M1 and M2 
relative to matched monocytes from same donor. (A) There was 
lower relative S1PR1 expression in M1 and M2 macrophages 
compared to matched monocytes in 34 donors.  (B) There was a higher 
relative S1PR2 expression in M1 and M2 macrophages compared to 




















Figure 4.3 Volcano plots of FDR (q< .01) vs mean difference of CT for 
S1PR1 and S1PR2 expression of monocytes and M1 or M2 macrophages.  
FDR adjusted p-values were calculated by paired t-test adjusted for multiple 
testing with cut-off for significance set at FDR< .01 using mean and standard 
error of CT technical triplicates.  Red signifies up-regulated and green 
signifies down-regulated. Greyed out area = not significant.  (A) In 27/34 
donors, their M1 macrophages had a significant negative mean difference 
CT compared to monocytes.  3/34 had a significant higher mean difference 
ΔCT than monocytes.  For M2 macrophages, 20/34 donors had a significant 
negative mean difference ΔCT of S1PR1 compared to monocytes.  (B)  Similar 
analysis for S1PR2 show a majority of M1 and M2 macrophages with higher 







4.2.3 Monocytes, M1 and M2 macrophages express low levels of 
S1PR3, S1PR4, and S1PR5 
 Next, the expression of S1PR3, S1PR4, and S1PR5 in a subset of the 
same donors previously analysed for S1PR1 and S1PR2 was investigated.  
Results showed that S1PR3 and S1PR5 expression was decreased in M1 and 
M2 macrophages compared to monocytes (Figure 4.4A and B).  The expression 
of S1PR4 was more variable (Figure 4.4C).  Volcano plots of FDR < .01 of the 
mean difference of ΔCT in monocytes vs M1 or M2 macrophages clearly 
illustrates these differences (Figure 4.5A-C).  A summary of relative expression 
of S1PR1-5 for M1 and M2 macrophages relative to matched monocytes from 


































Figure 4.4 Relative expression of S1PR3 and S1PR5 was lower in M1 and 
M2 macrophages compared to monocytes while S1PR4 was higher in M1 
macrophages. Relative expression of (A) S1PR3 N=11 and (C) S1PR5 N=8 
in M1 and M2 in vitro polarised macrophages was significantly lower than 
their comparative monocytes.  (B) S1PR4 relative expression was higher in 

























Figure 4.5 Volcano plots of FDR (q< .01) versus mean difference CT for S1PR3, 
S1PR4, and S1PR5 show that these S1P receptors are generally more lowly 
expressed in M1 and M2 compared to monocytes. (A) Nearly all of M1 and all of M2 
from N=11 donors tested had a negative mean difference CT of S1PR3 compared to 
monocytes. (B) S1PR4 was variable in the N=11 donors tested and the mean difference 
ΔCT was not significant in the majority of donors.  (C) For S1PR5, the donors tested 





















Figure 4.6 Summary of relative S1P receptor expression in M1 and M2 macrophages 
compared to matched monocytes from healthy donors. The S1PR1-5 expression of M1 
and M2 macrophages from each donor are shown highlighting higher expression compared 
to monocytes shown in dark pink and lower expression compared to monocytes shown in 
yellow.  Grey denotes donors that were not tested and ‘x’ insignificant ΔΔCT values.  





4.2.4 Monocytes, M1 and M2 macrophages express S1PR1 protein 
 The protein expression of S1PR1 on monocytes and M1/M2 macrophages 
was next examined by flow cytometry.  CD14+ monocytes and M1 and M2 
polarised macrophages from three donors were stained with anti-S1PR1-APC.  
Figure 4.7 shows the decreased but detectable expression of expression of 
surface S1PR1 in polarised macrophages compared to monocytes (black line) 











Unstained, Monocytes, M1 macrophages, M2 macrophages 
Donor S Donor T Donor U 
S1PR1-APC 
Figure 4.7 S1PR1 is detected in M1 and M2 macrophages.  Representative 
graphs of CD14+ monocytes and M1 and M2 macrophages were stained 
with S1PR1-APC and analysed by flow cytometry.  There were varied levels 
of expression of S1PR1 observed between donors.  Here, three donors are 
shown with grey curve denoting unstained cells, black curve= monocytes, 





4.3 Studying S1P mediated migration of CD14+ 
monocytes and macrophages  
4.3.1 CD14+ monocytes migrate to S1P 
 Having confirmed the polarisation of M1 and M2 from monocytes with 
cytokines in vitro and their S1P receptor expression, the S1P-mediated 
migration of monocytes was next examined.  Monocytes are already known to 
readily migrate to sites of infection through the blood stream (Shi and Pamer, 
2011).  MCP-1 is a known chemoattractant for monocytes during inflammation 
and therefore, was used as a positive control for transwell migration assays 
(Yoshimura et al., 1989).  Monocytes isolated from three donors showed 
significant monocyte migration to 50ng/ml MCP-1 over 4 hr (Figure 4.8A). 
Testing the migration of monocytes to 0.1, 1 and 10 µM S1P showed that 
monocytes significantly migrated to 0.1µM (Figure 4.8B).  Concentrations 
below 0.1 µM were not tested.  This experiment was repeated, this time using 
0.1µM S1P +/- Sphingomab (a neutralising antibody to S1P), or isotype control 
with freshly isolated monocytes from another three donors.  Monocytes from 
all three donors migrated to 0.1µM S1P and this migration was blocked by the 
addition of Sphingomab (Figure 4.8C).  I also treated these monocytes with 
0.01% DMSO or 100nM BAF312 for 30 min prior to allowing them to migrate 
to 0.1µM S1P.  Treatment with BAF312 also significantly blocked migration of 
monocytes to S1P showing that migration was mediated through S1PR1 or 
S1PR5.  In all migration experiments, monocytes were allowed to migrate over 



















































































































Figure 4.8 Migration of CD14+ monocytes can be mediated by S1P.  (A) 
CD14+ monocytes migrated to MCP-1 50ng/ml in an in vitro transwell assay 
over 4hr.  (B) Monocytes significantly migrated to 0.1µM S1P but not to 1µM 
or 10µM S1P.  (C) Monocyte migration to 0.1µM S1P was inhibited with 
Sphingomab (1µg/ml per 1µM S1P) as well as with 100nM BAF312.  Results 
shown are of 3 different donors in triplicate as indicated by grey, black and 





 Having demonstrated that monocyte migration to S1P could be blocked 
with Sphingomab, the monocyte migration to DLBCL conditioned medium was 
next examined.  S1PR1 has the highest binding affinity for S1P and important 
in leukocyte migration therefore, the antagonism of S1PR1 was the first 
receptor explored.  There are several S1PR1 antagonists commercially 
available: BAF312 (siponimod) and ponesimod but BAF312 antagonises both 
S1PR1 and S1PR5. 
 BAF312 was chosen for these series of experiments because of its proven 
inhibition of monocyte trafficking in vivo and because of its recent FDA 
approval for the treatment of multiple sclerosis (Kappos et al., 2018).  BAF312 
was part of a series of compounds developed to be specific for S1PR1 inhibition 
(Pan et al., 2013).  FTY720, the first S1PR inhibitor, antagonised nearly all the 
S1PRs (except for S1PR4) which lead to off target effects (Gergely et al., 2012).  
In vitro, BAF312 will antagonise S1PR1 and S1PR5 at an EC50 of 0.9nM and 
an EC80 of 100nM and ponesimod has an EC50 of 5.7nM (Kappos et al., 2018, 
Lewis et al., 2013, D'Ambrosio et al., 2016).  The selective affinity for 
S1PR1/S1PR5 was reported to be lost at concentrations >700nM where 
indiscriminate binding to the other S1P receptors was found (Gergely et al., 
2012, Lewis et al., 2013).  Therefore, 100nM BAF312 was the concentration 
used in order to achieve maximum antagonism of S1PR1/S1PR5. 
  Monocytes were treated with 100nM BAF312 for 30 minutes and then 
allowed to migrate to DLBCL conditioned medium for 4 hr.  Monocytes from 





treatment with BAF312 (Figure 4.9A).  The S1PR1 antagonist, ponesimod, was 
also tested in these experiments to confirm if S1PR1 was the main receptor 
involved in monocyte migration.  Pre-treatment with 100nM ponesimod had 
the same effect as BAF312, reducing monocyte migration to DLBCL 
conditioned medium (Figure 4.9B).   




































































































Figure 4.9 Monocyte migration to DLBCL conditioned medium was 
reduced by S1PR1 inhibitors.  (A) SUDHL6 and OCI-Ly3 conditioned 
medium was used as a chemo-attractant in transwell migration assays with 
CD14+ monocytes.  Monocyte migration to DLBCL conditioned medium 
was partially blocked by pre-treated with 100nM BAF312 for 30 minutes.  
Triplicate values of 3 different donors from independent experiments are 
indicated by grey, black and white circles. P-values were calculated using 2-
way ANOVA.  (B) The migration of the monocytes from two different donors 
in triplicate to SUDHL6 conditioned medium was also partially blocked 









4.3.2 Migration of M1 and M2 is mediated by S1P 
 Next, the migration of M1 and M2 macrophages S1P was also assessed, 
on the basis that mature macrophages already resident in surrounding tissues 
may also be recruited to tumour sites as part of the microenvironment.  As 
with monocytes, the migration of M1 and M2 macrophages to MCP-1 was 
evaluated.  Only 2/4 donors tested showed significantly increased migration to 
MCP-1 compared to controls (Figure 4.10A).  This result was in keeping with 
previous reports showing that MCP-1 is predominantly a chemoattractant for 
monocytes (Deshmane et al., 2009).  
 CXCL12 is a known chemoattractant for macrophages and along with 
its receptor, CXCR4, also been shown to recruit T-regs creating an immune 
suppressive environment in DLBCL (Xuan et al., 2015, Durr et al., 2010).  To 
determine if macrophages polarised in vitro with GM-CSF and M-CSF would 
migrate to CXCL12, three donors were tested in triplicate using a transwell 
migration assay with 100ng/ml CXCL12.  All three donors showed significantly 



























Figure 4.10 M1 and M2 macrophages migrated to CXCL12 but variably to 
MCP-1.  (A) Triplicate M1 and M2 macrophages from each donor are 
represented on the graph in colour code.  There was donor variability of 
migration to 50ng/ml MCP-1. (B)  Another chemoattractant for 
macrophages, CXCL12, was tested.  3/3 donors tested showed migration to 
100ng/ml CXCL12 compared to controls. P values were calculated using 2-
way ANOVA. 






























































 Having shown that macrophages can migrate to CXCL12 in vitro, I next 
assessed migration to S1P. The M1 and M2 macrophages from three donors 
showed significantly increased migration to 0.1M S1P but there was no 
significant migration to 1M and 10M S1P (Figure 4.11A).  Next, 
Sphingomab was used to test for the blocking of macrophage migration to S1P 
with fresh M1 and M2 macrophages.  M1 and M2 macrophages significantly 
migrated to isotype control + 0.1M S1P and their migration was significantly 
blocked with Sphingomab to a level below baseline migration with vehicle 
(Figure 4.11B).   
 Migration of M1 and M2 macrophages to DLBCL conditioned medium 
was evaluated.  M1 and M2 macrophages were treated with 100nM BAF312 
and 100nM ponesimod and then allowed to migrate to DLBCL conditioned 
medium.  Results showed that migration of M1 and M2 macrophages to 
SUDHL6 conditioned medium was not significantly different to controls. 
However, the baseline levels of M1 and M2 macrophage migration was reduced 















































































































Figure 4.11 M1 and M2 polarised macrophages migrated to 0.1M 
S1P.  (A) M1 and M2 macrophages migrated to 0.1M S1P but not to 1 
or 10 M S1P.  Three donors tested in triplicate migrated to 0.1µM S1P 
M1 and M2 macrophages to 0.1M S1P was blocked with Sphingomab 










































































































































































































































































SUDHL6 CM SUDHL6 CM
Figure 4.12 Baseline migration of M1 and M2 macrophages is S1PR1-
dependent.  M1 polarised macrophages showed a significant increase 
in migration to SUDHL6 conditioned medium and M2 macrophages 
showed no increase compared to controls. (Outlier      was removed for 
2-way ANOVA analysis). However, baseline migration of both M1 and 
M2 macrophages were blocked with 100nM BAF312 or with 100nM 























































































4.4 Recruitment of mouse F4/80+CD11b+ cells to mouse 
DLBCL tumours 
4.4.1 Host macrophages are recruited to xenografts tumours of 
DLBCL 
 To study the recruitment of host macrophages to tumours, xenograft 
models of DLBCL using cell lines were optimised.  DLBCL cell lines SUDHL6, 
OCI-Ly1, OCI-Ly3 and U2932 were injected subcutaneously in four NSG mice 
each to determine engraftment kinetics.  Mice injected with GCB-type DLBCL 
cell lines engrafted within four weeks of injection.  All four mice injected with 
OCI-Ly1 had measurable tumours within 22 days of injection (Figure 4.13A-
B).   2/4 mice injected with OCI-Ly1 reached >800mm3 tumour volume by day 
33.  In SUDHL6 injected mice, 3/4 mice had measurable tumours within 33 
days post injection.  2/4 mice with SUDHL6 tumours reached >800mm3 
tumour volume by day 40 post injection and one mouse never engrafted.    
Mice injected with ABC-type DLBCL cell lines did not engraft as 
robustly compared to GCB-type DLBCL cell lines.  One mouse injected with 
OCI-Ly3 had a measurable tumour by day 35 post injection and the tumour 
growth plateaued by day 50.  A second mouse injected with OCI-Ly3 engrafted 
by day 50 and reached a tumour volume of >1000mm3 by day 87.  Two mice 
injected with OCI-Ly3 never engrafted.   3/4 mice injected with U2932 had 





plateaued by day 45 with one mouse reaching a tumour volume of >1000mm3 

















Figure 4.13 Engraftment kinetics of human DLBCL cell lines injected 
subcutaneously in NSG mice. (A-B) Human GCB-DLBCL cell lines were 
injected subcutaneously on the flank of NSG mice and monitored weekly 
for the presence of tumours. N=4 mice were injected for each cell line. 
Once tumours were palpable, they were measured every 2-3 days. All 
mice injected with OCI-Ly1 engrafted and 3/4 mice engrafted with 
SUDHL6.  2/4 mice from each cohort reached >800mm3 tumour volume 
<45days post injection.  (C-D) Human ABC-DLBCL cell lines were 
injected into N=4 mice per cell line.  2/4 mice with OCI-Ly3 injection 
never engrafted and the tumour growth from one mouse plateaued after 
54 days post injection. In 2/4 mice injected with U2932, their tumour 









Tumours from engrafted mice were analysed ex vivo for F4/80+CD11b+ 
cells. By IHC, I found F4/80+CD11b+ mouse macrophages were recruited to 
subcutaneous xenograft tumours of OCI-Ly1, SUDHL6, OCI-Ly3 and U2932 
(Figure 4.14).  The presence and F4/80+CD11b+ cells in these xenografts were 
also confirmed by flow cytometry.  Representative dot plots of gating strategy 
for F4/80+CD11b+ are shown (Figure 4.15A).  Mouse CD45+ cells were present 
in subcutaneous (SC) xenografts at levels around 1-10% of the tumour 
population (Figure 4.15B).  Within the mCD45 populations, about 80-90% were 
F4/80+CD11b+ (Figure 4.15B).  The presence of mouse B220 and mouse CD3 
was also assessed.  There was a small population of B220+ cells and there was 
no population of CD3+ cells (Figure 4.15C).  Xenografts from OCI-Ly3 and 
U2932 had a lower percentage of mouse CD45 and F4/80+CD11b+ cells in the 





























Figure 4.14 IHC analysis of tumours from engrafted mice showed an infiltration 
of host F4/80+ cells.  Representative images of F4/80 staining from each DLBCL 
cell line grown as xenografts engraftment kinetics study. All tumours had 
positive staining for F4/80 visible throughout (examples of positive F4/80 cells 


































Figure 4.15 Gating strategy for flow cytometry analysis of xenograft tumours.  
Representative dot plots showing gating strategy for flow cytometry analysis of 
xenograft tumours. (A) Singlet population was gated. Then from this, cells were gated 
to exclude debris and dead cells. (B) Tumours from each mouse had variable levels of 
mouse CD45 ranging from a minimum 0.5% to a maximum of 10% mouse CD45 in 
tumours.  From the mouseCD45 population, I gated for mouse F4/80, CD11b, B220, 
and CD3 positive populations.  Shown are representative dot plots of high and low 
infiltration of mouse CD45+F4/80+CD11b+ from the same experiment injected with 
SUDHL6.   The majority if not all of the mouse cells found to infiltrate the xenografts 
were F4/80+CD11b+.  (C)  There was only a small population of B220+ cells making up 
<1% of infiltration mouse population as shown by the representative dot plot and no 
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Figure 4.16 Percentage of mouse CD45+ and F4/80+CD11b+ varied between 
GCB and ABC-type DLBCL cell line xenografts.  The percentage of mouse 
CD45 cells varied between the xenografts derived from DLBCL cell line.  The 
two GCB-type DLBCL xenografts had a higher percentage of mouse 






4.4.2 Reduced infiltration of F4/80+CD11b+ cells in xenograft 
tumours from mice treated with BAF312 
 OCI-Ly1 and SUDHL6 xenografts from mice treated with 3mg/kg 
BAF312 had reduced F4/80+CD11b+ infiltration to their tumours compared to 
vehicle treated mice.  Xenografts were established using OCI-Ly1 and 
SUDHL6 in NSG mice.  OCI-Ly1 engrafted mice were given 3mg/kg BAF312 
or vehicle on Monday, Wednesday, and Friday for total of 3 doses.  Experiment 
ended when at least one mouse had a tumour length of 1.1cm, the maximum 
tumour size under our Home Office project licence.  Flow cytometry gating 
strategy to determine absolute numbers of the F4/80+CD11b+ cells in 
xenografts (Figure 4.17). There was no significant difference in tumour volume 
between BAF312 and vehicle treated mice (Figure 4.18A).  BAF312 was well 
tolerated with no weight loss observed (Figure 4.18B). Flow cytometry for 
F4/80+CD11b+ cells in xenografts were significantly reduced in BAF312 
treated tumours (Figure 4.18C). 
 SUDHL6 engrafted mice were given 3mg/kg BAF312 or vehicle every 
other day for a total of five doses.  There was a significant difference in tumour 
volume on day 26 (Figure 4.19A).  Mice did not lose body weight throughout 
treatment with BAF312 (Figure 4.19B).  Flow cytometry analysis of SUDHL6 
xenograft tumours, showed there was a significant decrease in the absolute 























Figure 4.17 Gating strategy for quantitating absolute numbers of 
F4/80+CD11b+ cells in xenograft tumours.  Representative dot plots 
showing gating strategy for flow cytometry quantitation of xenograft 
tumours using Count Bright beads.  (A) First singlets were gated.  (B) 
Count Bright beads and live cells were gated on FSC/SSC.   (C) From 
this gate, mouse CD45-AlexaFluor 700 vs human CD45-Pacific blue 
gates were set and (D) from cells in mouse CD45 gate, I gated on F4/80-
PE and CD11b-PECy7.  See Materials and Methods for method of 
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Figure 4.18 BAF312 reduced infiltration of F4/80+CD11b+ cells to OCI-Ly1 
xenografts.  (A) Tumour measurements show there was no difference in the tumour 
volumes of vehicle compared to BAF312 treated mice. There were 4 mice per 
treatment group.  I performed these experiments published in Lupino et al (2019). 
(B) 3mg/kg daily treatment with BAF312 was well tolerated and body weight 
remained steady throughout study.   (C) Flow cytometry analysis of tumours did 
show a significant reduction of F4/80 +CD11b+ mouse cells.   
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Figure 4.19 BAF312 reduced infiltration of F4/80+CD11b+ cells to SUDHL6 
xenografts.  (A) Tumour measurements show there was a significant difference 
in the tumour volumes of vehicle compared to BAF312 treated mice on day 26.  
There were 4 mice per treatment group.  I performed these experiments 
published in Lupino et al (2019) (B) 3mg/kg daily treatment with BAF312 was 
well tolerated and body weight remained steady throughout study.   (C) Flow 
cytometry analysis of tumours did show a significant reduction of F4/80 
+CD11b+ mouse cells.   

























 SUDHL6 xenografts treated with BAF312 were also evaluated for 
apoptosis marker, cPARP (Lupino et al., 2019).  There was an increase in 
cPARP in the tumours treated with BAF312 compared to vehicle treated 
tumours (Figure 4.20A).  This is in keeping with the anti-apoptotic effect of 
S1P which was reduced with the inhibition of S1PR1.  Total number of CD31+ 
cells, endothelial cells, was measured by flow cytometry and there was a 




























































































cPARP       SUDHL6- Control cPARP      SUDHL6- BAF312 
Figure 4.20 cPARP expression was increased and absolute numbers of CD31 
was decreased in BAF312 treated SUDHL6.  (A) Representative images of 
SUDHL6 xenografts treated with control or BAF312 3mg/kg were evaluated for 
presence cPARP as measure of apoptosis.  BAF312 treated animals had 
increased apoptosis compared to control.  cPARP counts show a significant 
increase of cPARP staining in the BAF312 treated tumours compared to control.   
Staining was performed by Dr Gary Reynolds and counts per 3xHPF (40x) was 
performed by pathologist, Dr Matt Pugh (Lupinoet al, 2019).  Student’s t-test 
was used to determine value. (B) Mouse CD31 was evaluated in DLBCL 
xenografts treated with BAF312.  There was a significant reduction of CD31 in 
SUDHL6 BAF312 treated tumours.  I analysed tumours for CD31 by flow 


















4.4.3 Optimising A20, a syngeneic model of DLBCL  
 A20 mouse lymphoma was derived from an aging BALB/c mouse and 
therefore, could be engrafted in immune competent BALB/c mice (Donnou et 
al., 2012, Kim et al., 1979, Palmieri et al., 2010).  Engraftment kinetics of A20 
cells injected subcutaneously (SC) and intravenously (IV) in BALB/c mice is 
shown in Figure 4.21.  SC will result in solid tumour on flank and IV injection 
leads to systemic engraftment including spleen and liver involvement. 
 Three BALB/c mice subcutaneously injected with A20 had measurable 
tumours on day 13.  These tumours reached maximum tumour size by day 27 
in 3/3 mice injected (Figure 4.21A).  Flow cytometry showed that F4/80+ 
CD11b+ cells had infiltrated the SC A20 tumours. Using three more BALB/c 
mice, A20 cells were injected IV in the tail vein and were monitored every 
other day by palpation of the abdomen, for body condition, and body weight.  
While the IV injected mice did not lose body weight or show signs of reduced 
body condition, enlarged organs were detected by palpation of the abdomen.  
IV injected mice were culled on day 27 where post-mortem revealed significant 
enlargement of both spleen and liver in A20 engrafted mice compared to 
controls (Figure 4.21B).  H&E staining confirmed the presence of neoplastic 
lesions in the engrafted spleens and livers (Figure 4.22A-B).  The population of 
F4/80+CD11b+ cells were significantly higher in engrafted mice compared to 
normal BALB/c spleens and livers. This was confirmed by IHC staining for 
F4/80 in SC tumours where there was an increased infiltration in engrafted 






















A20 syngeneic model of DLBCL injected subcutaneously 
Figure 4.21 Determining engraftment kinetics of mouse DLBCL cell line, A20, injected 
subcutaneously or intravenously in BALB/c mice.  (A) A20 cells were injected 
subcutaneously on the flank of BALB/c mice.  Once tumours were measurable, they were 
measured every 2-3 days. N=3 mice were injected.  By day 27, 3/3 mice engrafted with 
A20 at maximum tumour length of 1.1cm.  SC tumours have an infiltration of 
F4/80+CD11b+ host mouse cells. (B)  A20 cells were injected intravenously in the tail 
vein of BALB/c mice.  Mice were monitored weekly by abdomen palpation.  Mice were 
culled at day 27 as abdomen palpation indicated enlarged spleens compared to control.  
F4/80+CD11b+ macrophages were increased in the engrafted spleens and livers. 
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Figure 4.22 F4/80+ cells present in SC tumours, spleen and liver tumours from 
A20 engrafted mice.  Representative images of F4/80 staining A20 engraftment 
kinetics study.  (A) A20 cells injected subcutaneously in BALB/c mice show an 
infiltration of F4/80+ cells. Black arrows indicate positive F4/80 staining. (B) A20 
cells injected IV in BALB/C mice with tumour engraftment to spleen and liver. 
Resulting tumours had positive staining for F4/80 visible throughout the tumours.  






4.4.4 Reduced infiltration of F4/80+CD11b+ cells to spleen and liver 
from systemically engrafted A20 after BAF312 treatment 
 A20 engrafted BALB/c mice were treated on day 4 post IV injection with 
3mg/kg BAF312.  Mice were treated every other day except weekends for three 
weeks for a total of nine doses with BAF312.  On day 25 mice were culled and 
liver and spleen weights were compared with three normal BALB/c mice.  
Spleen and liver were significantly enlarged in vehicle treated mice compared 
to normal mice (Figure 4.23A).  Treatment with BAF312 did not significantly 
reduce spleen or liver weight (Figure 4.23A).  Spleens and livers from BALB/c, 
vehicle or BAF312 treated mice were analysed by flow cytometry for 
F4/80+CD11b+ cells.  There was a significant reduction in F4/80+CD11b+ cells 
in BAF312 treated mice compared to vehicle (Figure 4.23C).  Again BALB/c 
mice tolerated treatment with BAF312 during three weeks of daily dosing 
(except weekends) and showed no weight loss throughout experiment (Figure 





























































































Figure 4.23 In vivo effects of BAF312 in A20 syngeneic grafts.  A20 was injected in BALB/c 
mice by IV injection. On Day 4, mice were randomised into vehicle and BAF312 treatment 
groups.  Mice were given vehicle or 3 mg/kg BAF312 P.O. Three times a week for three weeks.  
Mice were culled on day 27.  (A) Spleen and liver weight of engrafted mice (N=5 per group) 
was significantly higher than normal BALB/c spleen (N=3). There was no significant 
difference in spleen or liver weight in BAF312 treated mice compared to vehicle.  I performed 
these experiments published in Lupino et al (2019). (B) Body weight of mice remained 
unchanged throughout treatment. (C) Spleen and liver from BALB/c were analysed by flow 
cytometry for F4/80 and CD11b.  Spleen and liver from mice treated with BAF312 had lower 
total F4/80CD11b + cells than vehicle treated mice although spleen and liver weight were not 
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4.5 Discussion   
TAMs are largely made up of recruited monocytes that have been 
polarised within the microenvironment but can also include tissue resident 
macrophages (Franklin and Li, 2016).  There is contradicting evidence on the 
effect of macrophage infiltration on prognosis in DLBCL which may be to the 
different methods, reagents, and cohorts used to evaluate macrophages in 
DLBCL   (Shen et al., 2016, Wang et al., 2017, Gomez-Gelvez et al., 2016, 
Hasselblom et al., 2008, Konig et al., 2010).  Nonetheless, macrophages are the 
dominant non-malignant cell type in DLBCL tumours and evidence continues 
to accumulate showing that macrophages contribute to the pathogenesis of 
DLBCL (Pham et al., 2018, Li et al., 2019, Scott and Gascoyne, 2014).   
 Ceramide/sphingosine was shown to induce apoptosis while S1P had an 
anti-apoptotic effect as discussed in the Introduction section 1.4.5. The S1P 
secreted by apoptotic cells is said to be primarily formed by SPHK2 and while 
extracellular S1P, considered to be the onco-lipid, is formed by SPHK1 (Gude 
et al., 2008, Weigert et al., 2006). Therefore, cell death or apoptosis in 
monocytes and macrophages after S1P treatment was not evaluated.  
Apoptosis was evaluated in the xenograft tumours treated with BAF312 which 
indicated  
GM-CSF M1 and M-CSF M2 had different phenotype shown by the 
absence of CD163+ in GM-CSF polarised M1 macrophages as well as typical 





receptor expression for M1 and M2 macrophages were similar.  Both M1 and 
M2 had lower S1PR1 expression and higher S1PR2 expression compared to 
matched monocytes.  This is in keeping with migration results to S1P.   
This inverse expression of S1PR1 and S1PR2 has been reported in 
dendritic cells. In immature dendritic cells, RAC signalling by CCL19/CCR7 
binding is limited whilst binding of S1P to S1PR2 leads to higher RHO 
signalling (Konig et al., 2010).  Increased RHO results in translocation of 
FHL2 to the nucleus inhibiting S1PR1 expression.  As dendritic cells mature, 
CCR7 surface expression increases and S1PR2 expression decreases leading to 
increased RAC and increased expression of S1PR1 (Konig et al., 2010, Spiegel 
and Milstien, 2011). S1PR2 was also shown to antagonise S1PR1 expression in 
endothelial cells where the balance of signalling through these receptors 
regulated their migration (Spiegel and Milstien, 2011).   
Previous reports of expression of S1P receptors in monocytes and 
macrophages have mainly been described in mouse macrophages (Muller et al., 
2017, Yang et al., 2018).  Expression of S1PR1, S1PR2 and S1PR5 were 
decreased in M1 and M2 macrophages compared to monocytes and S1PR2 
expression was significantly increased. Whilst, expression of S1PR3 and 
S1PR4 was higher in M2 macrophages but lower in M1 macrophages 
compared with monocytes (Muller et al., 2017).  Muller’s results with mouse 
macrophages were similar with the S1P receptor expression profiles reported 
in this thesis for human macrophages. Discrepancies may be attributed to 





S1PR1 is important for migration while S1PR2 is important in cell 
retention (Wang et al., 1999).  With most cells expressing all 5 S1P receptors, 
the binding of S1P is preferential for S1PR1 as it has the highest affinity for 
S1P (Hanson and Peach, 2014). Antagonism of S1PR1  is an accepted 
intervention for the treatment of diseases such as multiple sclerosis and there 
is evidence it may be therapeutic for the treatment of DLBCL (Hanson and 
Peach, 2014, Liu et al., 2012).  Several antagonists to S1PR1 have been 
developed; ponesimod, ozanimod, and BAF312 that are potent and highly 
specific (O'Sullivan and Dev, 2013).  Both ponesimod and BAF312 blocked 
migration of monocytes to DLBCL conditioned medium showing that migration 
to DLBCL was mediated by S1PR1 signalling. 
S1PR2 is a tumour suppressor in DLBCL (Stelling et al., 2018).  Despite 
the low expression of S1PR2 in malignant B cells, a lower S1PR1/S1PR2 ratio 
of expression in TAMs may lead to increased recruitment and retention of 
macrophages. Several studies has found that increased number of 
macrophages confers a better survival for patients with R-CHOP (Riihijarvi et 
al., 2015, Wang et al., 2017, Marchesi et al., 2015).  S1P attracts monocytes 
and macrophages in DLBCL where it can contribute to therapeutic responses.  
BAF312 blocked the migration of monocytes in vitro and in vivo although 
reducing the infiltration of monocytes/macrophages may not be sufficient to 
reduced tumour volume.  It remains to be established if this is an appropriate 


























Evaluating the effect of S1P on phagocytosis in 
rituximab-opsonised DLBCL  
5.1 Introduction 
 Macrophages are vital players in innate immunity providing first-line 
defence during inflammation and infection (Mills and Ley, 2014).  Once 
monocytes arrive to the site of inflammation, they can be classically activated, 
secreting inflammatory cytokines to recruit other immune cells.  As the 
inflammation subsides, the switch from an inflammatory state to a wound 
healing state requires the removal of neutrophils by apoptosis and 
phagocytosis.  S1P acts as a “find me” signal released by apoptotic cells 
recruiting more monocytes via S1PR1 to phagocytose dying cells.  (Martinez 
and Gordon, 2014, Shi and Pamer, 2011, Mantovani et al., 2010, Wang et al., 
1999)  Besides recruitment of macrophages, McQuiston et al demonstrated 
that at lower concentrations of S1P there was an increase in phagocytic index 
while at higher concentrations such as 1µM S1P there was a reduction in the 
phagocytic index of Cryptococcus neoformans by alveolar macrophages 
(McQuiston et al., 2011).   
 In the previous chapter, tumours were shown to have elevated S1P 
levels can mimic this “find me” signal and recruit monocytes/macrophages to 





in the context of macrophage function, phagocytosis (Nagahashi et al., 2012, 
Kunkel et al., 2013).  Specifically, in vitro polarised macrophages were 
assessed for their ability to phagocytose latex beads and of rituximab-treated 
DLBCL cell lines in the presence of S1P.  
5.2 Phagocytosis of FITC+ latex beads 
5.2.1 Establishing the optimum time point for phagocytosis assays 
 To establish the optimal timepoint to study phagocytosis, a time course 
experiment was done using three donors.  M1 and M2 macrophages from these 
donors were stained with eFluor450 dye and resuspended to 1x106 cells /ml.  In 
flow cytometry tubes, 100μl of the macrophage cell suspension was added to 
1μl of FITC+ beads (Figure 5.1). Macrophages were incubated with beads for 
15, 30, 60, and 90 minutes.  Trypan blue was added to quench the signal from 
FITC+ beads not engulfed by macrophages.  Phagocytosis was then assessed 
by flow cytometry for eFluor450+ macrophages that have engulfed FITC+ 
beads.  Representative dot plots that illustrated the gating for FITC+ 
eFluor450+ macrophages are shown in Figure 5.2A.  The phagocytosis ratio 
was calculated by dividing the number of FITC+ eFluor450+ macrophages by 
the total number of macrophages counted.  Median fluorescent intensity (MFI) 
for FITC was also measured for each sample.  For some donors, phagocytosis 
already began to slow at 90 minutes (Figure 5.2B-C).  Therefore, this time 
point was chosen for subsequent assays.  






















Figure 5.1 Flow diagram of phagocytosis assay using FITC+ beads.  
Macrophages were resuspended in 1%FBS/RPMI 1640 and added to FACS 
tubes.  FITC+ beads were then spiked into the FACS tube in 1:100 
dilution.  FACS tubes were incubated at 37°C for 15, 30, 60, and 90 
minutes.  At each time point, a FACS tube was removed from the 
incubator and trypan blue was added to quench beads that had not been 
phagocytosed.  The cells were kept on ice and washed twice with cold assay 
buffer.  Tubes were kept cold until analysed on the flow cytometer.   
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N= 3, Donors L, W and X 
 
Figure 5.2 Time course to determine optimal time point for phagocytosis in 
vitro (A) Representative graphs of FITC+ rabbit IgG coated latex beads 
incubated with macrophages and analysed by flow cytometry.  Macrophages 
with no beads were used as controls.   (B) 1x10
5
/100l of macrophages from 
three donors were incubated with beads in 1:100 ratio at 37°C for 15 min, 30 
min, 60 min, and 90 min. The mean fluorescent intensity of FITC was plotted 
for each time point.  In addition, the number of FITC+ macrophages/total 
number of macrophages counted was used to calculate a phagocytosis ratio.  



















































































5.2.2 S1P-treated M1 had reduced phagocytosis of FITC+ beads 
 Next, the effect of S1P on phagocytosis was examined. To do this, M1 
and M2 macrophages from at least two donors in three independent 
experiments was pre-treated with 1µM S1P for one hour followed by the 
addition of FITC+ beads.  The samples were analysed by flow cytometry as 
previously described in Figure 5.1.  M1 macrophages treated with 1µM S1P 
had significantly reduced phagocytosis across all seven donors tested.  In 
contrast, S1P had no effect on phagocytosis by M2 macrophages (Figure 5.3A).    
 To validate the flow assay, microscopy was used to visualise FITC+ 
macrophages.  Macrophages from six donors were plated in duplicate on 8-well 
chamber slides in two separate experiments.  Cells were treated with 1µM S1P 
or vehicle for one hour before FITC+ beads were added in a ratio of 1:100.  
Then five high-power fields (40x) from duplicate wells were counted, then the 
phagocytosis ration was calculated but taking the total number of FITC+ 
macrophages as a proportion of the total number of macrophages.  Using this 
method, reduced phagocytosis by M1 macrophages in the presence of 1µM S1P 
compared with vehicle was observed (Figure 5.3B).  Overall, there were fewer 
FITC+ M2 macrophages and no difference between S1P treated and vehicle 
treated (Figure 5.3B).   
 Having shown that macrophages can phagocytose FITC+ beads, next 
phagocytosis of DLBCL cell lines was examined.  Flow cytometry was used to 





single experiment.  Analysis by phagocytosis ratio and median fluorescent 
intensity (MFI) provided similar results, therefore the phagocytosis ratio was 




































Figure 5.3 M1 macrophages pre-treated with 1 µM S1P showed reduced 
phagocytosis of FITC+ latex beads.  (A) Phagocytosis of FITC+ beads assessed by 
flow cytometry of a total of 7 donors (donors M, N, O, P, Q, R, S) tested in 3 
independent experiments showing an S1P-mediated decrease in phagocytosis M1 
compared to control.  Median Fluorescent Intensity (MFI) was also calculated and 
showed reduced MFI in S1P treated M1. P values were calculated using 2-way 
ANOVA.  (B)  To validate the phagocytosis assay, three donors in independent 
experiments (donors 2O, 2P, 2Q and donors 2R,2S, 2T) were plated in duplicate on 
chamber slides.  FITC+ beads were added in 1:100 ratio.  Counting at least 5-high 
power fields (40x), a reduced proportion of FITC+ macrophages in S1P treated M1 and 
M2 cultures was observed. M2 macrophages overall had a lower level of phagocytosis 
compared to M1 macrophages in this assay as shown by the representative images of 
the phagocytosis of FITC+ beads. 
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5.3 Phagocytosis of rituximab-opsonised DLBCL cell 
lines 
5.3.1 Evaluate surface expression of CD20 in DLBCL cell lines 
 Flow cytometry was used to study the expression of CD19 and CD20 in 
DLBCL cell lines with the intention of confirming expression of rituximab 
target (CD20).  OCI-Ly1, SUDHL6, OCI-Ly3, and U2932 all had high 
expression of CD20 (Figure 5.4).  U2932 and OCI-Ly3 expressed low levels of 
CD19 compared OCI-Ly1 and SUDHL6.  It has been reported that U2932 and 
OCI-Ly3 has lower CD19 surface expression than SUDHL6 (Hojer et al., 2014).  










Figure 5.4 DLBCL cell lines expressed CD20.  Dot plots for ABC and 
GCB type DLBCL cell lines assessed for CD19/ CD20 expression using 
flow cytometry.  There was a lower expression of CD19 in the two ABC-
type DLBCL cell lines compared to the GCB-type DLBCL cell lines.   In 
all cell lines, >75% of live DLBCL cells expressed CD20.   
ABC-type GCB-type 





5.3.2 S1P reduced phagocytosis of DLBCL cell lines by M1/M2 
macrophages 
The specificity of rituximab-induced phagocytosis was tested by using 
cells that were not a target for rituximab to evaluate base level phagocytosis of 
primary macrophages to human cells.  Jurkat, a T-lymphoblastic leukaemia 
cell line, was stained with eFluor450 cell dye and then treated with 10 g/ml 
rituximab or with isotype (IgG) control for >2hrs (Figure 5.5).  M1and M2 
macrophages were stained with CFSE and then co-cultured the tumour cells 
with macrophages for 90min.  Then co-cultures were evaluated for CFSE+ 
eFluor450+ cells using flow cytometry. Both rituximab and isotype control had 
similar levels of phagocytosis (<6%) of Jurkat cells.  This result reveals that 
the phagocytosis of rituximab-treated DLBCL cell lines I observed is mediated 
by rituximab. 
S1P concentration is said to be elevated in the tumour 
microenvironment while circulating levels of S1P remain relatively unchanged 
and this may point to tumour-associated S1P acting only within the tumour 
(Ramanathan et al., 2017).   The same concentrations used in migration assay 
were tested in the phagocytosis assay with DLBCL cell lines.  CFSE+ M1 and 
CFSE+ M2 macrophages from three donors were with 0.1, 1, and 10 µM S1P.   
SUDHL6, a GCB-type DLBCL cell line, was stained with eFluor450 and 























Figure 5.5 No effect of rituximab in the Jurkat cell line. Jurkat, an acute T-
cell leukaemia cell line, was treated with 10 μg/ml of rituximab or IgG 
isotype control as then co-cultured with M1 or M2 for 90 minutes.  
Phagocytosis was not enhanced after treatment with rituximab.  Data is 
representative of three donors (I2, J2, K2) analysed in triplicate.  
Phagocytosis ratio was calculated by taking double positive macrophages as 
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Rituximab-treated SUDHL6 cells was co-cultured with S1P-treated M1 or M2 
for 90 minutes.  Co-cultures were analysed by flow cytometry to detect the 
double positive macrophage population (CFSE+ eFluor450+) indicating 
phagocytosis. Experimental design and flow cytometry gating is shown in 
figure (5.6).   
 I found that 0.1, 1, and 10 µM S1P all significantly reduced the 
phagocytosis of SUDHL6 by both M1 and M2 macrophages (Figure 5.7A).  This 
experiment was repeated twice with a total of six donors and thus showed that 
in my experimental system, even low concentrations of S1P were sufficient to 
reduce phagocytosis of rituximab-treated DLBCL.  Having shown that all 
concentrations of S1P used were effective in inhibiting phagocytosis, I next 
wanted to confirm the effect of elevated S1P (1µM) on additional donors.  I 
found that M1 and M2 macrophages from 6/9 donors displayed significantly 
reduced phagocytosis after S1P treatment (Figure 5.7B).  There were 2/9 
donors (2D and 2E) that had reduced phagocytosis in M1 only.  One donor had 
no reduction of phagocytosis (donor 2C).  
 To confirm if the effect was rituximab dependent, ofatumumab (gift from 
Professor Tatjana Stankovic) was also used in similar phagocytosis 
experiments using 3 donors (C2, D2, E2).  I found that there was also a 
reduction in phagocytosis after S1P treatment in the ofatumumab treated 
SUDHL6 (Figure 5.8).  There was a small reduction though not significant 
with the M2 macrophages. This experiment should be repeated with more 






















Figure 5.6 Phagocytosis assay: experimental design and flow 
cytometry gating strategy.  (A) Macrophages (CFSE-positive) were pre-
treated with 1µM S1P or vehicle and DLBCL cell lines (eFluor450-
positive) were pre-treated with 10 µg/ml rituximab or isotype control and 
then co-cultured for 1.5 hr.  (B) Samples were visualised on BD LSRII 
and analysed with FACS Diva 8.0.  Isotype control treated DLBCL cells 
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Figure 5.7 Macrophages pre-treated with 1µM S1P had reduced phagocytosis of rituximab 
treated SUDHL6.  (A) Macrophages from six donors in two independent experiments (donors 
3A,3B,3C, and donors 2X, 2Y, and 2Z) were treated with vehicle, 0.1,1, or 10 µM S1P and 
then co-cultured with 10µg/ml rituximab treated SUDHL6 for 90 minutes.  There was a 
significant reduction of phagocytosis in the S1P treated M1 macrophages.  There was a 
smaller yet significant reduction in M2 macrophages.  (B) In nine donors tested in three 
independent experiments (Table 5.1) there was a small but significant reduction in 
phagocytosis by M1 and M2 macrophages of rituximab-treated SUDHL6. Phagocytosis ratio 
was calculated by determining the number of double positive macrophages as a proportion 
of macrophages and p value was calculated using 2-way ANOVA. 
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 To determine if the effect of S1P on phagocytosis could be relevant to 
other DLBCL cell lines, OCI-Ly1 (GCB-type) and OCI-Ly3 (ABC-type) DLBCL 
cells were tested.  A total of nine donors in triplicate for each cell line over 
three independent experiments were evaluated in the phagocytosis assay 
(Table 5.1).  There was a significant reduction in phagocytosis by M1 
macrophages of both rituximab treated OCI-Ly1 and OCI-Ly3 cells (Figure 
5.9A and B).  All donors tested had a significant reduction of phagocytosis after 
S1P treatment when co-cultured with OCI-Ly1.   For OCI-Ly3, only 6/9 donors 
showed a significant reduction in phagocytosis after S1P treatment (there was 
no significant phagocytosis in donors C2, D2, E2).  For both cell lines and all 
Figure 5.8 M1 and M2 macrophages were pre-treated with 1µM S1P had reduced 
phagocytosis of ofatumumab treated SUDHL6.  (A) Macrophages from three donors in a 
single experiment were treated with vehicle or 1 µM S1P and then co-cultured with 10µg/ml 
ofatumumab treated SUDHL6 for 90 minutes.  There was a significant reduction of 
phagocytosis in the S1P treated M1 macrophages.  There was a reduction though not 
significant with M2 macrophages.  2-way ANOVA was used to calculate P values. 





donors, there was no significant difference in phagocytosis between vehicle 
treated or S1P treated M2 macrophages.   
 Taken together, these results reveal that S1P reduced the phagocytosis 
of rituximab-treated DLBCL cell lines by M1 macrophages and in the case of 
SUDHL6, also by M2 macrophages. Donor ID of macrophages used in 
phagocytosis experiments is shown in Table 5.1. 























C2 C2 A2 C2 F2 L2 
D2 D2 B2 D2 G2 M2 
E2 E2 I2 E2 H2 N2 
O2  J2 H2 I2 R2 
P2  K2 I2 K2 S2 
Q2  O2 Q2 J2 T2 
R2  M M   
S2  U U   
























Figure 5.9 S1P reduced the phagocytosis of rituximab-treatment OCI-Ly1 and OCI-Ly3 
cells.  M1 and M2 macrophages co-cultured with rituximab treated (10 µg/ml) DLBCL cell 
lines OCI-Ly1 (top panel, A GCB type) and OCI-Ly3 (bottom panel, B; ABC type) were 
tested for phagocytosis +/- 1µM S1P.  A total of nine donors per cell line in three 
independent experiments were tested (Table 5.1).  Despite the variability between donors 
there was a significant decrease in phagocytosis of both OCI-Ly1 and OCI-Ly3 in S1P 
treated M1 macrophages. There was no significant difference in phagocytosis in M2 
macrophages.  There was a lower overall level of phagocytosis of OCI-Ly3 compared to the 











N= 9 donors 





5.3.3 Treatment with S1P receptor antagonist reverses the effect of 
S1P on phagocytosis 
 Having shown that S1P reduced the phagocytosis of rituximab-treated 
DLBCL cell lines, I next explored which S1P receptor was responsible.  To do 
this, CYM5220, an S1PR2 agonist and BAF312, an antagonist to S1PR1 and 
S1PR5 previously used in the analysis of migration were used (section 4.3.2).  
Rituximab-treated (10 µg/ml) SUDHL6 was co-cultured with either M1 or M2 
macrophages from three donors pre-treated with 1µM CYM5220, 1µM S1P, or 
1µM S1P + 100nM BAF312 in two independent experiments.  Phagocytosis 
was not reduced by treatment with CYM5220.  In contrast, the addition of 
BAF312 increased phagocytosis compared to treatment with S1P alone (Figure 
5.10A).  This indicated that S1PR1 or S1PR5 may be involved in phagocytosis 
and that S1PR2 was likely not. 
 To confirm that S1PR2 had no effect on phagocytosis, rituximab-
opsonised SUDHL6 was treated with 100nM JTE013, an antagonist of S1PR2.  
M1 and M2 macrophages from three donors treated with 1µM S1P+JTE013 
showed no difference in phagocytosis compared to 1µM S1P alone (Figure 
5.10B).  From these results, S1PR1, or S1PR5, or both may be responsible for 
the reduced phagocytosis of rituximab-opsonised SUDHL6 cells observed in 

























Figure 5.10 S1P receptor antagonist BAF312 blocked the effect of S1P on phagocytosis 
of SUDHL6 cells.  (A) Left panel: M1 and M2 macrophages pre-treated with S1PR1/S1PR5 
antagonist, BAF312 and S1PR2 agonist, CYM5220 1µM.  There was a decrease in 
phagocytosis by M1 and M2 after S1P treatment which was reversed with BAF312.  There 
was no effect of CYM5220.  Right panel shows no significant decrease with S1P treatment 
but a significant increase in phagocytosis with BAF312.  (B) To confirm that S1PR2 had no 
effect in reducing phagocytosis, cells were treated with JTE013, an S1PR2 antagonist and 
was compared to CYM5220 treatment.  JTE013 did not reverse the effect of S1P on 
phagocytosis.  Each experiment was performed with three donors in two independent 





























































































































N= 6 donors N= 6 donors 





5.3.4 100nm BAF312 and 10 µg/ml rituximab were not cytotoxic to 
SUDHL6 cells in vitro 
 To confirm that BAF312 did not induce apoptosis of the DLBCL cell 
lines, SUDHL6 cells were treated with 100nM BAF312 and analysed for 
apoptosis using Annexin V/PI assay.  Assessing apoptosis was essential 
apoptotic cells are known to release S1P and induce migration and 
phagocytosis by macrophages.  Vincristine (100nM) was used as a positive 
control.  After 24 hrs, cells were stained for Annexin V/PI and analysed on flow 
cytometer to assess levels of phagocytosis.  Only about 20% of the SUDHL6 
cells treated with 100nM vincristine survived SUDHL6 cells after 24hr.  There 
was no change in survival of SUDHL6 cell treated with BAF312 compared to 
untreated/DMSO controls (Figure 5.11).   
 Given the mechanisms of action of rituximab, I next determined if 
10µg/ml rituximab would induce apoptosis in SUDHL6 cells.  As with BAF312, 
SUDHL6 cells were treated with10 µg/ml rituximab for 24hr and for the 
positive control, 10nM vincristine.  A lower dose of vincristine was used in this 
experiment as 100nM vincristine had killed the majority of SUDHL6 cells 
after 24hr.  With the 10nM vincristine, nearly 40% of the SUDHL6 cells were 
apoptotic/dead and there was no change in survival of SUDHL6 cells after 


































































Annexin V Annexin V 
Vincristine 100nM BAF312 100nM 
Figure 5.11 BAF312 did not induce apoptosis or cell death SUDHL6 
cells after 24 hr.  The SUDHL6 cell line was treated with DMSO, 100nM 
vincristine or 100nM BAF312 for 24rs.  Cells were assessed for apoptosis using 
Annexin V/PI.  DMSO control and BAF312 treated cells did not differ from 
untreated cells.  As a positive control, cells were also treated with vincristine, 
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Figure 5.12 Rituximab did not induce apoptosis or cell death SUDHL6 
cells after 24hr.  SUDHL6 cell line was treated with DMSO, isotype control, 
0.01µM vincristine, or 10µg/ml rituximab for 24rs.  Cells were assessed for 
apoptosis using Annexin V/PI.  There was no significant difference in 
apoptosis between rituximab treated cells compared to DMSO or isotype 
control treated cells. The positive control, vincristine had increased cell 





5.4 Optimisation of rituximab-chemotherapy for mouse 
models of DLBCL   
5.4.1 Vincristine and doxorubicin are cytotoxic to DLBCL cell lines 
 Thus far, I have demonstrated that S1P can reduce phagocytosis of 
rituximab-treated DLBCL cells in vitro and that this effect could be ablated in 
the presence of BAF312. In all cell lines, the effect was mainly in M1 though 
this decrease could also be seen in M2 with SUDHL6.   In vivo, mouse 
macrophages were shown to be recruited to the tumour environment during 
engraftment of DLBCL and treatment with BAF312 reduced the number of 
macrophages in the tumour compared to controls with no effect on tumour 
burden except in the SUDHL6 xenograft.  Next, the efficacy of the combination 
of BAF312 and rituximab-chemotherapy treatment in mouse xenografts was 
evaluated.   
 The in vitro cytotoxicity of two chemotherapy compounds, vincristine 
and doxorubicin, routinely used in the treatment of DLBCL patients was 
determined.  Four DLBCL cell lines were tested; OCI-Ly1, SUDHL6, OCI-Ly3 
and A20.  Cell viability was assessed using the Cell Titre Glo (Promega) 
luminescent cell viability assay which measures adenosine triphosphate (ATP) 
release of live cells. Varying concentrations of vincristine or doxorubicin in 96-
well plates was added to DLBCL cells and incubated for 96 hr.  The surviving 
fraction was then calculated by taking relative light units (RLU) of 





control cells.  The IC50 of vincristine and doxorubicin was then calculated 
using Graph Pad Prism v8.   
 All DLBCL cell lines tested were sensitive to vincristine in nanomolar 
concentrations (Figure 5.13).  The IC50 for 96hr treatment with vincristine of 
these cell lines are as follows: OCI-Ly1 IC50= 5nM; SUDHL6 IC50= 2nM; OCI-
Ly3 IC50= 9nM; and for the mouse A20 lymphoma cell line, the IC50= 19nM.  
The four DLBCL cell lines were also sensitive to doxorubicin but the IC50s 
were 30-50X higher than for vincristine.  The IC50 for 96hr treatment with 
doxorubicin is as follows: OCI-Ly1 IC50= 178nM; SUDHL6 IC50=106nM; OCI-
Ly3 IC50= 444nM; and A20 IC50= 82nM (Figure 5.14).   
 The IC50 of rituximab was also assessed in two DLBCL cell lines, OCI-
Ly1 and OCI-Ly3 using Cell Titre Glo assay after 96 hrs treatment.  The IC50 
was not reached in the rituximab (1nm – 1000nm) treated cells (Figure 5.15).  
OCI-Ly1 had a maximum of 20% cell death at 25nM rituximab (Figure 5.15 
top panel).  Overall there was no difference in viability with rituximab treated 
and the matching concentrations of IgG isotype treated cells as seen in the 
apoptosis assay. 
 Vincristine was chosen for in vivo experiments because of its high 
potency (low IC50s) against the DLBCL cell lines tested.  SUDHL6 was the 
most sensitive DLBCL cell line to vincristine and had a high expression of 
CD20 shown in the previous chapter.  SUDHL6 was also the cell line where 





described earlier in this chapter.  Therefore, SUDHL6 was chosen for the in 











































































































Figure 5.13 DLBCL cell lines were sensitive to vincristine.  OCI-Ly1, SUDHL6, 
OCI-Ly3, and mouse cell line, A20 were treated with vincristine for 96 hours.  
All three human DLBCL cell lines were highly sensitive to vincristine with 
IC50s ranging from 2nM – 9nM. The A20 cell line was also sensitive with an 
IC50 19nM.  Each cell line was tested in three independent experiments which 
is represented on each graph.  Error bars represent standard deviation and the 



























log concentration µM 
log concentration µM 




























































































Figure 5.14 DLBCL cell lines are sensitive to doxorubicin.  Human DLBCL 
cell lines; OCI-Ly1, SUDHL6, OCI-Ly3, and the mouse cell line, A20 were 
treated with doxorubicin for 96 hrs.  IC50 was determined for each cell line.  
OCI-Ly1 and SUDHL6, both GCB-type DLBCL cell lines, were more sensitive 
to doxorubicin compared to OCI-Ly3, an ABC-type DLBCL cell lines with the 
IC50>100nM. For the A20 cell line, the IC50 for doxorubicin was 82nM.  Each 
cell line was tested in three independent experiments which is represented on 
each graph.  Error bars represent standard deviation and the IC50 was 
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Figure 5.15 Rituximab treated DLBCL cell lines were assessed for cell 
viability after 96hrs treatment. OCI-Ly1 and OCI-Ly3 were treated with varying 
concentrations of rituximab for 96 hrs.  Cell Titre Glo assay was used to assess surviving 
fraction as a proportion of control (isotype control) but there was no cell death evident at 
any concentration.  Two independent experiments were done with each point in 
triplicate. Error bars represent standard deviation and the IC50 was 






5.4.2 1mg/kg vincristine was sufficient to reduce tumour burden in 
SUDHL6 xenografts 
 SUDHL6 was subcutaneously engrafted on the flank of eight NSG mice. 
Tumours became measurable on day 17 post injection.  Mice were then 
randomised as described in Materials and Methods 2.4.2, into vehicle (N=4) or 
vincristine (N=4) treatment groups.  Vehicle (water for injection) or 1mg/kg 
vincristine was administered by IV injection and monitored for weight loss and 
tumour growth every other day.   Experiment was ended on day 24 when some 
of the control mice reached >900mm3 tumour volume.  Vincristine treated mice 
had significantly delayed tumour growth compared to vehicle treated mice 
(Figure 5.16A). 
 Percent change in tumour volume was calculated using the formula:                  
((Final tumour volume – Initial tumour volume)/ Initial tumour volume) X 100 (Gao 
et al., 2015).  Vincristine treated mice had significantly reduced in tumour 
volume compared to vehicle treated mice (Figure 5.16B). To calculate the 
percent tumour growth inhibition (TGI), the average tumour volume of  the 
vincristine treated group (483.98 mm3) was taken and was divided by the 
average tumour volume of the control group was (1883.23 mm3) (Blumenthal, 
2005).  The result was subtracted from 1 and multiplied by 100.  Thus, by this 
calculation, 1mg/kg vincristine reduced tumour growth by 75% and therefore, 





 Tumours were analysed by flow cytometry for F4/80+/CD11b+ cells. 
Despite the 75% reduction of vincristine tumour volumes, the difference in the 
number of F4/80+CD11b+ cells between vincristine treated tumours and 
vehicle treated tumours went from 13% down to 8% (Figure 5.16C). 
 
 






% Tumour growth 
inhibition (TGI) 
Vehicle control 1883.23  




























Figure 5.16 1mg/kg vincristine showed potent anti-tumour effect against SUDHL6 
xenografts.  (A) SUDHL6 engrafted mice were injected with vincristine on day 17 
post injection. There was a significant difference in tumour volume between 
vincristine treated mice vs control treated mice.  (B) Percent change in tumour 
volume calculated using formula: ((tumour volume final – tumour volume initial) / 
tumour volume initial) X 100 for each mouse indicates that vincristine inhibited 
tumour growth in 3/4 vincristine treated NSG mice.  (C) Tumours were analysed by 
flow cytometry for the presence of mouse macrophages.  There were nearly double 














































































































5.4.3 SUDHL6 engrafted mice treated with 0.5mg/kg vincristine 
combined with 1mg/kg rituximab had a complete response 
 Having shown that 1mg/kg vincristine was sufficient to reduce tumour 
volume of SUDHL6 xenografts, next the combination of rituximab with 
vincristine was tested.  A suboptimal dose of vincristine, 0.5mg/kg, was used 
instead of the full 1mg/kg for two reasons: first, to reduce the risks for adverse 
effects in mice given drug combination of vincristine and rituximab and 
second, to determine the efficacy of reduced vincristine dosage combined with 
rituximab.  NSG mice were engrafted subcutaneously with SUDHL6 and then 
randomised into treatment groups with N=4 mice per group: vehicle, 0.5mg/kg 
vincristine, 1mg/kg rituximab, 0.5mg/kg vincristine + 1mg/kg rituximab.  
Vincristine was given on day 19 and rituximab treatment began on day 20 
(both by IV injection) (Figure 5.17A). 
 There was no significant tumour inhibition in the vincristine or 
rituximab treatment groups compared to control but there was a significant 
difference in tumour volume observed in the combination treatment group 
compared to control beginning on day 22 (Figure 5.17A).  From the percent 
change in tumour volume, a complete response in 3/4 mice in the combination 
treatment group was evident (Figure 5.17B).  The TGI was calculated and 
summarised in Table 5.1, vincristine group had TGI=42.1%, rituximab group 
had TGI=26.3% and combination group had TGI=93.4%.  The absolute number 
of infiltrating F4/80+CD11b+ cells was lower in the treatment groups 





a second time which confirmed that mice given rituximab+0.5mg/kg vincristine 
had a complete response to the treatment.   
 
 






% Tumour growth 
inhibition (TGI) 
Vehicle control 869.3  
Vincristine 0.5mg/kg 502.4 42.1 




% tumour growth inhibition (TGI) calculated using the following formula 
























































Figure 5.17 Combination treatment with rituximab and 0.5mg/kg vincristine 
resulted in complete response in SUDHL6 engrafted mice.    (A) Average 
tumour volumes for each group were measured on each treatment day.  
Randomisation and treatment began on day 19 and experiment ended on 
day27 due to control mice reaching >900mm
3
.  There was significant 
regression of tumour growth in vincristine + rituximab treated mice by day 22 
(* p= .0260, *** p= .0008, **** p< .0001).  Treating mice with 0.5mg/kg 
vincristine and 1mg/kg rituximab as single agents did not have significant 
tumour inhibition compared to control. (B) Percent change in tumour volume 












































































































































































Figure 5.18 Compared to controls, vincristine and rituximab treated mice 
had reduced absolute numbers of F4/80+ cells compared to control in 
SUDHL6 xenografts.  Rituximab and combination treatment groups had 
reduced F4/80+/CD11b+ cells compared to control, as assessed by flow 
cytometry.  There was only one mouse left in the combination treatment 





5.4.4 BAF312 given prior to rituximab reduces the efficacy of 
rituximab and vincristine treatment in vivo 
 Next, the addition of BAF312 to the combination of vincristine/ 
rituximab would affect the growth of SUDHL6 tumours was studied.  In the 
previous section, it was demonstrated that the combination of rituximab and 
vincristine resulted in complete response in 3/4 treated mice.  For this 
experiment, the dose of vincristine was reduced to 25% of the original dose i.e. 
0.25mg/kg and the dose of rituximab was reduced to 50% of the original dose 
i.e. 0.5mg/kg.  Several publications reported the testing of 0.03mg/kg, 0.3mg/kg 
and 3mg/kg BAF312 for therapeutic efficacy using the rat and mouse models 
for experimental autoimmune encephalomyelitis (EAE) (Gergely et al., 2012, 
Lewis et al., 2013).  BAF312 treatment at 0.3mg/kg and 3mg/kg given daily for 
>20 days reduced the clinical score in preclinical models.  According to the 
growth kinetics, the window of treatment for SUDHL6 was a maximum of 10 
days.  Therefore, I opted to use the highest dose employed in these published 
experiments.  This was the same dose used in the previous chapter where 
treatment with 3mg/kg BAF312 reduced the infiltration of F4/80+ cells in 
DLBCL xenografts.   
 Twenty NSG mice were injected with SUDHL6 subcutaneously.  On day 
18 mice were randomised into four treatment groups: (1) vehicle; (2) vehicle / 
vincristine / rituximab; (3) BAF312 / vincristine / rituximab; (4) vincristine / 
rituximab / BAF312.  The treatment schedule for this experiment is shown in 





did not have significant tumour inhibition compared to control (Figure 5.19).  
Vincristine and rituximab without BAF312 showed a significantly reduced 
tumour volume compared to control.   Furthermore, the addition of BAF312 
post vincristine and rituximab treatment also led to the significant inhibition 
of tumour growth compared to control (Figure 5.19).  There was no significant 
difference between tumour volumes in mice treated with BAF312 following 
vincristine/rituximab and tumour volumes in mice treated with 
vincristine/rituximab only.   The TGI for each group were: Group 2 TGI=36.8%; 
Group3 TGI=32.1%; Group 4 TGI=54.9% (Table 5.5). 
 Survival of mice in this experiment was plotted on a Kaplan Meier 
graph.  Mice were censured when their tumours reached 1.1cm, the maximum 
tumour size allowed under our Home Office licence (Figure 5.20).  Mice treated 
with BAF312 after vincristine and rituximab had better survival than all other 
groups and this was significant for all groups (p values for group1 vs group 2 












Table 5.4 Treatment schedule for in vivo evaluation of BAF312 with rituximab 
and vincristine. 
 





Chart shows the treatment schedule for each group. Group 1: control; Group 2: 
vehicle/ vincristine followed by rituximab; Group 3: BAF312/vincristine 
followed by rituximab; Group 4: vincristine followed by rituximab/BAF312 
 








1 control 777  
2 vehicle/vinc→rituximab 527.5 32.1% 
3 BAF312/vinc→rituximab 491.2 36.8% 
4 vinc→rituximab/BAF312 350.2 54.9% 
Vinc= vincristine, %TGI= (1-(avg tumour volume treated/avg tumour volume control)) x 100 








           



































Figure 5.19 BAF312 given prior to vincristine and rituximab had a reduced 
effect compared to giving BAF312 after vincristine and rituximab.  There was a 
significant difference in average tumour volume when BAF312 was given post 
vincristine and rituximab treatment.  Giving BAF312 prior to vincristine and 
rituximab did not have a significant effect unlike vincristine and rituximab 






















Figure 5.20 Kaplan Meier analysis shows that mice treated with vincristine 
and rituximab prior to BAF312 had better survival. Mice were censured when 
tumour size reached 1.1cm in size, the maximum tumour size allowed according to our 
Home Office licence.  All vehicle treated mice reached censure cut-off by day 27.  Mice 
from groups given vincristine and rituximab alone or BAF312 prior to combination 
treatment also had mice censured.  None of the mice treated with vincristine and 
rituximab combined prior to BAF312 were censured.  N=4 per group with student’s 
t-test used to determine p value. 
 































 Having shown that monocytes and macrophages migrate in an S1P-
dependent manner, I next explored the effect of S1P on phagocytosis and found 
that S1P reduced the phagocytosis of FITC+ latex beads coated with rabbit IgG 
by macrophages.  Moreover, S1P also was shown to reduce the phagocytosis of 
rituximab treated DLBCL cell lines.  Blocking S1PR1 (and S1PR5) with 
BAF312 reversed this inhibitory effect reduction and that S1PR2 agonist had 
no effect.  A limitation of my result is that the S1P experimentally added does 
not mimic the phenotypic effects of S1P produced within tumour cells.  
Another limitation of my study, is that macrophages are highly adherent and 
will stick to polystyrene tubes, culture dishes, and glass.  M2 macrophages 
were found to phagocytose at similar ratios but the total macrophages counted 
were lower than for M1.  Perhaps M2 macrophages are stickier than M1 
causing them to adhere to the flow cytometry tubes during the phagocytosis 
assay.  This could also be the reason for my results showing M2 macrophages 
were less likely to migrate as shown in chapter 4.  M1 may be less adherent as 
it is an inflammatory macrophage which should either migrate to appropriate 
sites or migrate away when no longer needed. 
  M1 (GM-CSF) macrophages were more phagocytic of rituximab treated 
DLBCL than M2 (M-CSF) macrophages.  My results were in contrast to results 
shown by Leidi et al who examined M1 and M2 phagocytosis of rituximab 
treated B-CLL (Leidi et al., 2009).  Leidi et al differentiated primary CD14+ 





to the GM-CSF culture for 24hr and added IL-10 and IL-4 for 48hr.  Adding 
cytokines and LPS, a lipoglycan/endotoxin from gram negative bacteria, may 
have driven their M1 and M2 macrophages polarise to more extreme 
phenotypes on the spectrum of macrophage polarisation.  Also, according to 
their materials and methods, for each experiment the comparison between M1 
and M2 were not always with matched donors (Leidi et al., 2009).  Leidi et al 
also do not indicate the number of donors and CLL cases that were evaluated 
while I have evaluated at least nine different donors in their response to each 
of the rituximab-opsonised DLBCL cell lines.   
 The use of cell lines as DLBCL targets in my studies may also account 
for the disparity with published phagocytosis data as cell lines are considered 
less representative of primary tumours.  Though, I have been careful in the 
choice of cell lines, using SUDHL6 and OCI-Ly3 which by gene expression 
were shown to cluster by COO with DLBCL patients (Alizadeh et al., 2000).  
Another study by Herter et al who studied the FC-mediated phagocytosis of 
different subsets of blood derived macrophages also showed that M1 
macrophages has a lower phagocytic index than M2 macrophages (Herter et 
al., 2014).  This discrepancy  could be due to the alternative method of 
polarisation used by Herter whereby monocytes isolated by indirect 
purification were polarised with M-CSF before a further polarisation with 
INFγ and LPS for M1 differentiation, and various cytokines such as IL-4 for 
M2a, LPS + undefined immune complexes for M2b, and IL-10 for M2c 





were conducted in polystyrene tubes as discussed in Chapter 5 discussion 
which may also account for the lower phagocytosis of M2 compared to M1.  
 Modulating the tumour associated macrophages in DLBCL with GM-
CSF was in clinical trials but was stopped due to its toxicity in patients (Kahl 
et al., 2006, Chang et al., 2010).  But clinical studies with GM-CSF show that 
more optimisation should be done as GM-CSF is reported to increase the CD20 
expression of B cells and enhance ADCP (Chang et al., 2010).  In my studies, I 
have shown that increased S1P could reduce ADCP in GM-CSF polarised 
macrophages and taken together with Chang’s data could point to a potential 
stratification of patients with SPHK1 that may not benefit from GM-CSF 
treatment.  Also, the addition of BAF312 may be beneficial to counter the 
effects of S1P on ADCP if administered in the appropriate treatment sequence 
so as to not reduce macrophages but enhance phagocytosis.   
 From the in vitro results, I hypothesised that treating tumour bearing 
mice with BAF312 would reduce migration of infiltrating monocytes and 
macrophages which would in turn reduce the availability of macrophages to 
phagocytose rituximab treated DLBCL cells.  Preliminary experiments suggest 
this is the case.  Mice treated with BAF312 prior to the suboptimal dose of 
vincristine/ rituximab had a small reduction in efficacy. Further work to 
determine if BAF312 given for at least a week prior optimal treatment would 

























Conclusions and future perspectives  
 During homeostasis, high levels of ceramide or sphingosine leads to 
increased apoptosis and senescence.   Conversely, high levels of sphingosine-1-
phosphate (S1P) will promote cell survival and proliferation.  These 
contradictory functions are modulated by SPHK1, the enzyme responsible for 
the phosphorylation of sphingosine to S1P.  (Spiegel and Milstien, 2003)  S1P 
has also been implicated in angiogenesis and immune responses due to its role 
in lymphocyte trafficking.  As such, S1P is recognised as an onco-lipid which 
contributes to the pathogenesis of cancers such as DLBCL (Lee et al., 1999, 
Bayerl et al., 2008, Nagahashi et al., 2018a).   
 Re-analysis of published gene expression data of primary DLBCL 
indicate that both GCB and ABC subtypes have a higher SPHK1 expression 
than normal germinal centre B cells.  Our group has shown that SPHK1 drives 
angiogenesis in DLBCL and others have shown that S1PR1 signalling is 
associated with poor OS in R-CHOP treated patients (Lupino et al., 2019, Paik 
et al., 2014).  Evidence of the role of S1P and S1P receptor signalling in 
DLBCL continues to mount with the determination of S1PR2 as a bona fide 
tumour suppressor in DLBCL (Stelling et al., 2018, Vockerodt et al., 2019, 
Cattoretti et al., 2009).   The cell types involved in the S1P receptor signalling 
in DLBCL has not been fully elucidated.  We showed that HUVECS signal via 





cells to obtain a set of differentially expressed genes associated with 
endothelial cells and S1P (Lupino et al., 2019).  From the HUVEC/S1P gene 
set, we found an enrichment of macrophage signature genes which was taken 
from Doig et al (Doig et al., 2013).  This enrichment of macrophage signature 
genes was confirmed in a set of genes positively correlated with SPHK1 in 
DLBCL provided by Professor Reuben Tooze (Care et al., 2015).  Gene set 
enrichment analysis showed that macrophage activation, migration and 
function were processes over-represented by the SPHK1 gene set. 
 Monocytes and macrophages are abundant in the tumour 
microenvironment of DLBCL.  With the primary mechanism of action of 
rituximab in DLBCL is ADCP, it was relevant to study the role of S1P in the 
recruitment and function of monocytes and macrophages in the context of 
DLBCL.  It may be that the enrichment of macrophage genes in the SPHK1 
data set is due to macrophages themselves expressing SPHK1.  The expression 
of SPHK1 in macrophages in healthy donors and found that there was variable 
expression between donors.  Examining a small cohort of primary DLBCL 
cases, macrophages were found to express SPHK1 at levels similar to tonsillar 
germinal centre B cells.   
 To examine the effect of S1P on macrophages in the context of DLBCL, I 
have used a model of in vitro of primary human monocytes and macrophages.  
THP-1, a myeloid leukaemia cell line, is a widely model for macrophage 
polarisation for in vitro studies but I have opted to use primary human 





Lacey et al., 2012).  Using primary monocytes will have variability from donor 
to donor as opposed to using a cell line such as THP-1.  Therefore, in order to 
account for the variability of primary cultures, three healthy donors were used 
for each experiment performed at least twice with another set of three healthy 
donors. Indeed, there was heterogeneity amongst the primary macrophages in 
their response to rituximab treated target cells (DLBCL).  Each donor’s level of 
response differed in scale but nearly all donors’ macrophages had a level of 
reduced phagocytosis when treated with S1P. 
 Careful consideration of the cytokines used for in vitro polarisation of 
monocytes to M1 and M2.  Surveying literature using primary monocytes for 
macrophage polarisation, most used additional cytokines such as INFγ for M1 
and for M2, IL-4 and IL-10 (Leidi et al., 2009, Herter et al., 2014, Zhang et al., 
2016a, Mendoza-Coronel and Ortega, 2017).  In this thesis, the in vitro model 
used by Lacey et al showed that GM-CSF and M-CSF were sufficient to 
achieve M1 and M2 polarisation and these cytokines have been associated with 
polarisation of tumour associated macrophages (Lacey et al., 2012, Van 
Overmeire et al., 2016, Martinez and Gordon, 2014).   
I have shown that migration of monocytes and macrophages to DLBCL 
is mediated through S1PR1.  Although S1P induced migration mediated 
through S1PR1 of monocytes and macrophages is known in the context of 
apoptosis and inflammation, it has not been described before in DLBCL 
(Weichand et al., 2013b, Pyne et al., 2016, Pappu et al., 2007).  I have shown 





to DLBCL xenograft tumours in an S1PR1 dependent manner.  The 
observation that changes in S1P receptor expression is associated with 
macrophage polarisation described in this thesis is the first comprehensive 
analysis of S1P receptor expression in human monocytes/macrophages.  With 
the panel of 34 healthy donors evaluated, S1PR1 was found to be decreased 
and S1PR2 increased upon differentiation from monocytes.   
 In the context of phagocytosis, regardless of the discrepancy in the levels 
of phagocytosis of M1 and M2 in my studies compared to previously published 
data, I have shown that the phagocytosis of rituximab-opsonised DLBCL was 
reduced when macrophages were exposed to high levels of S1P.  This reduction 
was abrogated in the presence of an S1PR1/S1PR5 antagonist. I did not 
evaluate which S1P receptor was involved in the reduced phagocytosis of 
FITC+ IgG opsonised latex beads observed after S1P treatment. There has 
been two reported observations of the reduced phagocytosis in the presence of 
S1P in a mouse model of chronic obstructive pulmonary disease (COPD) and 
sepsis (McQuiston et al., 2011, Hou et al., 2015).  
 In a murine COPD model using C57BL/6 mouse macrophages, they 
examined phagocytosis of a fungus, Cryptococcus neoformans (McQuiston et 
al., 2011).  They found that treatment with JTE013 and S1P reduced 
phagocytosis which indicates that this reduction may be through another S1P 
receptor such as S1PR1 or S1PR5 (McQuiston et al., 2011).  In the sepsis 
model, Hou et al used C57BL/6 mice that were S1PR2-/- and found that these 





also found that S1PR3 was upregulated in macrophages during sepsis and that 
S1PR3 was required for bacterial clearing (Hou et al., 2017).  These groups 
along with my results provide evidence of the importance of S1P and its 
receptors in phagocytosis function of macrophages.   
 There have not been any reports of S1P and phagocytosis in the context 
of DLBCL.  I have shown that S1P reduces phagocytosis of rituximab treated 
DLBCL in vitro, and have also examined if this observation was relevant in 
vivo.  The antagonism of S1PR1 in vivo was evaluated using xenograft model 
of DLBCL.  Mice were treated with BAF312 in combination with vincristine 
and rituximab. The addition of an BAF312 to vincristine/rituximab treatment 
had reduced efficacy when administered prior to rituximab compared to 
vehicle control.  Mice treated with BAF312 along with rituximab had smaller 
average tumour volume compared to mice given BAF312 prior to vincristine.  
The difference in tumour growth may be due to treatment scheduling of 
BAF312 but data was not statistically significant.  Further work to optimise 
treatment scheduling of BAF312 with vincristine and rituximab is needed.    
For future work, I propose the following: 
1. To explore the effect of S1P itself on macrophage polarisation.  In 
particular, to investigate if S1P induces macrophages to secrete 
TGFβ1, known to inhibit inflammatory responses 
2. To examine the effect of S1P signalling on DLBCL in the targeted 





similar to DLBCL (Cattoretti et al., 2009).  It will be of interest to 
study how S1PR2 impacts the macrophages in these animals.   
3. To more broadly explore the impact of S1P on other functions 
associated with TAMs, use published gene expression data for GM-
CSF M1 and M-CSF polarised M2.  
4. To do further in vivo studies with BAF312 and other S1PR1 
antagonists to determine the effect of reducing macrophage 







































Appendix A1 DLBCL case IDs summarising SPHK1 score, average CD68 score 









HPF (100x) *** 
 
SUBTYPE 
DLBCL 4 5 178 n/a NON-GCB 
DLBCL 6 3 141 5/25 NON-GCB 
DLBCL 95 6 171 no lesion NON-GCB 
DLBCL 123 5 187 no lesion GCB 
DLBCL 126 4 179 2/21 GCB 
DLBCL 134 3 255 n/a NON-GCB 
DLBCL 156 2 49 n/a GCB 
DLBCL 159 3 184 1/19 GCB 
DLBCL 165 6 118 3/27 GCB 
DLBCL 167 2 287 n/a GCB 
DLBCL 175 3 204 4/22 NON-GCB 
DLBCL 176 2 125 5/27 NON-GCB 
DLBCL 181 6 237 n/a GCB 
DLBCL 185 6 223 n/a NON-GCB 
DLBCL 190 6 305 3/24 NONGCB 
DLBCL 191 3 258 6/32 GCB 
DLBCL 200 6 226 n/a NON-GCB 
DLBCL 208 4 238 4/28 GCB 
DLBCL 213 3 199 n/a GCB 
DLBCL 299 6 287 n/a GCB 
tonsil 1 2 48 1/37  
tonsil 2 2 53 3/32  
tonsil 3 1 n/a n/a  
*SPHK1 score calculated as described in Chapter 3 section 3.2.1 using 60x 
**Average CD68+ cells per 5-HPF (high-power field) at 40x 
















































Appendix A6 Cytokine array from M1 and M2 macrophages from donor K.  
Conditioned medium from day 7 cultures of M1 and M2 macrophages were 
analysed on a cytokine array with 35 different cytokines.  The cytokines are 
spotted in duplicate and were analysed by densitometry relative to the 
unconditioned medium blot.   There were two cytokines highly secreted by M2; 
CCL2/MCP-1 and CXCL10.  I found seven cytokines more highly secreted by M1 
including GM-CSF which acted as an additional control as this cytokine was 
directly added to the culture medium of M1; CCL1, MIP1a/b, CXCL1, G-CSF, GM-
CSF, IL-8 and Serpin EI.  There was a high level of GM-CSF secreted by M2.   
HIGH, LOW, NO CHANGE 
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Appendix A7 Expression of SPHK1 was evaluated in three primary 
macrophages 
The expression of SPHK1 was evaluated by qPCR in three donors’ M1 and M2 
macrophages relative to their matched monocytes.  Expression between donors 
varied with donor (L) showing an overexpression of SPHK1 to donor (Q) 
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